pirenzepine has been researched along with Schizophrenia in 585 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities." | 9.11 | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. ( Banki, CM; Bartko, G; Bitter, I; Breier, A; Brook, S; Dossenbach, MR; Feldman, PD; Füredi, J; Gagiano, CA; Janka, Z; Kovacs, G; Metcalfe, S, 2004) |
| "Clinical trials indicate that glycine site agonists of the N-methyl-D-aspartate (NMDA) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine." | 9.11 | High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. ( Bar, G; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P, 2004) |
| "Available studies suggest comparable efficacy of olanzapine and risperidone for the treatment of schizophrenia over the short term." | 9.11 | A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. ( Dunayevich, E; Enerson, M; Sethuraman, G; Taylor, CC, 2005) |
| " In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia." | 9.10 | Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. ( Hadjez, J; Härtter, S; Hiemke, C; Jabarin, M; Modai, I; Peled, A; Ritsner, M; Silver, H; Weigmann, H, 2002) |
| "A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia." | 9.10 | An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. ( Buchanan, RW; Gold, J; Summerfelt, A; Tek, C, 2003) |
| "The subjects were 45 inpatients with DSM-IV schizophrenia or schizoaffective disorder who failed to respond to treatment during a 14-week double-blind trial comparing clozapine, olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. ( Chakos, M; Citrome, L; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia." | 9.10 | A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002) |
| "The aim of this study is to provide long-term data on the effectiveness and safety of olanzapine in a group of patients with severe refractory schizophrenia." | 9.10 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. ( Abel, A; Alvarez, V; Blanco, C; Ciudad, A; Cudeiro, F; Ferreiro, MJ; Gómez, Y; López, A; Peña, C; Prieto, R; Rego, C; Rodríguez-Pérez, V, 2002) |
| " haloperidol for elderly chronic schizophrenia patients." | 9.10 | Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. ( Barak, Y; Mirecki, I; Shamir, E; Toren, P; Weizman, R; Zemishlani, H, 2002) |
| "Little is known about the feasibility of switching patients with schizophrenia from long-acting injectable antipsychotics to oral olanzapine." | 9.10 | Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. ( Boulay, LJ; Bourget, D; Ellis, J; Labelle, A; Tessier, P, 2002) |
| "A multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine vs olanzapine was conducted in 980 patients with schizophrenia or schizoaffective disorder, 26." | 9.10 | Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). ( Alphs, L; Altamura, AC; Anand, R; Bertoldi, A; Bourgeois, M; Chouinard, G; Green, AI; Islam, MZ; Kane, J; Krishnan, R; Lindenmayer, JP; Meltzer, HY; Potkin, S, 2003) |
| "The selective norepinephrine reuptake inhibitor reboxetine may reduce olanzapine-induced weight gain in schizophrenia patients, and activation of the adrenergic system may attenuate weight gain induced by atypical antipsychotic agents." | 9.10 | Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. ( Faragian, S; Fuchs, C; Isaacs, I; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003) |
| "Subjects (N=24) who met DSM-IV criteria for schizophrenia were randomly assigned to 6 weeks of double-blind treatment with either olanzapine, 7." | 9.10 | Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M, 2003) |
| "Significant weight gain is a side effect associated with olanzapine treatment in some patients." | 9.10 | Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. ( Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L, 2003) |
| "In a 3-month open-label study, 26 clinically stable patients with schizophrenia taking depot antipsychotics for over 3 years were randomly assigned to continue on their current depot dose or to switch to oral olanzapine." | 9.10 | Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. ( Godleski, LS; Goldsmith, LJ; Lewis, SJ; Stikovac, DM; Vieweg, WV; Zettwoch, NC, 2003) |
| "Weight gain is associated with treatment with olanzapine and other psychotropic agents." | 9.10 | Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. ( Allison, DB; Breier, A; Cavazzoni, P; Roychowdhury, SM; Tanaka, Y, 2003) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone." | 9.10 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. ( Ames, D; Chiu, E; Hall, K; Harrigan, S; Hassett, A; Macfarlane, S; Mastwyk, M; O'Connor, DW; Opie, J; Ritchie, CW, 2003) |
| "This study evaluated the effectiveness, safety, and quality of life (Qol) offered by olanzapine in first-episode schizophrenia." | 9.10 | Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. ( Ciudad, A; Gascón, J; Gómez, JC; Montes, JM, 2003) |
| "Thirty-nine subjects with early phase schizophrenia were randomly assigned to double blind treatment with haloperidol, risperidone, or olanzapine." | 9.10 | Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. ( Lindborg, SR; Purdon, SE; Stip, E; Woodward, N, 2003) |
| "This naturalistic study aimed to determine whether olanzapine and clozapine improve cognitive functioning in a sample of 48 patients with chronic schizophrenia who had either failed to show sufficient clinical improvements or suffered from distressing side effects with conventional antipsychotics and were switched to either olanzapine or clozapine for clinical reasons and, if so, whether the two drugs produce similar or different cognitive effects." | 9.10 | Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. ( Hughes, C; Kumari, V; Sharma, T; Soni, W, 2003) |
| "The aim of the present study was to evaluate the objective and subjective efficacy as well as tolerability of olanzapine in acute treatment of schizophrenia spectrum disorders under naturalistic non-selective conditions." | 9.10 | Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. ( Holzbach, R; Krausz, M; Lambert, M; Moritz, S; Naber, D; Postel, N, 2003) |
| "A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea." | 9.10 | Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. ( Bahk, WM; Kim, JJ; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH, 2003) |
| "It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment." | 9.10 | Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 9.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "The role of olanzapine in treatment-resistant schizophrenia has still not been clearly resolved." | 9.10 | Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial. ( Chang, CC; Chen, PS; Chiu, NY; Lee, IH; Lee, JR; Yang, YK, 2003) |
| "To determine whether patients with treatment-resistant schizophrenia or schizoaffective disorder would respond when switched to olanzapine and whether they could maintain their response on this atypical antipsychotic." | 9.10 | Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. ( Karagianis, JL; LeDrew, KK; Walker, DJ, 2003) |
| "These results suggest that there is not a significant differential effect of olanzapine and haloperidol on the P50 sensory gating index in schizophrenia." | 9.10 | Olanzapine effects on auditory sensory gating in schizophrenia. ( Arango, C; Buchanan, RW; Summerfelt, A, 2003) |
| "To compare the six-week clinical response and safety profile of schizophrenia patients, age > or =60 years, receiving olanzapine (OLZ) vs haloperidol (HAL) in a double blind, randomized trial." | 9.10 | Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. ( Breier, A; Bymaster, FP; Dossenbach, M; Gilmore, JA; Golshan, S; Jeste, D; Kaiser, CJ; Kennedy, JS; Kinon, BJ; Maguire, GA; Sanger, T; Tollefson, G, 2003) |
| "To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia." | 9.10 | Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. ( Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S, 2003) |
| "We conducted a prospective, controlled, open study comparing body weight, fat mass, and indices of insulin resistance/ sensitivity in 10 olanzapine-treated patients with ICD-10 schizophrenia (olanzapine dose range, 7." | 9.10 | Olanzapine induces insulin resistance: results from a prospective study. ( Ebenbichler, CF; Eder, U; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Laimer, M; Lechleitner, M; Mangweth, B; Patsch, JR; Weiss, E, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "The authors investigated the clinical effects of D-cycloserine when added to treatment with conventional neuroleptics, olanzapine, or risperidone for treatment-resistant schizophrenia." | 9.10 | Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. ( Ermilov, M; Heresco-Levy, U; Javitt, DC; Shapira, B; Shimoni, J; Silipo, G, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 9.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia." | 9.10 | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 9.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 9.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 9.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15)." | 9.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| " A 6-week, double-blind randomized multicenter trial, with a long-term extension, was conducted to evaluate the clinical efficacy and QOL of olanzapine and haloperidol in treating schizophrenia and other psychotic disorders." | 9.09 | Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. ( Beasley, CM; Ganoczy, D; Genduso, LA; Hamilton, SH; Revicki, DA, 1999) |
| "This prospective, consecutive case-series outcome investigation evaluates the effectiveness of olanzapine in 16 patients with treatment-resistant schizophrenia." | 9.09 | Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. ( Bird, DC; Dursun, SM; Flinn, J; Gardner, DM, 1999) |
| "We utilize data from a large, double-blind, randomized clinical trial of treatment for schizophrenia to compare the effect of therapy with the second generation antipsychotic olanzapine versus therapy with the conventional agent haloperidol on the perceived functioning and well-being of patients over 1 year as measured by the Medical Outcome Study Short Form (SF-36)." | 9.09 | Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. ( Dulisse, BK; Gibson, PJ; Johnstone, BM; Loosbrock, DL; Tunis, SL, 1999) |
| "The purpose of this study was to compare, from the payor perspective, the clinical and economic outcomes of olanzapine to those of haloperidol for the treatment of schizophrenia." | 9.09 | Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. ( Edgell, ET; Genduso, LA; Hamilton, SH; Revicki, DA; Tollefson, G, 1999) |
| "Risperidone and olanzapine have each been demonstrated to be efficacious and safe in the treatment of patients with chronic schizophrenia." | 9.09 | A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. ( Andreasen, NC; Ho, BC; Miller, D; Nopoulos, P, 1999) |
| "Thirty adult patients with acute schizophrenia were included into six-week open-labelled, non-comparative trial of olanzapine with free dosing from 5 to 20 mg per day." | 9.09 | [The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia]. ( Beniashvili, AG; Morozova, MA; Zharkova, NB, 2000) |
| "Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine." | 9.09 | Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. ( Gonzalez, V; Kopelowicz, A; Mintz, J; Tripodis, K; Zarate, R, 2000) |
| "The primary aim of this study was to compare functional outcomes between patients with schizophrenia treated with olanzapine or haloperidol in Europe." | 9.09 | Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. ( Breier, A; Edgell, ET; Hamilton, SH; Revicki, DA, 2000) |
| "Coadministration of olanzapine, an atypical neuroleptic, with sulpiride, a selective D2 antagonist, is suggested as an efficient strategy for treating patients with resistant unremitting schizophrenia." | 9.09 | Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. ( Durst, R; Katz, G; Raskin, S; Zislin, J, 2000) |
| "This multicenter, open-label study was designed to assess the efficacy and tolerability of olanzapine in patients with chronic schizophrenia who are resistant to therapy with classic neuroleptic agents and are either not responsive to or unable to tolerate clozapine." | 9.09 | The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. ( Avnon, M; Belmaker, RH; Beuzen, JN; Elizur, A; Grundy, SL; Kratky, P; Mark, M; Munitz, H; Schneidman, M; Shoshani, D; Tollefson, GD, 2000) |
| "To compare the clinical and economic outcomes associated with olanzapine and risperidone treatment for schizophrenia." | 9.09 | Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. ( Andersen, SW; Breier, A; Dulisse, B; Edgell, ET; Johnstone, BM; Revicki, D, 2000) |
| "Previously, a double-blind, 6-week, parallel-group trial compared the therapeutic profiles of olanzapine (5-20 mg/day; N = 1,336) and haloperidol (5-20 mg/day; N = 660) in 1996 patients with DSM-III-R schizophrenia (83." | 9.09 | Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. ( Crawford, AM; Gomez, JC, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 9.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 9.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 9.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia." | 9.09 | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001) |
| "This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine." | 9.09 | Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 9.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| "The goal of this study was to explore the pathophysiology of weight gain during treatment with olanzapine for schizophrenia." | 9.09 | Association of olanzapine-induced weight gain with an increase in body fat. ( Ebenbichler, C; Eder, U; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Mangweth, B; Weiss, E, 2001) |
| "Twenty patients with schizophrenia (according to DSM-III-R criteria) treated with either clozapine (200-500 mg/day) or olanzapine (10-20 mg/day) as well as ten matched controls underwent simultaneous recordings of the skin conductance response (SCR) of sweat glands and of the inspiratory gasp response (IGR) of acral blood vessels." | 9.09 | Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. ( Acker, J; Agelink, MW; Mueck-Weymann, M, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 9.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "The objective of this study was to evaluate the efficacy and safety of olanzapine in patients with schizophrenia and comorbid substance abuse disorders." | 9.09 | Olanzapine treatment for patients with schizophrenia and substance abuse. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Peabody, CD; Petty, RG, 2001) |
| "Two studies compared the efficacy of standard-dose oral olanzapine (5 to 15 mg a day) with placebo and with ineffective-dose olanzapine (1 mg a day) in maintenance therapy of schizophrenia." | 9.08 | Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, P; Wentley, AL, 1997) |
| "This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d)." | 9.08 | Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. ( Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD, 1998) |
| "These data provide preliminary evidence for the efficacy of olanzapine for some children and adolescents with treatment-refractory schizophrenia, but they also suggest the need for a more rigorous double-blind comparison of these two atypical antipsychotics." | 9.08 | Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. ( Bedwell, J; Frazier, JA; Hamburger, S; Jacobsen, LK; Karp, BI; Kumra, S; Lee, P; Lenane, M; Malanga, CJ; Rapoport, JL; Smith, AK, 1998) |
| "In a 6-week placebo- and haloperidol (HAL)-controlled trial with 335 randomized subjects with chronic schizophrenia in an acute exacerbation, three fixed dose ranges of OLZ (5, 10, or 15 +/- 2." | 9.08 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. ( Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV, 1998) |
| "The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia." | 9.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| "Olanzapine is a new atypical antipsychotic recently introduced for the treatment of schizophrenia." | 9.08 | 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. ( DaSilva, J; Houle, S; Jones, C; Kapur, S; Remington, G; Wilson, AA; Zipursky, RB, 1998) |
| "To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses." | 8.82 | Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2003) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 8.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 8.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| "The high acquisition cost of olanzapine is offset by reductions in other treatment costs in patients with schizophrenia." | 8.80 | Olanzapine. A pharmacoeconomic review of its use in schizophrenia. ( Foster, RH; Goa, KL, 1999) |
| "To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses." | 8.80 | Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2000) |
| "Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics." | 8.80 | Risperidone versus other atypical antipsychotic medication for schizophrenia. ( Bagnall, AM; Duggan, L; Gilbody, SM; Tuunainen, A, 2000) |
| "The effects of olanzapine, risperidone, and haloperidol on PRL were assessed in patients with schizophrenia or related psychoses participating in 3 double-blind clinical trials: (1) a 6-week acute trial comparing olanzapine 5 to 20 mg/d (n = 1,336) and haloperidol 5 to 20 mg/d (n = 660), with a 1-year, open-label olanzapine extension for responders; (2) a 54-week study comparing olanzapine 5 to 20 mg/d (n = 21), risperidone 4 to 10 mg/d (n = 21), and haloperidol 5 to 20 mg/d (n = 23) in early illness; and (3) a 28-week study comparing olanzapine 10 to 20 mg/d (n = 172) and risperidone 4 to 12 mg/d (n = 167)." | 8.80 | The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. ( Breier, A; David, SR; Kinon, BJ; Taylor, CC, 2000) |
| "Olanzapine is a thienobenzodiazepine derivative which displays efficacy in patients with schizophrenia and related psychoses." | 8.79 | Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. ( Fulton, B; Goa, KL, 1997) |
| "To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of olanzapine as a treatment for schizophrenia and to determine the advantages and disadvantages of this atypical antipsychotic agent compared with currently marketed agents." | 8.79 | Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. ( Green, AI; Kando, JC; Patel, JK; Reams, SG; Satterlee, W; Shepski, JC, 1997) |
| "This therapeutic drug monitoring (TDM) study aimed to determine the role of olanzapine (OLZ) and N-desmethyl-OLZ (DMO) levels in the therapeutic efficacy of OLZ in patients with schizophrenia." | 7.83 | Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. ( Chen, CH; Chen, YH; Kuo, PT; Lin, CH; Lu, ML; Wu, TH; Wu, YX, 2016) |
| "Risperidone and olanzapine-administration data were collected for schizophrenia patients treated at four Taiwanese medical centres." | 7.72 | Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. ( Chiu, NY; Hsiao, MC; Liao, O; Liu, CY; Wu, CK; Yuan, LM, 2003) |
| "Premarketing trials of olanzapine reported an incidence of peripheral oedema of 3%." | 7.72 | Peripheral oedema in patients taking olanzapine. ( Ng, B; Postlethwaite, A; Rollnik, J, 2003) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 7.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "To examine both schizophrenia-related costs and total (schizophrenia plus non-schizophrenia) healthcare costs among Texas Medicaid recipients who had been diagnosed with a schizophrenic disorder and had been initiated on olanzapine or risperidone." | 7.72 | Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. ( Barber, BL; Crismon, ML; Johnsrud, MT; Lage, MJ; Rascati, KL, 2003) |
| "Since their introduction to the US market, atypical antipsychotic drugs, such as olanzapine, have been widely prescribed for the management of psychosis and have increasingly been used in dermatologic settings for the treatment of psychogenic dermatoses." | 7.72 | Eruptive xanthomas associated with olanzapine use. ( Chang, HY; Hughes, E; Kimball, AB; Oro, AE; Ridky, TW, 2003) |
| "In a cross-sectional study, consecutive premenopausal, female, DSM-IV schizophrenia patients who were treated with either risperidone (N = 12) or olanzapine (N = 14) for at least 2 years were included." | 7.72 | Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. ( Becker, D; Liver, O; Mester, R; Rapoport, M; Weiss, M; Weizman, A, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 7.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "Olanzapine is an atypical antipsychotic effective in the treatment of schizophrenia." | 7.72 | Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. ( Ahmad, F; Bulsara, MK; Castle, DJ; Dusci, LJ; Fellows, L; Ilett, KF, 2003) |
| "This pilot study investigates the dissolution profile, tolerability, and acceptability of an orally disintegrating olanzapine tablet in patients with schizophrenia." | 7.71 | Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. ( Chue, P; Dickson, R; Jones, B; Taylor, CC, 2002) |
| "Conventional as well as newer antipsychotics cause weight gain, and, in the regulation of body weight, both insulin and leptin are hormones involved." | 7.71 | Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents. ( Hulting, AL; Melkersson, KI, 2001) |
| "This study compared the discharge rates and drug costs of 789 patients with schizophrenia or schizoaffective disorder who began pharmacotherapy with olanzapine or risperidone between July 1997 and June 1998." | 7.71 | Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. ( Conley, RR; Kelly, DL; Love, RC; Nelson, MW; Yu, Y, 2001) |
| "To report two cases of new-onset diabetes mellitus resulting after the initiation of olanzapine treatment." | 7.71 | Olanzapine-induced diabetes mellitus. ( Bonanno, DG; Botts, SR; Davydov, L, 2001) |
| " In order to determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine." | 7.71 | Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. ( Ayrton, Z; Brar, JS; Ganguli, R, 2001) |
| "This study evaluated the effectiveness of a Weight Watchers program for patients with schizophrenia who had olanzapine-related weight gain and ascertained whether the severity of patients' psychiatric symptoms was correlated with the patients' success in losing weight." | 7.71 | A program for treating olanzapine-related weight gain. ( Ball, MP; Buchanan, RW; Coons, VB, 2001) |
| "The Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme was an international series of naturalistic studies designed to evaluate drug use patterns and outcomes." | 7.71 | Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. ( Duchesne, I; Kasper, S; Rosillon, D, 2001) |
| "We report the health economic data from the Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme." | 7.71 | Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. ( Duchesne, I; Jones, M; Kasper, S, 2001) |
| "To obtain an in vivo measurement of muscarinic receptor occupancy by olanzapine compared with risperidone in patients with schizophrenia stabilised on medication." | 7.71 | Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. ( Booij, J; Lavalaye, J; Linszen, DH; Reneman, L; van Royen, EA, 2001) |
| "The role of olanzapine in treatment-resistant schizophrenia is still unresolved." | 7.71 | Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. ( Chakos, M; Citrome, L; Czobor, P; Iskander, A; Lieberman, J; Lindenmayer, JP; Parker, B; Sheitman, B; Volavka, J, 2001) |
| "Both acute and chronic administration of N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine and dizocilpine have been proposed to mimic some of the symptoms of schizophrenia." | 7.71 | Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. ( Johnson, KM; McInnis, J; Ross-Sanchez, M; Shinnick-Gallagher, P; Wang, C; Wiley, JL, 2001) |
| "This retrospective study evaluates drug treatment patterns and economic outcomes of olanzapine in comparison with risperidone in the treatment of schizophrenia in usual practice." | 7.71 | A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. ( Zhao, Z, 2002) |
| "The authors studied the efficacy of olanzapine and risperidone among patients with treatment-refractory schizophrenia who had been hospitalized for more than five years and who were not suitable candidates for a clozapine trial." | 7.71 | Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients. ( Bopp, JH; Daniels, A; Dinakar, HS; Mauro, S; Sobel, RN, 2002) |
| "The authors compared the changes in health care utilization and costs between a group of patients with schizophrenia who started treatment with risperidone and a group that started treatment with olanzapine." | 7.71 | Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. ( Durkin, MB; Fuller, MA; Laich, JS; Secic, M; Shermock, KM, 2002) |
| "In the second of this series of updates on recent advances in medication, RICHARD GRAY summarises trials into the novel antipsychotic olanzapine, which has been shown to compare well to haloperidol, and is now widely used for treating schizophrenia and related psychoses." | 7.70 | Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia. ( Gray, R, 1998) |
| "Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses." | 7.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "Forty-four patients with schizophrenia (16 taking risperidone, 2-12 mg/day; 17 taking olanzapine, 5-60 mg/day; and 11 taking clozapine, 75-900 mg/day) had their D2 and 5-HT2 occupancies determined with the use of [11C]raclopride and [18F]setoperone, respectively, and positron emission tomography imaging." | 7.70 | Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. ( Kapur, S; Remington, G; Zipursky, RB, 1999) |
| "The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia." | 7.70 | Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D, 2000) |
| "To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia." | 7.70 | Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. ( Almond, S; O'Donnell, O, 2000) |
| "To date only five reports of neuroleptic malignant syndrome (NMS) related to olanzapine exist." | 7.70 | Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. ( Järventausta, K; Leinonen, E, 2000) |
| "We present the case of a 42-year-old male with a history of schizophrenia who developed signs and symptoms consistent with Neuroleptic Malignant Syndrome (NMS) after 3 weeks of treatment with Olanzapine." | 7.70 | Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. ( Privette, T; Stanfield, SC, 2000) |
| "Fourteen patients on treatment with olanzapine (all meeting DSM-IV criteria for schizophrenia or related psychoses) were studied." | 7.70 | Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. ( Brismar, KE; Hulting, AL; Melkersson, KI, 2000) |
| "Olanzapine has been shown to be better tolerated in comparison with conventional antipsychotics in a large unselected sample of acutely psychotic schizophrenic in-patients." | 6.71 | Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. ( Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M; Sacristán, JA, 2003) |
| " Treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia." | 6.71 | Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. ( Casey, DE; Daniel, DG; Sommerville, KW; Tracy, KA; Wassef, AA; Wozniak, P, 2003) |
| "Olanzapine is an atypical antipsychotic that has efficacy in adults with psychotic disorders." | 6.71 | A prospective, open-label trial of olanzapine in adolescents with schizophrenia. ( Branicky, LA; Demeter, CA; Findling, RL; McNamara, NK; Schulz, SC; Youngstrom, EA, 2003) |
| "Olanzapine-treated patients showed a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores at endpoint compared to the risperidone-treated patients." | 6.71 | Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. ( Andersen, S; Catts, S; Crawford, AM; Fraser, A; Grainger, D; Gureje, O; Hustig, H; Keks, N; Lambert, T; McGrath, J; Miles, W; Tran, P, 2003) |
| " Daily dosage was subsequently adjusted between 5 and 20 mg/d based on individual clinical status." | 6.71 | A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. ( Chokka, PR; Dickson, RA; Dursun, SM; Jones, B; MacEwan, GW; Reiss, JP; Remington, GJ; Rotstein, E; Stip, E, 2003) |
| "Weight gain is an important side effect of antipsychotic (AP) treatment." | 6.71 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. ( de Castella, AR; Fitzgerald, PB; Kulkarni, J; Morris, MJ; Scaffidi, A, 2003) |
| "In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ." | 6.70 | Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001) |
| "Olanzapine has been reported as less likely to cause EPS and may improve some negative signs." | 6.69 | The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. ( Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE, 1998) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 6.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "Olanzapine is an effective antipsychotic medication in older adults with schizophrenia, and is associated with significant improvement in extrapyramidal side effects." | 6.69 | Olanzapine therapy in elderly patients with schizophrenia. ( Brescan, D; Perez, D; Ramirez, LF; Sajatovic, M, 1998) |
| " Safety was evaluated through the collection of spontaneous adverse events and a specific questionnaire for extrapyramidal symptoms." | 6.69 | The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. ( Antón Saiz, C; Breier, A; Fontova Carbonell, E; Gómez, JC; Hernández, J; Ruiz Carrasco, P; Sacristán, JA, 2000) |
| " It does not appear to be free of adverse effects on liver function." | 6.68 | First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. ( Baldwin, DS; Montgomery, SA, 1995) |
| "Olanzapine is a new antipsychotic drug that has shown efficacy against positive and negative symptoms of schizophrenia, with minimal extrapyramidal side effects." | 6.68 | Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. ( Alvarez, E; Cuesta, M; García-Bernardo, E; Gómez, JC; Gurpegui, M; Martín, J, 1997) |
| "Neuroleptic malignant syndrome is the rarest and the most serious of the neuroleptic induced movement disorders." | 6.42 | Olanzapine induced neuroleptic malignant syndrome--a case review. ( Kogoj, A; Velikonja, I, 2003) |
| "Olanzapine can cause NMS, mainly in susceptible or predisposed patients." | 6.41 | Olanzapine-associated neuroleptic malignant syndrome. ( Christodoulou, NG; Havaki-Kontaxaki, BJ; Kontaxakis, VP; Paplos, KG, 2002) |
| "Olanzapine is a serotonin-dopamine receptor antagonist primarily used in the treatment of psychotic illnesses." | 6.41 | Olanzapine: an atypical antipsychotic for schizophrenia. ( Lund, BC; Perry, PJ, 2000) |
| " The manuscript describes the pharmacology, efficacy and tolerability studies, adverse effects and dosing considerations in the elderly." | 6.41 | Use of olanzapine for elderly patients with psychotic disorders: a review. ( Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Sinha, S, 2001) |
| " Proper dosing has emerged as a vital factor in the effective use of these newer drugs." | 6.40 | Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. ( Kasper, S, 1998) |
| " To provide the therapeutic benefits of maintenance medication without its drawbacks, intermittent dosing and long-term therapy with reduced doses of conventional medications have been explored." | 6.40 | Olanzapine in the long-term treatment of schizophrenia. ( Kane, J, 1999) |
| "We conducted a post hoc analysis of an international, multicenter, double-blind, 28-week study of 339 patients who met DSM-IV criteria for schizophrenia, schizophreniform, or schizoaffective disorder and were randomized to treatment with either olanzapine or risperidone." | 6.19 | Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? ( Andersen, SW; Tollefson, GD, 1999) |
| "Olanzapine is an atypical antipsychotic with potent antimuscarinic properties in vitro (K(i) = 2-25 nM)." | 5.31 | In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. ( Egan, MF; Jones, DW; Knable, MB; Lafargue, T; Pickar, D; Raedler, TJ; Urbina, RA; Weinberger, DR, 2000) |
| "Olanzapine is a newly developed atypical neuroleptic with a marked affinity to the 5-HT2, D2 and D4 dopamine receptors." | 5.30 | Severe akathisia during olanzapine treatment of acute schizophrenia. ( Bachmann, S; Gerdsen, I; Jauss, M; Mundt, C; Pantel, J; Schröder, J, 1998) |
| "We report a case of agranulocytosis induced by olanzapine." | 5.30 | Olanzapine-induced agranulocytosis. ( Felber, W; Heilemann, H; Naumann, R; Reuster, T, 1999) |
| "Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities." | 5.11 | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. ( Banki, CM; Bartko, G; Bitter, I; Breier, A; Brook, S; Dossenbach, MR; Feldman, PD; Füredi, J; Gagiano, CA; Janka, Z; Kovacs, G; Metcalfe, S, 2004) |
| "Clinical trials indicate that glycine site agonists of the N-methyl-D-aspartate (NMDA) receptors may reduce negative and cognitive symptoms in treatment-resistant schizophrenia when used as adjuvants to conventional antipsychotics but possibly not to clozapine." | 5.11 | High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. ( Bar, G; Ermilov, M; Heresco-Levy, U; Javitt, DC; Lichtenberg, P, 2004) |
| "Available studies suggest comparable efficacy of olanzapine and risperidone for the treatment of schizophrenia over the short term." | 5.11 | A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia. ( Dunayevich, E; Enerson, M; Sethuraman, G; Taylor, CC, 2005) |
| "This open-label, multicenter, randomized study compared the efficacy and safety of switching moderately ill Asian patients with schizophrenia from their current regimen of antipsychotic medication to the atypical antipsychotic olanzapine using either a direct switch method or a start-taper switch method." | 5.10 | Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. ( Conde, BJ; Lee, CT; Mazlan, M; Roychowdhury, SM; Tran, PV; Visanuyothin, T; Walker, DJ; Wang, A; Wang, H; Wong, MM, 2002) |
| "In a prospective, single-blinded, naturalistic study, a cohort of subjects (n=150) with schizophrenia or schizo-affective disorder (DSM-IV) were switched from conventional neuroleptic drugs to either risperidone (n=50), olanzepine (n=50) or quetiapine (n=50), and monitored for a period of 2 to 6 years." | 5.10 | Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. ( Awad, A; Cernovsky, Z; Cortese, L; Kotteda, V; Owyeumi, L; Voruganti, L; Zirul, S, 2002) |
| " In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia." | 5.10 | Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. ( Hadjez, J; Härtter, S; Hiemke, C; Jabarin, M; Modai, I; Peled, A; Ritsner, M; Silver, H; Weigmann, H, 2002) |
| "A pilot study was conducted to examine if donepezil could enhance cognitive function in patients with schizophrenia." | 5.10 | An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. ( Buchanan, RW; Gold, J; Summerfelt, A; Tek, C, 2003) |
| "The subjects were 45 inpatients with DSM-IV schizophrenia or schizoaffective disorder who failed to respond to treatment during a 14-week double-blind trial comparing clozapine, olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. ( Chakos, M; Citrome, L; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia." | 5.10 | A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002) |
| "The aim of this study is to provide long-term data on the effectiveness and safety of olanzapine in a group of patients with severe refractory schizophrenia." | 5.10 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. ( Abel, A; Alvarez, V; Blanco, C; Ciudad, A; Cudeiro, F; Ferreiro, MJ; Gómez, Y; López, A; Peña, C; Prieto, R; Rego, C; Rodríguez-Pérez, V, 2002) |
| " haloperidol for elderly chronic schizophrenia patients." | 5.10 | Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. ( Barak, Y; Mirecki, I; Shamir, E; Toren, P; Weizman, R; Zemishlani, H, 2002) |
| "Little is known about the feasibility of switching patients with schizophrenia from long-acting injectable antipsychotics to oral olanzapine." | 5.10 | Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study. ( Boulay, LJ; Bourget, D; Ellis, J; Labelle, A; Tessier, P, 2002) |
| "The superiority of olanzapine to haloperidol with respect to a decreased incidence of treatment-emergent extrapyramidal syndromes (EPS) in patients with schizophrenia was demonstrated in studies conducted in both Japan and Western countries." | 5.10 | Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. ( Beasley, CM; Inada, T; Tanaka, Y; Walker, DJ, 2003) |
| "A multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine vs olanzapine was conducted in 980 patients with schizophrenia or schizoaffective disorder, 26." | 5.10 | Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). ( Alphs, L; Altamura, AC; Anand, R; Bertoldi, A; Bourgeois, M; Chouinard, G; Green, AI; Islam, MZ; Kane, J; Krishnan, R; Lindenmayer, JP; Meltzer, HY; Potkin, S, 2003) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "The selective norepinephrine reuptake inhibitor reboxetine may reduce olanzapine-induced weight gain in schizophrenia patients, and activation of the adrenergic system may attenuate weight gain induced by atypical antipsychotic agents." | 5.10 | Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. ( Faragian, S; Fuchs, C; Isaacs, I; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003) |
| "Subjects (N=24) who met DSM-IV criteria for schizophrenia were randomly assigned to 6 weeks of double-blind treatment with either olanzapine, 7." | 5.10 | Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D; van Bruggen, M, 2003) |
| "The effects of risperidone and olanzapine on cognitive functioning in patients with schizophrenia were compared in a randomized, double-blind trial." | 5.10 | Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. ( Green, MF; Harvey, PD; McGurk, SR; Meltzer, HY, 2003) |
| "Significant weight gain is a side effect associated with olanzapine treatment in some patients." | 5.10 | Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. ( Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L, 2003) |
| "In a 3-month open-label study, 26 clinically stable patients with schizophrenia taking depot antipsychotics for over 3 years were randomly assigned to continue on their current depot dose or to switch to oral olanzapine." | 5.10 | Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. ( Godleski, LS; Goldsmith, LJ; Lewis, SJ; Stikovac, DM; Vieweg, WV; Zettwoch, NC, 2003) |
| "The aim of the study was to investigate patterns of the P600 component of event-related potentials (ERPs) elicited during a working memory test in 16 male schizophrenic patients experiencing auditory hallucinations before and after treatment with clozapine and olanzapine, and 13 male normal subjects matched for age and educational level." | 5.10 | Do atypical antipsychotics fail to exert cognitive sparing effects? ( Christodoulou, GN; Matsopoulos, GK; Oulis, P; Papageorgiou, C; Rabavilas, A; Uzunoglu, N; Vasios, C, 2003) |
| "Weight gain is associated with treatment with olanzapine and other psychotropic agents." | 5.10 | Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. ( Allison, DB; Breier, A; Cavazzoni, P; Roychowdhury, SM; Tanaka, Y, 2003) |
| " In recent years atypical antipsychotics such as olanzapine, which have high serotonin 5-HT(2A)/dopamine D(2) occupation ratios, have been shown to be more effective in the treatment of schizophrenia symptoms." | 5.10 | Tc-99 HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated schizophrenic patients. ( Esel, E; Gonul, AS; Kula, M; Sofuoglu, S; Tutus, A, 2003) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone." | 5.10 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. ( Ames, D; Chiu, E; Hall, K; Harrigan, S; Hassett, A; Macfarlane, S; Mastwyk, M; O'Connor, DW; Opie, J; Ritchie, CW, 2003) |
| "This study evaluated the effectiveness, safety, and quality of life (Qol) offered by olanzapine in first-episode schizophrenia." | 5.10 | Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. ( Ciudad, A; Gascón, J; Gómez, JC; Montes, JM, 2003) |
| " In 3 double-blind studies, acutely agitated patients with schizophrenia (N = 311), bipolar mania (N = 201), or dementia (N = 206) were treated with intramuscular (1-3 injections/24 hrs) olanzapine (2." | 5.10 | Calming versus sedative effects of intramuscular olanzapine in agitated patients. ( Alaka, K; Battaglia, J; Lindborg, SR; Meehan, K; Wright, P, 2003) |
| "Thirty-nine subjects with early phase schizophrenia were randomly assigned to double blind treatment with haloperidol, risperidone, or olanzapine." | 5.10 | Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. ( Lindborg, SR; Purdon, SE; Stip, E; Woodward, N, 2003) |
| "This naturalistic study aimed to determine whether olanzapine and clozapine improve cognitive functioning in a sample of 48 patients with chronic schizophrenia who had either failed to show sufficient clinical improvements or suffered from distressing side effects with conventional antipsychotics and were switched to either olanzapine or clozapine for clinical reasons and, if so, whether the two drugs produce similar or different cognitive effects." | 5.10 | Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. ( Hughes, C; Kumari, V; Sharma, T; Soni, W, 2003) |
| " Acutely agitated inpatients with schizophrenia were treated with 1 to 3 IM injections to olanzapine 10 mg or haloperidol 7." | 5.10 | A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. ( Birkett, M; Breier, A; Lindborg, SR; Meehan, K; Morris, P; Taylor, CC; Wright, P, 2003) |
| "The aim of the present study was to evaluate the objective and subjective efficacy as well as tolerability of olanzapine in acute treatment of schizophrenia spectrum disorders under naturalistic non-selective conditions." | 5.10 | Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. ( Holzbach, R; Krausz, M; Lambert, M; Moritz, S; Naber, D; Postel, N, 2003) |
| "A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea." | 5.10 | Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. ( Bahk, WM; Kim, JJ; Lee, C; Lee, CU; Lee, KU; Lee, SJ; Pae, CU; Paik, IH, 2003) |
| "It has been reported that nizatidine may reduce the weight gain in schizophrenic patients receiving olanzapine treatment." | 5.10 | Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder." | 5.10 | Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. ( Gharabawi, G; Harvey, PD; Mao, L; Napolitano, JA, 2003) |
| "The role of olanzapine in treatment-resistant schizophrenia has still not been clearly resolved." | 5.10 | Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial. ( Chang, CC; Chen, PS; Chiu, NY; Lee, IH; Lee, JR; Yang, YK, 2003) |
| "To determine whether patients with treatment-resistant schizophrenia or schizoaffective disorder would respond when switched to olanzapine and whether they could maintain their response on this atypical antipsychotic." | 5.10 | Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up. ( Karagianis, JL; LeDrew, KK; Walker, DJ, 2003) |
| "These results suggest that there is not a significant differential effect of olanzapine and haloperidol on the P50 sensory gating index in schizophrenia." | 5.10 | Olanzapine effects on auditory sensory gating in schizophrenia. ( Arango, C; Buchanan, RW; Summerfelt, A, 2003) |
| "To compare the six-week clinical response and safety profile of schizophrenia patients, age > or =60 years, receiving olanzapine (OLZ) vs haloperidol (HAL) in a double blind, randomized trial." | 5.10 | Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. ( Breier, A; Bymaster, FP; Dossenbach, M; Gilmore, JA; Golshan, S; Jeste, D; Kaiser, CJ; Kennedy, JS; Kinon, BJ; Maguire, GA; Sanger, T; Tollefson, G, 2003) |
| "To evaluate the effectiveness and cost impact of olanzapine compared with haloperidol in the treatment of schizophrenia." | 5.10 | Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. ( Allan, E; Bingham, S; Campbell, EC; Caroff, S; Collins, J; Corwin, J; Davis, L; Douyon, R; Dunn, L; Evans, D; Frecska, E; Grabowski, J; Graeber, D; Herz, L; Kwon, K; Lawson, W; Leslie, D; Liu-Mares, W; Mena, F; Perlick, D; Rosenheck, R; Sheikh, J; Smelson, D; Smith-Gamble, V; Warren, S, 2003) |
| "We conducted a prospective, controlled, open study comparing body weight, fat mass, and indices of insulin resistance/ sensitivity in 10 olanzapine-treated patients with ICD-10 schizophrenia (olanzapine dose range, 7." | 5.10 | Olanzapine induces insulin resistance: results from a prospective study. ( Ebenbichler, CF; Eder, U; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Laimer, M; Lechleitner, M; Mangweth, B; Patsch, JR; Weiss, E, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "The authors investigated the clinical effects of D-cycloserine when added to treatment with conventional neuroleptics, olanzapine, or risperidone for treatment-resistant schizophrenia." | 5.10 | Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. ( Ermilov, M; Heresco-Levy, U; Javitt, DC; Shapira, B; Shimoni, J; Silipo, G, 2002) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 5.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "To more clearly clarify the efficacy of the atypical antipsychotics compared to conventional antipsychotics, we add data on the outcome of patients diagnosed with schizophrenia from two large, international clinical trials comparing olanzapine with haloperidol (n = 1996) and olanzapine with risperidone (n = 339)." | 5.10 | Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. ( Berg, PH; Glick, ID, 2002) |
| "An intramuscular (IM) formulation of olanzapine has been developed because there are no rapid-acting IM atypical antipsychotic drugs currently available in the United States for treating acute agitation in patients with schizophrenia." | 5.10 | A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. ( Birkett, M; Breier, A; Brook, S; David, S; Dossenbach, M; Ferchland, I; Kiesler, G; Meehan, K; Palmer, R; Sutton, V; Taylor, CC; Wright, P, 2002) |
| "This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction." | 5.10 | Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. ( Bahk, WM; Chae, JH; Dickson, RA; Jun, TY; Kim, DJ; Kim, KS; Pae, CU, 2002) |
| "Newer antipsychotic drugs have shown promise in ameliorating neurocognitive deficits in patients with schizophrenia, but few studies have compared newer antipsychotic drugs with both clozapine and conventional agents, particularly in patients who have had suboptimal response to prior treatments." | 5.10 | Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. ( Bilder, RM; Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Goldman, RS; Hoptman, M; Horowitz, TL; Kunz, M; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2002) |
| "The authors studied weight gain mechanisms and energy balance in patients treated with olanzapine." | 5.10 | Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. ( Apter, A; Constantini, N; Falk, B; Frishman, S; Gothelf, D; Kairi, M; Phillip, M; Poraz, I; Singer, P; Weizman, A; Zalsman, G; Zigel, L, 2002) |
| "First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15)." | 5.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| " In this post hoc analysis of the Brief Psychiatric Rating Scale anxiety-depression cluster, olanzapine therapy was associated with a significantly greater baseline-to-end-point improvement in the cluster compared with haloperidol therapy among 1996 randomized, double-blind subjects." | 5.09 | Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? ( Sanger, TM; Tollefson, GD, 1999) |
| "We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol." | 5.09 | Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999) |
| " A 6-week, double-blind randomized multicenter trial, with a long-term extension, was conducted to evaluate the clinical efficacy and QOL of olanzapine and haloperidol in treating schizophrenia and other psychotic disorders." | 5.09 | Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. ( Beasley, CM; Ganoczy, D; Genduso, LA; Hamilton, SH; Revicki, DA, 1999) |
| "This prospective, consecutive case-series outcome investigation evaluates the effectiveness of olanzapine in 16 patients with treatment-resistant schizophrenia." | 5.09 | Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. ( Bird, DC; Dursun, SM; Flinn, J; Gardner, DM, 1999) |
| "We utilize data from a large, double-blind, randomized clinical trial of treatment for schizophrenia to compare the effect of therapy with the second generation antipsychotic olanzapine versus therapy with the conventional agent haloperidol on the perceived functioning and well-being of patients over 1 year as measured by the Medical Outcome Study Short Form (SF-36)." | 5.09 | Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. ( Dulisse, BK; Gibson, PJ; Johnstone, BM; Loosbrock, DL; Tunis, SL, 1999) |
| "The purpose of this study was to compare, from the payor perspective, the clinical and economic outcomes of olanzapine to those of haloperidol for the treatment of schizophrenia." | 5.09 | Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial. ( Edgell, ET; Genduso, LA; Hamilton, SH; Revicki, DA; Tollefson, G, 1999) |
| "Risperidone and olanzapine have each been demonstrated to be efficacious and safe in the treatment of patients with chronic schizophrenia." | 5.09 | A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. ( Andreasen, NC; Ho, BC; Miller, D; Nopoulos, P, 1999) |
| "Thirty adult patients with acute schizophrenia were included into six-week open-labelled, non-comparative trial of olanzapine with free dosing from 5 to 20 mg per day." | 5.09 | [The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia]. ( Beniashvili, AG; Morozova, MA; Zharkova, NB, 2000) |
| "Thirty-nine outpatients with schizophrenia and severe negative symptoms were assessed for the presence of the deficit syndrome and entered into a 12-week, open-label study of olanzapine." | 5.09 | Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. ( Gonzalez, V; Kopelowicz, A; Mintz, J; Tripodis, K; Zarate, R, 2000) |
| "The primary aim of this study was to compare functional outcomes between patients with schizophrenia treated with olanzapine or haloperidol in Europe." | 5.09 | Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. ( Breier, A; Edgell, ET; Hamilton, SH; Revicki, DA, 2000) |
| "This open-label clinical study was conducted for patients with schizophrenia in order to investigate the efficacy, safety and optimal dose of olanzapine." | 5.09 | Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group. ( Ishigooka, J; Miura, S; Murasaki, M, 2000) |
| "Coadministration of olanzapine, an atypical neuroleptic, with sulpiride, a selective D2 antagonist, is suggested as an efficient strategy for treating patients with resistant unremitting schizophrenia." | 5.09 | Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. ( Durst, R; Katz, G; Raskin, S; Zislin, J, 2000) |
| "This multicenter, open-label study was designed to assess the efficacy and tolerability of olanzapine in patients with chronic schizophrenia who are resistant to therapy with classic neuroleptic agents and are either not responsive to or unable to tolerate clozapine." | 5.09 | The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. ( Avnon, M; Belmaker, RH; Beuzen, JN; Elizur, A; Grundy, SL; Kratky, P; Mark, M; Munitz, H; Schneidman, M; Shoshani, D; Tollefson, GD, 2000) |
| "Two hundred nine outpatients with a DSM-IV diagnosis of schizophrenia or schizo-affective disorder who were clinically stable while being treated with a conventional antipsychotic drug or risperidone were openly randomly assigned to either abrupt or gradual discontinuation of their prior antipsychotic drug." | 5.09 | Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. ( Basson, BR; Gilmore, JA; Kinon, BJ; Malcolm, S; Stauffer, VL, 2000) |
| "Olanzapine is an atypical antipsychotic that is effective in the treatment of schizophrenia." | 5.09 | Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. ( Beasley, C; Lund, BC; Perry, PJ; Sanger, T, 2001) |
| "Clozapine is an atypical antipsychotic indicated for the management of severely ill patients with schizophrenia who have failed to respond adequately to standard drug treatment." | 5.09 | Switching clozapine responders to olanzapine. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Littrell, SH; Peabody, CD, 2000) |
| "To compare the clinical and economic outcomes associated with olanzapine and risperidone treatment for schizophrenia." | 5.09 | Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. ( Andersen, SW; Breier, A; Dulisse, B; Edgell, ET; Johnstone, BM; Revicki, D, 2000) |
| "This multicenter, open-label study evaluated the efficacy and safety of olanzapine in patients with schizophrenia who had been nonresponsive or intolerant to a course of risperidone (mean duration of risperidone treatment = 46." | 5.09 | Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. ( Belmaker, RH; Dossenbach, MR; Grundy, SL; Kratky, P; Metcalfe, S; Schneidman, M; Tollefson, GD, 2001) |
| "Previously, a double-blind, 6-week, parallel-group trial compared the therapeutic profiles of olanzapine (5-20 mg/day; N = 1,336) and haloperidol (5-20 mg/day; N = 660) in 1996 patients with DSM-III-R schizophrenia (83." | 5.09 | Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. ( Crawford, AM; Gomez, JC, 2001) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 5.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "Results of these analyses suggest that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute to QTc prolongation resulting in potentially fatal ventricular arrhythmias." | 5.09 | Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. ( Beasley, CM; Berg, PH; Czekalla, J; Dellva, MA; Grundy, S, 2001) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 5.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "The authors evaluated the comparative efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular placebo for the treatment of acute agitation in schizophrenia." | 5.09 | Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. ( Alaka, KJ; Bernardo, M; Birkett, M; Bradley, P; Breier, A; David, SR; Ferchland, I; Krueger, J; Meehan, K; Reinstein, M; San, L; Saunders, JC; Wright, P, 2001) |
| "This first clinical study of olanzapine in Japanese patients with schizophrenia was conducted to investigate the efficacy and safety of olanzapine." | 5.09 | Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan. ( Ishigooka, J; Miura, S; Murasaki, M, 2001) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 5.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| " Patients with schizophrenia and related disorders (ICD-10) who were taking haloperidol (N = 94; mean dose = 12." | 5.09 | Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. ( Alvarez, N; Costa e Silva, JA; Cousins, L; Gattaz, WF; Larach, V; Mazzotti, G; Oliva, D; Ospina, J; Starkstein, S; Taylor, CC; Tohen, M; Tran, PV; Wang, J, 2001) |
| ", who received at least 6 weeks of add-on olanzapine treatment for psychotic mood disorders (schizoaffective disorders [bipolar and depressive type], bipolar disorders [I, II, and NOS], and major depressive disorder)." | 5.09 | Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. ( Grace, JJ; Narendran, R; Pato, MT; Pristach, CA; Valenti, AM; Young, CM, 2001) |
| "The goal of this study was to explore the pathophysiology of weight gain during treatment with olanzapine for schizophrenia." | 5.09 | Association of olanzapine-induced weight gain with an increase in body fat. ( Ebenbichler, C; Eder, U; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Lechleitner, M; Mangweth, B; Weiss, E, 2001) |
| "Twenty patients with schizophrenia (according to DSM-III-R criteria) treated with either clozapine (200-500 mg/day) or olanzapine (10-20 mg/day) as well as ten matched controls underwent simultaneous recordings of the skin conductance response (SCR) of sweat glands and of the inspiratory gasp response (IGR) of acral blood vessels." | 5.09 | Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine. ( Acker, J; Agelink, MW; Mueck-Weymann, M, 2001) |
| "A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial." | 5.09 | Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, J; Sheitman, B; Volavka, J, 2001) |
| "The objective of this study was to evaluate the efficacy and safety of olanzapine in patients with schizophrenia and comorbid substance abuse disorders." | 5.09 | Olanzapine treatment for patients with schizophrenia and substance abuse. ( Hilligoss, NM; Johnson, CG; Littrell, KH; Peabody, CD; Petty, RG, 2001) |
| "5 mg/day [Olz-H]) to a dosage range of haloperidol (15 +/- 5 mg/day [Hal]) and to placebo in the treatment of 335 patients who met the DSM-III-R criteria for schizophrenia." | 5.08 | Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. ( Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P, 1996) |
| "0 mg/day) and with a dose range of haloperidol (15 +/- 5 mg/day) in the treatment of 431 patients with schizophrenia." | 5.08 | Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. ( Beasley, CM; Beuzen, JN; Blin, O; Crawford, AM; Dellva, MA; Hamilton, SH; Tollefson, GD; Tran, PV, 1997) |
| "Data were analyzed from three actively controlled and blind long-term responder studies of subjects meeting DSM-III-R criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 707, up to 20 mg/day, 237 median days of exposure) or haloperidol (N = 197, up to 20 mg/day, 203 median days of exposure) who did not have evidence of tardive dyskinesia at baseline." | 5.08 | Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. ( Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV, 1997) |
| "Two studies compared the efficacy of standard-dose oral olanzapine (5 to 15 mg a day) with placebo and with ineffective-dose olanzapine (1 mg a day) in maintenance therapy of schizophrenia." | 5.08 | Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, P; Wentley, AL, 1997) |
| "This double-blind study evaluated the impact of treatment with olanzapine compared with haloperidol, and placebo on improvements in symptomatology and quality of life in patients with a DSM-III-R diagnosis of schizophrenia." | 5.08 | Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. ( Beasley, CM; Genduso, LA; Hamilton, SH; Revicki, DA, 1998) |
| "This was a 17-country investigation of 1996 patients with schizophrenia or a related diagnosis randomly assigned to a blinded, comparative trial of the novel antipsychotic agent olanzapine (5-20 mg/d) or the conventional D2 antagonist haloperidol (5-20 mg/d)." | 5.08 | Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. ( Lu, Y; Sanger, TM; Thieme, ME; Tollefson, GD, 1998) |
| "These data provide preliminary evidence for the efficacy of olanzapine for some children and adolescents with treatment-refractory schizophrenia, but they also suggest the need for a more rigorous double-blind comparison of these two atypical antipsychotics." | 5.08 | Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. ( Bedwell, J; Frazier, JA; Hamburger, S; Jacobsen, LK; Karp, BI; Kumra, S; Lee, P; Lenane, M; Malanga, CJ; Rapoport, JL; Smith, AK, 1998) |
| "The effects of the availability of risperidone and olanzapine on the indications for which clozapine is prescribed (treatment-resistance, treatment-intolerance, and/or negative symptoms) were examined for 252 patients with schizophrenia who began treatment at our hospital between June 1990 and June 1997." | 5.08 | The effects of risperidone and olanzapine on the indications for clozapine. ( Brar, JS; Ganguli, R, 1998) |
| "In a 6-week placebo- and haloperidol (HAL)-controlled trial with 335 randomized subjects with chronic schizophrenia in an acute exacerbation, three fixed dose ranges of OLZ (5, 10, or 15 +/- 2." | 5.08 | A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. ( Beasley, CM; Sanger, TM; Tollefson, GD; Tran, PV, 1998) |
| "The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia." | 5.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| "Olanzapine is a new atypical antipsychotic recently introduced for the treatment of schizophrenia." | 5.08 | 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. ( DaSilva, J; Houle, S; Jones, C; Kapur, S; Remington, G; Wilson, AA; Zipursky, RB, 1998) |
| "To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses." | 4.82 | Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2003) |
| "In schizophrenia, comparing treatment dropouts between olanzapine and risperidone can be useful to better understand their relative effectiveness." | 4.82 | Clinical trial response and dropout rates with olanzapine versus risperidone. ( Messori, A; Santarlasci, B, 2003) |
| "The frequency and severity of extrapyramidal syndrome (EPS) were evaluated in patients with DSM-III or DSM-IV schizophrenia in the acute phase (- 8 weeks) of randomized, double-blind, controlled trials from the integrated olanzapine clinical trial database." | 4.82 | An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. ( Beasley, CM; Berg, PH; Carlson, CD; Cavazzoni, PA; Kane, JM; Wei, H, 2003) |
| " ziprasidone and olanzapine for treating acute agitation in patients with schizophrenia are described, along with factors to consider when evaluating the cost-effectiveness of these agents." | 4.81 | Continuum of care: stabilizing the acutely agitated patient. ( Bellnier, TJ, 2002) |
| "Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia." | 4.81 | Olanzapine: an updated review of its use in the management of schizophrenia. ( Bhana, N; Foster, RH; Olney, R; Plosker, GL, 2001) |
| " The present article reviews important differences among antipsychotic drugs in the potential for, and occurrence of, serious adverse cardiac outcomes and suggests that olanzapine, as therapeutically administered to patients with schizophrenia and related psychoses, does not contribute significantly to a QTc prolongation that could result in potentially fatal ventricular arrhythmias." | 4.81 | Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. ( Beasley, CM; Czekalla, J; Kollack-Walker, S, 2001) |
| " Weight gain has become an issue recently as a result of reports that 2 of the atypical antipsychotic agents, clozapine and olanzapine, are associated with a higher risk than other drugs of causing excessive weight gain." | 4.81 | Review of atypical antipsychotics and weight gain. ( Sussman, N, 2001) |
| " Ziprasidone, a recently launched agent, is available in tablet form for schizophrenia/schizoaffective disorder, psychotic depression and mania." | 4.81 | Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. ( Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP, 2002) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "The most convincing evidence of the efficacy of atypical neuroleptics in children and adolescents concerns clozapine in the treatment of schizophrenia." | 4.80 | Use of atypical neuroleptics in child and adolescent psychiatry. ( Laor, N; Toren, P; Weizman, A, 1998) |
| "The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics." | 4.80 | Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. ( Abraham, D; Kissling, W; Leucht, S; Pitschel-Walz, G, 1999) |
| "Olanzapine, an atypical antipsychotic, has a broad receptor binding profile, which may account for its pharmacological effects in schizophrenia." | 4.80 | Olanzapine: a basic science update. ( Bymaster, F; Calligaro, DO; Moore, NA; Nelson, DL; Perry, KW; Rasmussen, K; Wong, DT, 1999) |
| "Three atypical antipsychotics are currently considered to be first-line therapies for schizophrenia, namely risperidone, olanzapine, and quetiapine." | 4.80 | Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. ( Stahl, SM, 1999) |
| "The introduction of the atypical antipsychotics clozapine, risperidone, olanzapine, quetiapine and sertindole for the treatment of schizophrenia has coincided with an increased awareness of the potential of drug-drug interactions, particularly involving the cytochrome P450 (CYP) enzymes." | 4.80 | Drug metabolism and atypical antipsychotics. ( Baker, GB; Chue, PS; Prior, TI; Tibbo, P, 1999) |
| " Olanzapine shows a superior and broader spectrum of efficacy in the treatment of schizophrenia, particularly its negative symptoms, with a substantially more favorable safety profile than conventional antipsychotic agents (e." | 4.80 | [Clinical efficacy of olanzapine]. ( Yui, K, 1999) |
| "The high acquisition cost of olanzapine is offset by reductions in other treatment costs in patients with schizophrenia." | 4.80 | Olanzapine. A pharmacoeconomic review of its use in schizophrenia. ( Foster, RH; Goa, KL, 1999) |
| "To determine the clinical effects and safety of olanzapine as compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and schizophreniform psychoses." | 4.80 | Olanzapine for schizophrenia. ( Dardennes, RM; Duggan, L; El-Dosoky, A; Fenton, M; Indran, S, 2000) |
| " Risperidone is associated with relatively few motor side effects compared with the traditional antipsychotics, and weight gain is less likely with risperidone than with either clozapine or olanzapine." | 4.80 | Risperidone side effects. ( Conley, RR, 2000) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| "Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics." | 4.80 | Risperidone versus other atypical antipsychotic medication for schizophrenia. ( Bagnall, AM; Duggan, L; Gilbody, SM; Tuunainen, A, 2000) |
| "The effects of olanzapine, risperidone, and haloperidol on PRL were assessed in patients with schizophrenia or related psychoses participating in 3 double-blind clinical trials: (1) a 6-week acute trial comparing olanzapine 5 to 20 mg/d (n = 1,336) and haloperidol 5 to 20 mg/d (n = 660), with a 1-year, open-label olanzapine extension for responders; (2) a 54-week study comparing olanzapine 5 to 20 mg/d (n = 21), risperidone 4 to 10 mg/d (n = 21), and haloperidol 5 to 20 mg/d (n = 23) in early illness; and (3) a 28-week study comparing olanzapine 10 to 20 mg/d (n = 172) and risperidone 4 to 12 mg/d (n = 167)." | 4.80 | The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. ( Breier, A; David, SR; Kinon, BJ; Taylor, CC, 2000) |
| "Olanzapine is a thienobenzodiazepine derivative which displays efficacy in patients with schizophrenia and related psychoses." | 4.79 | Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. ( Fulton, B; Goa, KL, 1997) |
| "Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychotic agent, are summarized." | 4.79 | Safety of olanzapine. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| " This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays." | 4.79 | Olanzapine and the new generation of antipsychotic agents: patterns of use. ( Glazer, WM, 1997) |
| " Efficacy in treating overall psychopathology in acute schizophrenia as measured by the BPRS0-6 total score was demonstrated at 10 mg/day versus placebo; at doses in a 5-20 mg/day range, olanzapine was comparable or superior to haloperidol." | 4.79 | Dosing the antipsychotic medication olanzapine. ( Nemeroff, CB, 1997) |
| "To review the pharmacology, pharmacokinetics, efficacy data, and adverse effects of olanzapine as a treatment for schizophrenia and to determine the advantages and disadvantages of this atypical antipsychotic agent compared with currently marketed agents." | 4.79 | Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. ( Green, AI; Kando, JC; Patel, JK; Reams, SG; Satterlee, W; Shepski, JC, 1997) |
| "The unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the US Food and Drug Administration for treatment of refractory schizophrenia." | 4.79 | New antipsychotic medications: strategies for evaluation and selected findings. ( Schooler, NR, 1997) |
| "This therapeutic drug monitoring (TDM) study aimed to determine the role of olanzapine (OLZ) and N-desmethyl-OLZ (DMO) levels in the therapeutic efficacy of OLZ in patients with schizophrenia." | 3.83 | Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia. ( Chen, CH; Chen, YH; Kuo, PT; Lin, CH; Lu, ML; Wu, TH; Wu, YX, 2016) |
| "Having separated a sub-group of people with schizophrenia based on a marked loss of cortical [(3)H]pirenzepine binding (MRDS); we wished to determine if MRDS had lower levels of [(3)H]pirenzepine and other muscarinic receptor antagonist binding to the striatum and if this was due to loss of pre- or post-synaptic neurons or glia measured using surrogate markers (25 kilodalton synaptosomal-associated protein (SNAP 25), postsynaptic density protein 95 (PSD 95), glial fibrillary acidic protein (GFAP) 41/43) of cell number." | 3.81 | Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia. ( Chen, WJ; Dean, B; Lai, CY; Scarr, E; Thomas, N, 2015) |
| "These studies were undertaken to investigate the selectivity of cortical muscarinic receptor radioligand binding in muscarinic M(1) and M(4) receptor knockout mice and to determine whether a marked decrease in [(3)H]pirenzepine binding in Brodmann's area (BA) 9 from a subset of people with schizophrenia was predictive of decreased muscarinic receptors in other central nervous system (CNS) regions." | 3.79 | Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. ( Boer, S; Dean, B; Felder, C; Gibbons, AS; Jeon, WJ; Money, T; Scarr, E, 2013) |
| "Having shown a decrease in [3H]pirenzepine binding in the hippocampus from subjects with schizophrenia, we wished to determine whether such a change in radioligand binding was associated with changes in hippocampal mRNA for the muscarinic1 (M1) and muscarinic4 (M4) receptors in tissue from different cohorts of subjects." | 3.74 | Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. ( Dean, B; Keriakous, D; Scarr, E; Sundram, S, 2007) |
| "We have previously shown a decrease in [(3)H]pirenzepine binding to M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia but not in major depression or bipolar disorder." | 3.73 | M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. ( Huang, XF; Katsifis, A; Yu, Y; Zavitsanou, K, 2005) |
| "Risperidone and olanzapine-administration data were collected for schizophrenia patients treated at four Taiwanese medical centres." | 3.72 | Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. ( Chiu, NY; Hsiao, MC; Liao, O; Liu, CY; Wu, CK; Yuan, LM, 2003) |
| "Premarketing trials of olanzapine reported an incidence of peripheral oedema of 3%." | 3.72 | Peripheral oedema in patients taking olanzapine. ( Ng, B; Postlethwaite, A; Rollnik, J, 2003) |
| "The objective of the European Schizophrenia Outpatient Health Outcomes (SOHO) study is to understand the comparative costs and outcomes of antipsychotic drug treatment, with specific focus on olanzapine." | 3.72 | The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. ( Alonso, J; Edgell, ET; Gavart, S; Gregor, KJ; Haro, JM; Jones, PB; Knapp, M; Wright, P, 2003) |
| "Factors that influenced the risk of hyperprolactinemia included gender, with females appearing to be more sensitive than males, and drug treatment, with risperidone and conventional antipsychotic agents increasing prolactin more than olanzapine." | 3.72 | Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. ( Gilmore, JA; Halbreich, UM; Kinon, BJ; Liu, H, 2003) |
| "Texas Medicaid claims were retrieved for persons aged 21-65 years, diagnosed with schizophrenia or schizoaffective disorder, after initiating treatment with olanzapine (n = 1875), risperidone (n = 982), or haloperidol (n = 726) between January 1997 and August 1998." | 3.72 | Role of ethnicity in predicting antipsychotic medication adherence. ( Brown, CM; Gibson, PJ; Opolka, JL; Rascati, KL, 2003) |
| "This study evaluated costs associated with risperidone and olanzapine treatment for schizophrenia." | 3.72 | Cost evaluation of risperidone compared with olanzapine. ( Brooks, D; Byerly, MJ; Casey, SB; Elliot, S; Hawkins, J; Weber, M, 2003) |
| " Because reduced glutamatergic function represents a major feature of schizophrenia, we investigated the effects of the concomitant administration of haloperidol or olanzapine with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 on BDNF expression." | 3.72 | Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. ( Bedogni, F; Fossati, C; Fumagalli, F; Gennarelli, M; Molteni, R; Racagni, G; Riva, MA; Roceri, M; Santero, R, 2003) |
| "The study population comprised 56 patients with DSM-IV schizophrenia, who were divided into 4 treatment groups: quetiapine (N = 14), olanzapine (N = 14), risperidone (N = 14), or clozapine (N = 14) monotherapy, and a control group of 11 patients receiving no psychopharmacologic treatment." | 3.72 | Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| " Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS-UK) program consisted of a retrospective review of medical notes and prescription charts for 501 patients with schizophrenia or schizoaffective disorder who had been admitted to the hospital for the treatment of psychosis." | 3.72 | Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. ( Libretto, SE; Taylor, DM; Wright, T, 2003) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 3.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "To examine both schizophrenia-related costs and total (schizophrenia plus non-schizophrenia) healthcare costs among Texas Medicaid recipients who had been diagnosed with a schizophrenic disorder and had been initiated on olanzapine or risperidone." | 3.72 | Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. ( Barber, BL; Crismon, ML; Johnsrud, MT; Lage, MJ; Rascati, KL, 2003) |
| " The patient was previously treated with olanzapine and developed priapism, which required emergency medical treatment." | 3.72 | Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. ( Weisman, RL, 2003) |
| "Since their introduction to the US market, atypical antipsychotic drugs, such as olanzapine, have been widely prescribed for the management of psychosis and have increasingly been used in dermatologic settings for the treatment of psychogenic dermatoses." | 3.72 | Eruptive xanthomas associated with olanzapine use. ( Chang, HY; Hughes, E; Kimball, AB; Oro, AE; Ridky, TW, 2003) |
| "In a cross-sectional study, consecutive premenopausal, female, DSM-IV schizophrenia patients who were treated with either risperidone (N = 12) or olanzapine (N = 14) for at least 2 years were included." | 3.72 | Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. ( Becker, D; Liver, O; Mester, R; Rapoport, M; Weiss, M; Weizman, A, 2003) |
| "Since the prefrontal cortex (PFC) is thought to play an important role in depression and schizophrenia, we studied the effects of fluoxetine and olanzapine on PFC neurons in rats using extracellular, in vivo recordings." | 3.72 | Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. ( Gronier, BS; Rasmussen, K, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 3.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "Ten of 20 stable patients with schizophrenia or schizoaffective disorder who were treated with olanzapine for at least 4 weeks had the opportunity to receive access to a Young Men's Christian Association (YMCA) fitness facility, based on random allocation." | 3.72 | Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients. ( Archie, S; Hobbs, H; McNiven, J; Osborne, S; Wilson, JH, 2003) |
| "Olanzapine is an atypical antipsychotic effective in the treatment of schizophrenia." | 3.72 | Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. ( Ahmad, F; Bulsara, MK; Castle, DJ; Dusci, LJ; Fellows, L; Ilett, KF, 2003) |
| "Twenty-four patients taking daily doses of olanzapine of 20, 25, 30, and 40 mg for DSM-IV schizophrenia or schizoaffective disorder had serum prolactin levels measured." | 3.72 | High-dose olanzapine and prolactin levels. ( Baksh, A; Karagianis, JL, 2003) |
| "Most antipsychotic drugs act equivalently and potently on the symptoms of schizophrenia, with clozapine as the notable exception." | 3.72 | Similarities and differences among antipsychotics. ( Tamminga, CA, 2003) |
| "Patients with a Diagnostic and Statistical Manual of Mental Disorders (third edition, revised) diagnosis of schizophrenia or psychotic disorder not otherwise specified with onset of psychosis before the age of 13 participated in 6- to 8-week open or double-blind trials of haloperidol (n = 15, mean dose 15." | 3.71 | Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. ( Alfaro, CL; Gochman, P; Lenane, M; Nicolson, R; Rapoport, JL; Sporn, A; Wudarsky, M, 2002) |
| "This pilot study investigates the dissolution profile, tolerability, and acceptability of an orally disintegrating olanzapine tablet in patients with schizophrenia." | 3.71 | Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. ( Chue, P; Dickson, R; Jones, B; Taylor, CC, 2002) |
| "To test the hypothesis that muscarinic receptors are involved in the pathology of schizophrenia, we measured muscarinic(1) (M1R) and muscarinic(4)(M4R) protein and mRNA as well as [(3)H]pirenzepine binding in Brodmann's areas (BA) 9 and 40 obtained postmortem from 20 schizophrenic and 20 age/sex-matched control subjects." | 3.71 | Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. ( Dean, B; Keriakous, D; McKenzie, J; McLeod, M; Scarr, E, 2002) |
| "By using Israel's National Psychiatric Hospitalization Case Registry, rehospitalization status was monitored for all patients with schizophrenia who were discharged from any inpatient psychiatric facility in Israel while taking risperidone (N=268) or olanzapine (N=313) between Jan." | 3.71 | Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. ( Davidson, M; Kaplan, Z; Lichtenberg, P; Mark, M; Nahon, D; Rabinowitz, J, 2001) |
| "Conventional as well as newer antipsychotics cause weight gain, and, in the regulation of body weight, both insulin and leptin are hormones involved." | 3.71 | Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents. ( Hulting, AL; Melkersson, KI, 2001) |
| "This study compared the discharge rates and drug costs of 789 patients with schizophrenia or schizoaffective disorder who began pharmacotherapy with olanzapine or risperidone between July 1997 and June 1998." | 3.71 | Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. ( Conley, RR; Kelly, DL; Love, RC; Nelson, MW; Yu, Y, 2001) |
| "To report two cases of new-onset diabetes mellitus resulting after the initiation of olanzapine treatment." | 3.71 | Olanzapine-induced diabetes mellitus. ( Bonanno, DG; Botts, SR; Davydov, L, 2001) |
| " In order to determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine." | 3.71 | Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. ( Ayrton, Z; Brar, JS; Ganguli, R, 2001) |
| "Using quantitative autoradiography, the authors analyzed the binding of the M(1)/M(4) receptor selective antagonist [(3)H]pirenzepine in prefrontal cortex (Brodmann's areas 8, 9, 10, and 46) from schizophrenia patients who had (N=6) or had not (N=11) been treated with the anticholinergic agent benztropine mesylate and from normal comparison subjects (N=20)." | 3.71 | Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. ( Copolov, DL; Crook, JM; Dean, B; Tomaskovic-Crook, E, 2001) |
| "This study evaluated the effectiveness of a Weight Watchers program for patients with schizophrenia who had olanzapine-related weight gain and ascertained whether the severity of patients' psychiatric symptoms was correlated with the patients' success in losing weight." | 3.71 | A program for treating olanzapine-related weight gain. ( Ball, MP; Buchanan, RW; Coons, VB, 2001) |
| "The Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme was an international series of naturalistic studies designed to evaluate drug use patterns and outcomes." | 3.71 | Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. ( Duchesne, I; Kasper, S; Rosillon, D, 2001) |
| "We report the health economic data from the Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme." | 3.71 | Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. ( Duchesne, I; Jones, M; Kasper, S, 2001) |
| "To obtain an in vivo measurement of muscarinic receptor occupancy by olanzapine compared with risperidone in patients with schizophrenia stabilised on medication." | 3.71 | Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. ( Booij, J; Lavalaye, J; Linszen, DH; Reneman, L; van Royen, EA, 2001) |
| "The role of olanzapine in treatment-resistant schizophrenia is still unresolved." | 3.71 | Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. ( Chakos, M; Citrome, L; Czobor, P; Iskander, A; Lieberman, J; Lindenmayer, JP; Parker, B; Sheitman, B; Volavka, J, 2001) |
| "One of my patients is taking olanzapine for schizophrenia." | 3.71 | Maternal obesity and risk of neural tube defects. ( Koren, G, 2001) |
| "Olanzapine is a relatively new antipsychotic drug used in the United States for the treatment of schizophrenia." | 3.71 | Tissue distribution of olanzapine in a postmortem case. ( Felo, JA; Jenkins, AJ; Merrick, TC, 2001) |
| "Both acute and chronic administration of N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine and dizocilpine have been proposed to mimic some of the symptoms of schizophrenia." | 3.71 | Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. ( Johnson, KM; McInnis, J; Ross-Sanchez, M; Shinnick-Gallagher, P; Wang, C; Wiley, JL, 2001) |
| "Olanzapine is an 'atypical' antipsychotic indicated for the treatment of schizophrenia." | 3.71 | The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. ( Biswasl, PN; Freemantle, S; Pearcel, GL; Shakir, SA; Wilton, LV, 2001) |
| "Prolactin levels in 18 male patients with schizophrenia who were receiving atypical antipsychotics were monitored over the 24-hour period following administration of their daily oral dose of risperidone, olanzapine, or clozapine." | 3.71 | Elevation of prolactin levels by atypical antipsychotics. ( Flint, AJ; Kapur, S; Seeman, MV; Turrone, P, 2002) |
| "Clozapine was reserved for more severe forms of schizophrenia, but its cost impact was relatively low." | 3.71 | Service use and costs of treating schizophrenia with atypical antipsychotics. ( Frangou, S; Lewis, M; McCrone, P, 2001) |
| "This retrospective study evaluates drug treatment patterns and economic outcomes of olanzapine in comparison with risperidone in the treatment of schizophrenia in usual practice." | 3.71 | A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. ( Zhao, Z, 2002) |
| "Glutamate concentrations were measured in serum and were estimated (Glx/Cr) in cingulate cortex by proton magnetic resonance spectroscopy (MRS) in schizophrenia patients while they were being treated with conventional neuroleptics and then 8 weeks after switching to olanzapine." | 3.71 | Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. ( Evins, AE; Goff, DC; Hennen, J; Lyoo, IK; Renshaw, PF; Tsai, G; Wald, LL; Yurgelun-Todd, DA, 2002) |
| " Patients with schizophrenia according to DSM-IV treated with olanzapine (n =10) or haloperidol (n=10) were compared to healthy controls (n =10) and untreated patients (n=10)." | 3.71 | Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study. ( Klein, HE; Müller, JL; Röder, C; Schuierer, G, 2002) |
| "The authors studied the efficacy of olanzapine and risperidone among patients with treatment-refractory schizophrenia who had been hospitalized for more than five years and who were not suitable candidates for a clozapine trial." | 3.71 | Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients. ( Bopp, JH; Daniels, A; Dinakar, HS; Mauro, S; Sobel, RN, 2002) |
| "Two cases of light-headedness or 'fainting' in patients with schizophrenia treated with olanzapine are presented." | 3.71 | A possible association between high normal and high dose olanzapine and prolongation of the PR interval. ( Kosky, N, 2002) |
| "The authors compared the changes in health care utilization and costs between a group of patients with schizophrenia who started treatment with risperidone and a group that started treatment with olanzapine." | 3.71 | Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. ( Durkin, MB; Fuller, MA; Laich, JS; Secic, M; Shermock, KM, 2002) |
| " The plasma concentrations of the atypical antipsychotics clozapine and olanzapine correlated with parameters of HRV in 59 patients suffering from schizophrenia or schizoaffective disorder." | 3.71 | Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine? ( Bartels, M; Eschweiler, GW; Gaertner, I; Längle, G; Nickola, M; Wild, B, 2002) |
| "In the second of this series of updates on recent advances in medication, RICHARD GRAY summarises trials into the novel antipsychotic olanzapine, which has been shown to compare well to haloperidol, and is now widely used for treating schizophrenia and related psychoses." | 3.70 | Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia. ( Gray, R, 1998) |
| "Three studies compared olanzapine and haloperidol given orally in maintenance therapy for schizophrenia and related psychoses." | 3.70 | Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. ( Beasley, CM; Dellva, MA; Tollefson, GD; Tran, PV; Wentley, AL, 1998) |
| "Forty-four patients with schizophrenia (16 taking risperidone, 2-12 mg/day; 17 taking olanzapine, 5-60 mg/day; and 11 taking clozapine, 75-900 mg/day) had their D2 and 5-HT2 occupancies determined with the use of [11C]raclopride and [18F]setoperone, respectively, and positron emission tomography imaging." | 3.70 | Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. ( Kapur, S; Remington, G; Zipursky, RB, 1999) |
| "How to best treat psychotic patients who have had past clozapine-induced agranulocytosis or granulocytopenia remains a problem." | 3.70 | Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients. ( Ananth, J; Arai, Y; Burgoyne, KS; Gadasally, R; Smith, MW; Swartz, JR, 1999) |
| "A model was developed to estimate the medical costs and effectiveness outcomes of three antipsychotic treatments (olanzapine, haloperidol, and risperidone) for patients with schizophrenia." | 3.70 | A cost-effectiveness clinical decision analysis model for schizophrenia. ( Brown, RE; Genduso, LA; Hamilton, SH; Palmer, CS; Revicki, DA, 1998) |
| "day-1), carbamazepine, levomepromazine and alprazolan, a severe shock with bradycardia (HR: 40 b." | 3.70 | [Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon]. ( Joye, F; Marion, F; Michoux, I; Orrillard, M; Parisot, R, 1999) |
| "Olanzapine (Zyprexa), a neuroleptic, has obtained marketing authorization for treatment of schizophrenia." | 3.70 | Olanzapine. Keep an eye on this neuroleptic. ( , 2000) |
| "P50 suppression of 13 patients with schizophrenia receiving clinically effective doses of clozapine, olanzapine, or risperidone (classified as atypical antipsychotic medications) was compared to that of 13 patients receiving conventional antipsychotic medications." | 3.70 | Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. ( Braff, DL; Cadenhead, KS; Clementz, BA; Geyer, MA; Light, GA, 2000) |
| "The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia." | 3.70 | Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. ( Booij, J; de Haan, L; Dingemans, PM; Lavalaye, J; Linszen, D, 2000) |
| "The objectives of this study were to determine the doses of olanzapine (OLZ), risperidone (RIS), and haloperidol (HAL) used in clinical practice in outpatients with schizophrenia and the rates of occurrence of extrapyramidal symptoms (EPS) and other adverse events, clinical response, and use of concomitant medications." | 3.70 | Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. ( Gómez, JC; Gregor, KJ; Montejo, AL; Sacristán, JA; Vieta, E, 2000) |
| "To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia." | 3.70 | Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. ( Almond, S; O'Donnell, O, 2000) |
| " We present three cases in which olanzapine caused a significant exacerbation of obsessive-compulsive symptoms in schizophrenia (two cases) and obsessive-compulsive disorder (one case)." | 3.70 | Olanzapine and obsessive-compulsive symptoms. ( Gournellis, R; Lykouras, L; Malliori, M; Rabavilas, A; Zervas, IM, 2000) |
| "To date only five reports of neuroleptic malignant syndrome (NMS) related to olanzapine exist." | 3.70 | Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. ( Järventausta, K; Leinonen, E, 2000) |
| "We present the case of a 42-year-old male with a history of schizophrenia who developed signs and symptoms consistent with Neuroleptic Malignant Syndrome (NMS) after 3 weeks of treatment with Olanzapine." | 3.70 | Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. ( Privette, T; Stanfield, SC, 2000) |
| "Fourteen patients on treatment with olanzapine (all meeting DSM-IV criteria for schizophrenia or related psychoses) were studied." | 3.70 | Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. ( Brismar, KE; Hulting, AL; Melkersson, KI, 2000) |
| "Olanzapine has been shown to be better tolerated in comparison with conventional antipsychotics in a large unselected sample of acutely psychotic schizophrenic in-patients." | 2.71 | Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. ( Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M; Sacristán, JA, 2003) |
| " Treatment with divalproex in combination with an atypical antipsychotic agent resulted in earlier improvements in a range of psychotic symptoms among acutely hospitalized patients with schizophrenia." | 2.71 | Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. ( Casey, DE; Daniel, DG; Sommerville, KW; Tracy, KA; Wassef, AA; Wozniak, P, 2003) |
| "Olanzapine is an atypical antipsychotic that has efficacy in adults with psychotic disorders." | 2.71 | A prospective, open-label trial of olanzapine in adolescents with schizophrenia. ( Branicky, LA; Demeter, CA; Findling, RL; McNamara, NK; Schulz, SC; Youngstrom, EA, 2003) |
| " Seventeen psychiatric patients (9 men and 8 women) were orally administered olanzapine, at a mean +/- standard deviation (SD) dosage of 10 mg/d for all smokers (n = 8) and 7." | 2.71 | Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. ( Benítez, J; Carrillo, JA; Gervasini, G; Herráiz, AG; Ramos, SI; Vizcaíno, S, 2003) |
| " The patients were treated with conventional antipsychotics for seven days after admission and were then randomised to the treatment arms with risperidone (4 mg/day) or with olanzapine (10 mg/day) at a fixed dosage in the first week and thereafter in flexible dosages for the remaining seven weeks." | 2.71 | Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. ( Kores Plesnicar, B; Krajnc, I; Tomori, M; Zalar, B, 2003) |
| " Safety was evaluated in terms of the spontaneous adverse events reported and a specific questionnaire for extrapyramidal symptoms (EPS)." | 2.71 | Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. ( Alvarez, E; Bobes, J; Cañas, F; Carrasco, JL; Ciudad, A; Gascón, J; Gibert, J; Gómez, JC; Gutiérrez, M, 2003) |
| "Olanzapine-treated patients showed a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) total, Brief Psychiatric Rating Scale (BPRS) total, and PANSS General Psychopathology scores at endpoint compared to the risperidone-treated patients." | 2.71 | Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. ( Andersen, S; Catts, S; Crawford, AM; Fraser, A; Grainger, D; Gureje, O; Hustig, H; Keks, N; Lambert, T; McGrath, J; Miles, W; Tran, P, 2003) |
| "Olanzapine-treated patients experienced a lower rate of treatment-emergent parkinsonism and akathisia but had significantly more weight gain, compared with the haloperidol-treated patients." | 2.71 | Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. ( Green, AI; Gur, RE; Hamer, RM; Kahn, R; Lieberman, JA; McEvoy, J; Perkins, D; Sharma, T; Tohen, M; Tollefson, G; Wei, H; Zipursky, R, 2003) |
| "This was a double-blind, randomized, parallel-groups, placebo-controlled trial with fixed-flexible dosing conducted at four sites." | 2.71 | Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. ( Addington, J; Breier, A; Hawkins, KA; Lindborg, SR; Marquez, E; McGlashan, TH; Miller, TJ; Perkins, DO; Tohen, M; Woods, SW; Zipursky, RB, 2003) |
| "Historical predictors were diagnosis of schizoaffective disorder, history or current use at baseline of alcohol or substance abuse, cigarette smoking, number of lifetime suicide attempts, and the number of hospitalizations in the previous 36 months to prevent suicide." | 2.71 | Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. ( Alphs, L; Anand, R; Green, A; Hsu, C; Krishnan, KR; Meltzer, H; Potkin, SG; Young, FK, 2003) |
| " Daily dosage was subsequently adjusted between 5 and 20 mg/d based on individual clinical status." | 2.71 | A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. ( Chokka, PR; Dickson, RA; Dursun, SM; Jones, B; MacEwan, GW; Reiss, JP; Remington, GJ; Rotstein, E; Stip, E, 2003) |
| "Weight gain is an important side effect of antipsychotic (AP) treatment." | 2.71 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. ( de Castella, AR; Fitzgerald, PB; Kulkarni, J; Morris, MJ; Scaffidi, A, 2003) |
| "In schizophrenia and Parkinson's disease, cortical and subcortical motor organization is influenced by primary disease conditions and neuroleptic treatment." | 2.71 | Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study. ( Deuticke, C; Hajak, G; Müller, JL; Putzhammer, A; Röder, CH; Winkler, J, 2003) |
| "Hypersalivation is known as a frequent, disturbing, and socially stigmatizing side effect of therapy with the atypical antipsychotic clozapine." | 2.71 | Reduction of clozapine-induced hypersalivation by pirenzepine is safe. ( Fritze, J; Hiemke, C; Schneider, B; Weber, B; Weigmann, H, 2004) |
| "In olanzapine-treated patients, improvement in BPRS agitation and positive symptom scores was significantly greater at weeks 4, 5, and 6 (agitation scores, p < or = ." | 2.70 | Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. ( Hill, AL; Kinon, BJ; Milton, DR; Roychowdhury, SM, 2001) |
| "Olanzapine induced a lower striatal D2 occupancy than haloperidol." | 2.70 | Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. ( Bernardo, M; Catafau, AM; Font, M; Gómez, JC; Gutiérrez, F; Lomeña, F; López-Carrero, C; Parellada, E; Pavía, J; Salamero, M, 2001) |
| "m." | 2.70 | Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. ( Hatzimanolis, J; Lykouras, L; Markianos, M, 2001) |
| " Subjective impairment, as assessed with the subscale 'mental functioning', was significantly correlated with greater conventional neuroleptic dosage after controlling for psychopathology (P<0." | 2.70 | Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. ( Krausz, M; Moritz, S; Naber, D; Woodward, TS, 2002) |
| "Olanzapine has been reported as less likely to cause EPS and may improve some negative signs." | 2.69 | The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. ( Allan, ER; Alpert, M; Connolly, B; Crichton, J; Sison, CE, 1998) |
| "Haloperidol-treated first-episode patients experienced statistically significantly more extrapyramidal symptoms than haloperidol-treated multiple-episode patients." | 2.69 | Olanzapine versus haloperidol treatment in first-episode psychosis. ( Beasley, C; Grundy, S; Lieberman, JA; Sanger, TM; Tohen, M; Tollefson, GD, 1999) |
| "Haloperidol-treated patients showed dose-dependently (Pearson r = 0." | 2.69 | In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. ( Asenbaum, S; Barnas, C; Brücke, T; Fischer, P; Kasper, S; Küfferle, B; Pezawas, L; Tauscher, J; Tauscher-Wisniewski, S, 1999) |
| "As olanzapine is a drug with a very similar biochemical profile to clozapine, it is important to evaluate whether non-response to olanzapine predicts clozapine non-response." | 2.69 | Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. ( Conley, RR; Kelly, DL; Richardson, CM; Tamminga, CA, 1999) |
| "Olanzapine-treated patients improved in 5 of 8 domains to a significantly greater degree than did haloperidol patients." | 2.69 | Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. ( Croghan, TW; Heilman, DK; Johnstone, BM; Obenchain, RL; Tunis, SL, 1999) |
| "Psychosis is a defining feature of schizophrenia consisting of formal thought disorder, delusions, and hallucinations." | 2.69 | The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome. ( Berg, PH; Breier, A, 1999) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 2.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "Olanzapine is an effective antipsychotic medication in older adults with schizophrenia, and is associated with significant improvement in extrapyramidal side effects." | 2.69 | Olanzapine therapy in elderly patients with schizophrenia. ( Brescan, D; Perez, D; Ramirez, LF; Sajatovic, M, 1998) |
| " Safety was evaluated through the collection of spontaneous adverse events and a specific questionnaire for extrapyramidal symptoms." | 2.69 | The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. ( Antón Saiz, C; Breier, A; Fontova Carbonell, E; Gómez, JC; Hernández, J; Ruiz Carrasco, P; Sacristán, JA, 2000) |
| " The D2 receptor availability revealed an exponential dose-response relationship (r = - 0." | 2.69 | D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. ( Dresel, S; Frodl, T; Hahn, K; Mager, T; Meisenzahl, EM; Möller, HJ; Preuss, UW; Rossmüller, B; Schmitt, GJ; Tatsch, K, 2000) |
| " It does not appear to be free of adverse effects on liver function." | 2.68 | First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. ( Baldwin, DS; Montgomery, SA, 1995) |
| "Olanzapine is a potential new "atypical" antipsychotic agent." | 2.68 | Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. ( Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P, 1996) |
| "Olanzapine is an atypical antipsychotic effective in the treatment of schizophrenic patients." | 2.68 | Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. ( Beasley, C; Perry, PJ; Sanger, T, 1997) |
| "Olanzapine is a new antipsychotic drug that has shown efficacy against positive and negative symptoms of schizophrenia, with minimal extrapyramidal side effects." | 2.68 | Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. ( Alvarez, E; Cuesta, M; García-Bernardo, E; Gómez, JC; Gurpegui, M; Martín, J, 1997) |
| "Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity." | 2.42 | Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. ( Potvin, S; Roy, JY; Stip, E, 2003) |
| "Neuroleptic malignant syndrome is the rarest and the most serious of the neuroleptic induced movement disorders." | 2.42 | Olanzapine induced neuroleptic malignant syndrome--a case review. ( Kogoj, A; Velikonja, I, 2003) |
| "Olanzapine can cause NMS, mainly in susceptible or predisposed patients." | 2.41 | Olanzapine-associated neuroleptic malignant syndrome. ( Christodoulou, NG; Havaki-Kontaxaki, BJ; Kontaxakis, VP; Paplos, KG, 2002) |
| " Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings." | 2.41 | New antipsychotic medications: more than old wine and new bottles. ( Schulz, SC, 2000) |
| "Schizophrenia is also associated with aggression directed at self and others." | 2.41 | The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. ( Keck, PE; McElroy, SL; Strakowski, SM, 2000) |
| "Olanzapine is a serotonin-dopamine receptor antagonist primarily used in the treatment of psychotic illnesses." | 2.41 | Olanzapine: an atypical antipsychotic for schizophrenia. ( Lund, BC; Perry, PJ, 2000) |
| " The manuscript describes the pharmacology, efficacy and tolerability studies, adverse effects and dosing considerations in the elderly." | 2.41 | Use of olanzapine for elderly patients with psychotic disorders: a review. ( Bogunovic, O; Brenner, R; Gupta, S; Madhusoodanan, S; Sinha, S, 2001) |
| "Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepine class." | 2.40 | Efficacy of olanzapine: an overview of pivotal clinical trials. ( Beasley, CM; Tollefson, GD; Tran, PV, 1997) |
| "The advantages of newer agents in treatment-resistant schizophrenia may arise in part from their preferential targeting of newer agents in treatment-resistant schizophrenia may arise in part from their preferential targeting of mesolimbic compared with motor and tuberoinfundibular dopaminergic pathways." | 2.40 | Treatment of the refractory schizophrenic patient. ( Daniel, DG; Whitcomb, SR, 1998) |
| "For comprehensive treatment of schizophrenia, the author advocates a polydimensional approach encompassing psychopharmacology, psychotherapy, psychosocial interventions (particularly with family members), and vocational training." | 2.40 | Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia. ( Ballús, C, 1997) |
| "Olanzapine is a serotonin-dopamine-receptor antagonist indicated for use in the treatment of schizophrenia and other psychotic disorders." | 2.40 | Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. ( Bever, KA; Perry, PJ, 1998) |
| " Proper dosing has emerged as a vital factor in the effective use of these newer drugs." | 2.40 | Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. ( Kasper, S, 1998) |
| " Dosing requirements for elderly patients tend to be much lower than those for younger adults." | 2.40 | Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999) |
| " To provide the therapeutic benefits of maintenance medication without its drawbacks, intermittent dosing and long-term therapy with reduced doses of conventional medications have been explored." | 2.40 | Olanzapine in the long-term treatment of schizophrenia. ( Kane, J, 1999) |
| "Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments." | 2.40 | Review of recent clinical studies with olanzapine. ( Kuntz, AJ; Tollefson, GD, 1999) |
| " Published studies have drawn criticism in terms of inappropriate titration schedules, nonequivalent dosing between treatment groups, short treatment duration, and inadequate sample sizes." | 2.40 | Clozapine: a comparison with other novel antipsychotics. ( Fleischhacker, WW, 1999) |
| "The pharmacologic treatment of schizophrenia remains a critical component in the short- and long-term management of this disease." | 2.40 | Pharmacologic treatment of schizophrenia. ( Kane, JM, 1999) |
| " They suggest that as atypical antipsychotics like olanzapine are more widely used, some problems associated with the long-term use of conventional antipsychotics will diminish, but other issues and concerns will be more common." | 2.39 | Atypical antipsychotic drugs and long-term outcome in schizophrenia. ( Aquila, R; Standard, J; Weiden, P, 1996) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| " The method was successfully used for the analysis of samples from nonsmoking patients (n = 48) treated with OLZ in the dosage range of 5-20 mg per day." | 1.39 | Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters. ( Chen, YC; Lin, CH; Lu, ML; Wu, TH; Yang, HC, 2013) |
| "Schizophrenia is widely acknowledged as being a syndrome, consisting of an undefined number of diseases probably with differing pathologies." | 1.35 | Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. ( Cowie, TF; Dean, B; Kanellakis, S; Pantelis, C; Scarr, E; Sundram, S, 2009) |
| " However, no correlation between prolactin levels and dosage could be found." | 1.32 | [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics]. ( Fric, M; Laux, G, 2003) |
| " The diagnosis of rhabdomyolysis was confirmed by myoglobinemia dosage and ortholuidine test." | 1.32 | [Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment]. ( Busiello, L; Cascella, M; De Robertis, E; Di Domenico, MG; Palmese, S; Pezza, M, 2003) |
| "This study examined the short-term efficacy of electroconvulsive therapy (ECT) combined with antipsychotic medication in treatment-resistant schizophrenia (TRS)." | 1.31 | Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial. ( Tang, WK; Ungvari, GS, 2002) |
| "Pharmacotherapy for schizophrenia is a dynamic process." | 1.31 | From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. ( Leslie, DL; Rosenheck, RA, 2002) |
| "Olanzapine and clozapine have been associated with the greatest weight gain of the newer antipsychotics." | 1.31 | Clinical issues associated with maintenance treatment of patients with schizophrenia. ( Guthrie, SK, 2002) |
| "Risperidone was not associated with increased odds of hyperlipidemia compared with no antipsychotic exposure (OR, 1." | 1.31 | An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. ( Buchanan, RW; Fedder, DO; Koro, CE; Kreyenbuhl, J; L'Italien, GJ; Magder, LS; Revicki, D; Weiss, S, 2002) |
| "The olanzapine-treated patients showed a significantly lower maximal DFEN-evoked PRL response and a significantly lower group x time overall PRL release compared with the untreated patient group." | 1.31 | D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients. ( Curtis, VA; Jones, H; Lucey, JV; Pilowsky, LS; Wright, P, 2002) |
| "The treatment of schizophrenia is therefore particularly important to reduce deficits across a large number of neurocognitive domains." | 1.31 | Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. ( Cunningham, F; Hamed, A; Huang, YH; Kazis, LE; Lee, AF; Miller, DR; Ren, XS, 2002) |
| "Olanzapine is an atypical antipsychotic with potent antimuscarinic properties in vitro (K(i) = 2-25 nM)." | 1.31 | In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. ( Egan, MF; Jones, DW; Knable, MB; Lafargue, T; Pickar, D; Raedler, TJ; Urbina, RA; Weinberger, DR, 2000) |
| "1." | 1.31 | Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine. ( Hatzimanolis, J; Lykouras, L; Markianos, M; Oulis, P, 2001) |
| "Susceptibility for malignant hyperthermia was detected by a positive in vitro contracture test." | 1.31 | [Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy]. ( Grohmann, R; Pedrosa Gil, F; Rüther, E; Schneider, C, 2001) |
| " We conducted a survey of Spanish psychiatrists in mental health centers and outpatient treatment units to assess the severity scores that they would assign to a list of the most common adverse events (AEs) that usually occur with antipsychotic treatment." | 1.31 | Global index of safety (GIS): a new instrument to assess drug safety. ( Badía, X; Gómez, JC; Kind, P; Sacristán, JA, 2001) |
| "Converging evidence indicates that, in controlled drug trials, individuals receiving novel antipsychotic medications have fewer adverse effects than those receiving conventional antipsychotic medications." | 1.31 | Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. ( Bromet, EJ; Davidson, M; Rabinowitz, J, 2001) |
| "A 27-year-old white woman was observed to have a seizure while receiving a stable dosage of olanzapine 15 mg/d, with the addition of quetiapine 100 mg in the evening 1 day before the occurrence of the seizure." | 1.31 | New-onset seizure associated with quetiapine and olanzapine. ( Hedges, DW; Jeppson, KG, 2002) |
| "Current dosing regimens of psychotropic drugs are based on plasma kinetic considerations, although it is unclear whether plasma levels faithfully reflect brain kinetics of drugs." | 1.31 | Significant dissociation of brain and plasma kinetics with antipsychotics. ( Jones, C; Kapur, S; Remington, G; Tauscher, J; Zipursky, RB, 2002) |
| "Olanzapine is a newly developed atypical neuroleptic with a marked affinity to the 5-HT2, D2 and D4 dopamine receptors." | 1.30 | Severe akathisia during olanzapine treatment of acute schizophrenia. ( Bachmann, S; Gerdsen, I; Jauss, M; Mundt, C; Pantel, J; Schröder, J, 1998) |
| " There are others who are unable to tolerate a high dosage of clozapine." | 1.30 | Olanzapine augmentation of clozapine. ( Frank, B; Gupta, S; Sonnenberg, SJ, 1998) |
| "This study determines the extent of substance abuse in a treatment-resistant population and assesses the response of this population to olanzapine treatment." | 1.30 | Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. ( Conley, RR; Gale, EA; Kelly, DL, 1998) |
| "Olanzapine is a novel atypical antipsychotic agent with affinity at dopaminergic, serotonergic, muscarinic, adrenergic and histaminergic binding sites." | 1.30 | Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. ( Galicia-Polo, L; Herrera-Estrella, M; Laurrabaquio, MR; Salin-Pascual, RJ, 1999) |
| "Olanzapine is a new atypical antipsychotic agent that belongs to the same chemical class as clozapine." | 1.30 | In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. ( Dresel, S; Hahn, K; Mager, T; Meisenzahl, E; Möller, HJ; Rossmüller, B; Tatsch, K, 1999) |
| " The withdrawal symptoms disappeared rapidly with an increase in olanzapine dosage and with anticholinergic started at the beginning of the switch." | 1.30 | Clozapine-olanzapine: a potentially dangerous switch. A report of two cases. ( Delassus-Guenault, N; Jegouzo, A; Odou, P; Robert, H; Seguret, T; Vignole, E; Zangerlin, H, 1999) |
| "We report a case of agranulocytosis induced by olanzapine." | 1.30 | Olanzapine-induced agranulocytosis. ( Felber, W; Heilemann, H; Naumann, R; Reuster, T, 1999) |
| "Weight gain has been reported with nearly every antipsychotic drug on the market (molindone is an exception)." | 1.30 | Weight gain associated with antipsychotic drugs. ( Ganguli, R, 1999) |
| " Dosing was 12." | 1.30 | Differential olanzapine plasma concentrations by sex in a fixed-dose study. ( Conley, RR; Kelly, DL; Tamminga, CA, 1999) |
| "Olanzapine treated patients had similar levels of striatal D2 binding in vivo (1." | 1.29 | Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study. ( Busatto, GF; Costa, DC; Ell, PJ; Kerwin, RW; Nohria, V; Pilowsky, LS; Sharma, T; Sigmundsson, T; Taylor, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 193 (32.99) | 18.2507 |
| 2000's | 382 (65.30) | 29.6817 |
| 2010's | 10 (1.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, ML | 2 |
| Lin, CH | 2 |
| Chen, YC | 1 |
| Yang, HC | 1 |
| Wu, TH | 2 |
| Steenen, SA | 1 |
| van Westrhenen, R | 1 |
| Olff, M | 1 |
| Lund, BC | 5 |
| Bernardy, NC | 1 |
| Alexander, B | 1 |
| Friedman, MJ | 1 |
| Seo, MS | 1 |
| Scarr, E | 10 |
| Dean, B | 16 |
| Hopper, S | 1 |
| Conn, PJ | 1 |
| Thomas, N | 1 |
| Lai, CY | 1 |
| Chen, WJ | 1 |
| Wu, YX | 1 |
| Chen, CH | 1 |
| Kuo, PT | 1 |
| Chen, YH | 1 |
| Soulby, A | 1 |
| Evin, GM | 1 |
| Malkoff, A | 1 |
| Weizman, A | 7 |
| Gozes, I | 1 |
| Rehavi, M | 1 |
| Salah-Uddin, H | 1 |
| Pavey, G | 4 |
| Harris, K | 1 |
| Hagan, JJ | 1 |
| Challiss, RA | 1 |
| Watson, JM | 1 |
| McLeod, MC | 1 |
| Gibbons, AS | 1 |
| Boer, S | 1 |
| Money, T | 1 |
| Jeon, WJ | 1 |
| Felder, C | 1 |
| Mao, M | 1 |
| Skogh, E | 1 |
| Scordo, MG | 1 |
| Dahl, ML | 1 |
| Shaw, JW | 1 |
| Ramsey, NF | 1 |
| Koning, HA | 1 |
| Welles, P | 1 |
| Cahn, W | 1 |
| van der Linden, JA | 1 |
| Kahn, RS | 5 |
| Meatherall, R | 1 |
| Younes, J | 1 |
| Canuso, CM | 2 |
| Goldstein, JM | 2 |
| Wojcik, J | 1 |
| Dawson, R | 1 |
| Brandman, D | 1 |
| Klibanski, A | 1 |
| Schildkraut, JJ | 1 |
| Green, AI | 5 |
| Lee, CT | 1 |
| Conde, BJ | 1 |
| Mazlan, M | 1 |
| Visanuyothin, T | 1 |
| Wang, A | 1 |
| Wong, MM | 1 |
| Walker, DJ | 4 |
| Roychowdhury, SM | 3 |
| Wang, H | 1 |
| Tran, PV | 13 |
| Koro, CE | 2 |
| Fedder, DO | 2 |
| L'Italien, GJ | 2 |
| Weiss, SS | 1 |
| Magder, LS | 2 |
| Kreyenbuhl, J | 3 |
| Revicki, DA | 7 |
| Buchanan, RW | 5 |
| Fukui, H | 1 |
| Murai, T | 1 |
| Mahendran, R | 1 |
| Littrell, KH | 7 |
| Petty, RG | 4 |
| Hilligoss, NM | 5 |
| Peabody, CD | 6 |
| Johnson, CG | 7 |
| Jessen, LM | 1 |
| Alfaro, CL | 1 |
| Wudarsky, M | 1 |
| Nicolson, R | 1 |
| Gochman, P | 1 |
| Sporn, A | 1 |
| Lenane, M | 2 |
| Rapoport, JL | 2 |
| Tang, WK | 1 |
| Ungvari, GS | 1 |
| Leslie, DL | 3 |
| Rosenheck, RA | 1 |
| Voruganti, L | 1 |
| Cortese, L | 1 |
| Owyeumi, L | 1 |
| Kotteda, V | 1 |
| Cernovsky, Z | 1 |
| Zirul, S | 1 |
| Awad, A | 1 |
| Inada, T | 3 |
| Yagi, G | 1 |
| Miura, S | 4 |
| Briken, P | 2 |
| Nika, E | 2 |
| Moritz, S | 3 |
| Haasen, C | 1 |
| Perro, C | 1 |
| Yagdiran, O | 1 |
| Naber, D | 5 |
| Krausz, M | 4 |
| Kozian, R | 1 |
| Bellnier, TJ | 1 |
| Guthrie, SK | 1 |
| Schmitt, GJ | 2 |
| Meisenzahl, EM | 2 |
| Dresel, S | 3 |
| Tatsch, K | 3 |
| Rossmüller, B | 3 |
| Frodl, T | 3 |
| Preuss, UW | 2 |
| Hahn, K | 3 |
| Möller, HJ | 5 |
| Hiemke, C | 2 |
| Peled, A | 1 |
| Jabarin, M | 1 |
| Hadjez, J | 1 |
| Weigmann, H | 2 |
| Härtter, S | 1 |
| Modai, I | 1 |
| Ritsner, M | 1 |
| Silver, H | 1 |
| Lane, HY | 2 |
| Guo, SC | 1 |
| Hwang, TJ | 1 |
| Chen, YS | 1 |
| Cheng, JJ | 1 |
| Lee, YC | 1 |
| Hong, CJ | 1 |
| Hwu, HG | 1 |
| Chang, WH | 2 |
| Kontaxakis, VP | 1 |
| Havaki-Kontaxaki, BJ | 1 |
| Christodoulou, NG | 1 |
| Paplos, KG | 1 |
| Lund, A | 1 |
| Kroken, R | 1 |
| Thomsen, T | 1 |
| Hugdahl, K | 1 |
| Smievoll, AI | 1 |
| Barndon, R | 1 |
| Iversen, J | 1 |
| Landrø, NI | 1 |
| Sundet, K | 1 |
| Rund, BR | 1 |
| Ersland, L | 1 |
| Lundervold, A | 1 |
| Asbjørnsen, A | 1 |
| Carrasco, JL | 3 |
| Gutiérrez, M | 3 |
| Gómez, JC | 10 |
| Escobar, R | 1 |
| Alvarez, E | 4 |
| Cañas, F | 3 |
| Bobes, J | 4 |
| Gascón, J | 4 |
| Gibert, J | 3 |
| Hermida, T | 1 |
| Franco, K | 1 |
| Hadi, F | 1 |
| Douyon, K | 1 |
| Summerfelt, A | 2 |
| Tek, C | 1 |
| Gold, J | 1 |
| Mueck-Weymann, M | 2 |
| Rechlin, T | 1 |
| Ehrengut, F | 1 |
| Rauh, R | 1 |
| Acker, J | 2 |
| Dittmann, RW | 1 |
| Czekalla, J | 4 |
| Joraschky, P | 1 |
| Musselman, D | 1 |
| Lindenmayer, JP | 12 |
| Czobor, P | 6 |
| Volavka, J | 6 |
| Lieberman, JA | 9 |
| Citrome, L | 6 |
| Sheitman, B | 6 |
| Chakos, M | 7 |
| McEvoy, JP | 3 |
| Weiss, S | 1 |
| Revicki, D | 2 |
| Chue, P | 1 |
| Jones, B | 4 |
| Taylor, CC | 8 |
| Dickson, R | 1 |
| Bilici, M | 2 |
| Cakirbay, H | 1 |
| Guler, M | 1 |
| Tosun, M | 1 |
| Ulgen, M | 2 |
| Tan, U | 1 |
| Broerse, A | 1 |
| Crawford, TJ | 1 |
| den Boer, JA | 1 |
| Martin, S | 1 |
| Lĵo, H | 1 |
| Peuskens, J | 1 |
| Thirumalai, S | 1 |
| Giudicelli, A | 1 |
| Fleurot, O | 1 |
| Rein, W | 1 |
| Litvintsev, SV | 2 |
| Reznik, AM | 1 |
| Arbuzov, AL | 1 |
| Kutushev, OT | 1 |
| Shcherbakov, DV | 1 |
| de Haan, L | 6 |
| van Amelsvoort, T | 1 |
| Rodríguez-Pérez, V | 1 |
| López, A | 3 |
| Blanco, C | 1 |
| Peña, C | 1 |
| Abel, A | 1 |
| Gómez, Y | 1 |
| Ferreiro, MJ | 1 |
| Rego, C | 1 |
| Cudeiro, F | 1 |
| Alvarez, V | 1 |
| Prieto, R | 1 |
| Ciudad, A | 3 |
| Barak, Y | 1 |
| Shamir, E | 1 |
| Zemishlani, H | 1 |
| Mirecki, I | 1 |
| Toren, P | 2 |
| Weizman, R | 3 |
| Labelle, A | 3 |
| Bourget, D | 1 |
| Boulay, LJ | 2 |
| Ellis, J | 1 |
| Tessier, P | 1 |
| Ellingrod, VL | 2 |
| Perry, PJ | 5 |
| Bever-Stille, K | 2 |
| Fleming, F | 2 |
| Holman, TL | 2 |
| Miller, D | 3 |
| Jones, H | 1 |
| Curtis, VA | 1 |
| Wright, P | 6 |
| Pilowsky, LS | 4 |
| Lucey, JV | 1 |
| Ichikawa, J | 1 |
| Chung, YC | 1 |
| Li, Z | 1 |
| Dai, J | 1 |
| Meltzer, HY | 5 |
| Ren, XS | 1 |
| Kazis, LE | 1 |
| Lee, AF | 1 |
| Hamed, A | 1 |
| Huang, YH | 1 |
| Cunningham, F | 1 |
| Miller, DR | 1 |
| McLeod, M | 1 |
| Keriakous, D | 2 |
| McKenzie, J | 1 |
| Sacristán, JA | 4 |
| Beasley, CM | 19 |
| Tanaka, Y | 3 |
| Liu, CY | 1 |
| Chiu, NY | 2 |
| Wu, CK | 1 |
| Yuan, LM | 1 |
| Hsiao, MC | 1 |
| Liao, O | 1 |
| Ng, B | 1 |
| Postlethwaite, A | 1 |
| Rollnik, J | 1 |
| Casey, DE | 5 |
| Daniel, DG | 2 |
| Wassef, AA | 1 |
| Tracy, KA | 1 |
| Wozniak, P | 1 |
| Sommerville, KW | 1 |
| Aguglia, E | 1 |
| De Vanna, M | 1 |
| Onor, ML | 1 |
| Ferrara, D | 1 |
| Atmaca, M | 3 |
| Kuloglu, M | 3 |
| Tezcan, E | 3 |
| Gecici, O | 1 |
| Ustundag, B | 3 |
| Alphs, L | 2 |
| Altamura, AC | 1 |
| Anand, R | 2 |
| Bertoldi, A | 1 |
| Bourgeois, M | 1 |
| Chouinard, G | 2 |
| Islam, MZ | 1 |
| Kane, J | 2 |
| Krishnan, R | 1 |
| Potkin, S | 1 |
| Barbui, C | 2 |
| Danese, A | 1 |
| Guaiana, G | 1 |
| Mapelli, L | 1 |
| Miele, L | 1 |
| Monzani, E | 1 |
| Percudani, M | 1 |
| Tsuang, J | 1 |
| Marder, SR | 4 |
| Han, A | 1 |
| Hsieh, W | 1 |
| Safranko, I | 1 |
| Duggan, L | 3 |
| Fenton, M | 2 |
| Dardennes, RM | 2 |
| El-Dosoky, A | 2 |
| Indran, S | 2 |
| Findling, RL | 1 |
| McNamara, NK | 1 |
| Youngstrom, EA | 1 |
| Branicky, LA | 1 |
| Demeter, CA | 1 |
| Schulz, SC | 2 |
| Gonul, AS | 2 |
| Suer, C | 1 |
| Coburn, K | 1 |
| Ozesmi, C | 1 |
| Oguz, A | 1 |
| Yilmaz, A | 1 |
| Cooper, TB | 4 |
| Poyurovsky, M | 3 |
| Isaacs, I | 1 |
| Fuchs, C | 2 |
| Schneidman, M | 4 |
| Faragian, S | 1 |
| van Bruggen, M | 1 |
| Lavalaye, J | 5 |
| Booij, J | 5 |
| Dingemans, PM | 4 |
| Linszen, D | 3 |
| Haro, JM | 2 |
| Edgell, ET | 5 |
| Jones, PB | 2 |
| Alonso, J | 2 |
| Gavart, S | 1 |
| Gregor, KJ | 2 |
| Knapp, M | 1 |
| Harvey, PD | 2 |
| Green, MF | 1 |
| McGurk, SR | 1 |
| Hudson, TJ | 1 |
| Sullivan, G | 1 |
| Feng, W | 1 |
| Owen, RR | 1 |
| Thrush, CR | 1 |
| Meibach, RC | 1 |
| Messori, A | 2 |
| Gupta, S | 3 |
| Bustillo, JR | 1 |
| Lauriello, J | 1 |
| Parker, K | 1 |
| Hammond, R | 1 |
| Rowland, L | 1 |
| Bogenschutz, M | 1 |
| Keith, S | 1 |
| Godleski, LS | 1 |
| Goldsmith, LJ | 1 |
| Vieweg, WV | 1 |
| Zettwoch, NC | 1 |
| Stikovac, DM | 1 |
| Lewis, SJ | 1 |
| Bellgrove, MA | 1 |
| Vance, A | 1 |
| Bradshaw, JL | 1 |
| Papageorgiou, C | 2 |
| Oulis, P | 2 |
| Vasios, C | 1 |
| Matsopoulos, GK | 1 |
| Uzunoglu, N | 1 |
| Rabavilas, A | 2 |
| Christodoulou, GN | 3 |
| Love, RC | 4 |
| Kelly, DL | 7 |
| Carrillo, JA | 1 |
| Herráiz, AG | 1 |
| Ramos, SI | 1 |
| Gervasini, G | 1 |
| Vizcaíno, S | 1 |
| Benítez, J | 1 |
| Ninan, I | 1 |
| Jardemark, KE | 1 |
| Wang, RY | 1 |
| Miller, TJ | 3 |
| Zipursky, RB | 6 |
| Perkins, D | 3 |
| Addington, J | 3 |
| Woods, SW | 4 |
| Hawkins, KA | 3 |
| Hoffman, R | 2 |
| Preda, A | 1 |
| Epstein, I | 1 |
| Addington, D | 2 |
| Lindborg, S | 2 |
| Marquez, E | 2 |
| Tohen, M | 7 |
| Breier, A | 19 |
| McGlashan, TH | 3 |
| Kinon, BJ | 11 |
| Gilmore, JA | 5 |
| Liu, H | 2 |
| Halbreich, UM | 1 |
| Cavazzoni, P | 1 |
| Allison, DB | 2 |
| Kores Plesnicar, B | 1 |
| Zalar, B | 1 |
| Tomori, M | 1 |
| Krajnc, I | 1 |
| Santarlasci, B | 1 |
| Kula, M | 2 |
| Sofuoglu, S | 2 |
| Tutus, A | 1 |
| Esel, E | 2 |
| Tekelioğlu, Y | 1 |
| Efendioğlu, S | 1 |
| Ovali, E | 1 |
| Potvin, S | 1 |
| Stip, E | 4 |
| Roy, JY | 1 |
| Opolka, JL | 2 |
| Rascati, KL | 3 |
| Brown, CM | 2 |
| Gibson, PJ | 3 |
| Byerly, MJ | 1 |
| Weber, M | 1 |
| Brooks, D | 1 |
| Casey, SB | 1 |
| Elliot, S | 1 |
| Hawkins, J | 1 |
| Lambert, TJ | 1 |
| Castle, DJ | 2 |
| Gothelf, D | 2 |
| Apter, A | 2 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 1 |
| Ratzoni, G | 1 |
| Alevizos, B | 1 |
| Gureje, O | 1 |
| Miles, W | 1 |
| Keks, N | 1 |
| Grainger, D | 1 |
| Lambert, T | 1 |
| McGrath, J | 1 |
| Tran, P | 4 |
| Catts, S | 1 |
| Fraser, A | 1 |
| Hustig, H | 1 |
| Andersen, S | 2 |
| Crawford, AM | 5 |
| Fumagalli, F | 1 |
| Molteni, R | 1 |
| Roceri, M | 1 |
| Bedogni, F | 1 |
| Santero, R | 1 |
| Fossati, C | 1 |
| Gennarelli, M | 1 |
| Racagni, G | 1 |
| Riva, MA | 1 |
| Søholm, B | 1 |
| Lublin, H | 1 |
| Weiden, PJ | 2 |
| Simpson, GM | 3 |
| Potkin, SG | 2 |
| O'Sullivan, RL | 1 |
| Taylor, DM | 2 |
| Wright, T | 1 |
| Libretto, SE | 1 |
| Frewer, P | 1 |
| Rejas, J | 1 |
| Garcia-Garcia, M | 1 |
| Rico-Villademoros, F | 1 |
| García-Portilla, MP | 1 |
| Fernández, I | 1 |
| Hernández, G | 1 |
| Ritchie, CW | 1 |
| Chiu, E | 1 |
| Harrigan, S | 1 |
| Hall, K | 1 |
| Hassett, A | 1 |
| Macfarlane, S | 1 |
| Mastwyk, M | 1 |
| O'Connor, DW | 1 |
| Opie, J | 1 |
| Ames, D | 2 |
| Kuniyoshi, M | 1 |
| Ohyama, S | 1 |
| Otsuka, M | 1 |
| Nishi, S | 1 |
| Inanaga, K | 1 |
| Mori, N | 1 |
| Kogoj, A | 1 |
| Velikonja, I | 1 |
| Montes, JM | 1 |
| Battaglia, J | 1 |
| Lindborg, SR | 4 |
| Alaka, K | 1 |
| Meehan, K | 5 |
| Barner, JC | 1 |
| Johnsrud, MT | 2 |
| Purdon, SE | 3 |
| Woodward, N | 1 |
| Crismon, ML | 2 |
| Lage, MJ | 1 |
| Barber, BL | 1 |
| Conley, RR | 10 |
| McMahon, RP | 1 |
| Sharma, T | 4 |
| Hughes, C | 1 |
| Soni, W | 1 |
| Kumari, V | 1 |
| Landry, P | 1 |
| Benaliouad, F | 1 |
| Dewan, V | 1 |
| Freudenreich, O | 1 |
| Birkett, M | 3 |
| Morris, P | 1 |
| Takeuchi, T | 1 |
| Nishikawa, T | 1 |
| Hill, AL | 2 |
| Kollack-Walker, S | 2 |
| Tollefson, G | 6 |
| Gur, RE | 2 |
| Kahn, R | 1 |
| McEvoy, J | 3 |
| Zipursky, R | 1 |
| Wei, H | 2 |
| Hamer, RM | 1 |
| Kohler, C | 1 |
| Ragland, JD | 1 |
| Siegel, SJ | 1 |
| Bilker, WB | 1 |
| Loughead, J | 1 |
| Phend, N | 1 |
| Gur, RC | 1 |
| Weisman, RL | 1 |
| Perkins, DO | 2 |
| Hsu, C | 1 |
| Krishnan, KR | 1 |
| Young, FK | 1 |
| Meltzer, H | 1 |
| Green, A | 1 |
| Lambert, M | 1 |
| Holzbach, R | 1 |
| Postel, N | 1 |
| Remington, GJ | 1 |
| Dursun, SM | 3 |
| Reiss, JP | 1 |
| Rotstein, E | 1 |
| MacEwan, GW | 2 |
| Chokka, PR | 1 |
| Dickson, RA | 3 |
| Pae, CU | 2 |
| Kim, JJ | 1 |
| Lee, KU | 1 |
| Lee, CU | 1 |
| Bahk, WM | 2 |
| Lee, SJ | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Chang, HY | 1 |
| Ridky, TW | 1 |
| Kimball, AB | 1 |
| Hughes, E | 1 |
| Oro, AE | 1 |
| Carlson, CD | 1 |
| Cavazzoni, PA | 1 |
| Berg, PH | 4 |
| Kane, JM | 4 |
| Becker, D | 1 |
| Liver, O | 1 |
| Mester, R | 1 |
| Rapoport, M | 1 |
| Weiss, M | 1 |
| Haberfellner, EM | 1 |
| Honsig, T | 1 |
| Napolitano, JA | 1 |
| Mao, L | 1 |
| Gharabawi, G | 1 |
| Yang, YK | 1 |
| Chen, PS | 1 |
| Chang, CC | 1 |
| Lee, IH | 1 |
| Lee, JR | 1 |
| Gronier, BS | 1 |
| Rasmussen, K | 2 |
| Isaac, MB | 1 |
| Isaac, MT | 1 |
| Fric, M | 1 |
| Laux, G | 2 |
| Brunnauer, A | 1 |
| Geiger, E | 1 |
| Putzhammer, A | 2 |
| Heindl, B | 1 |
| Müller, J | 1 |
| Broll, K | 1 |
| Pfeiff, L | 1 |
| Perfahl, M | 1 |
| Hess, L | 1 |
| Koch, H | 1 |
| Stroup, TS | 1 |
| Copeland, LA | 1 |
| Zeber, JE | 1 |
| Valenstein, M | 1 |
| Blow, FC | 1 |
| Kirshner, CD | 2 |
| Fitzgerald, PB | 2 |
| Scaffidi, A | 1 |
| Morris, MJ | 1 |
| de Castella, AR | 1 |
| Kulkarni, J | 2 |
| Pezza, M | 1 |
| Busiello, L | 1 |
| Palmese, S | 1 |
| Cascella, M | 1 |
| Di Domenico, MG | 1 |
| De Robertis, E | 1 |
| Perry, P | 1 |
| Karagianis, JL | 2 |
| LeDrew, KK | 1 |
| Arango, C | 1 |
| Fortier, P | 1 |
| Mottard, JP | 3 |
| Trudel, G | 1 |
| Even, S | 1 |
| Kennedy, JS | 2 |
| Jeste, D | 1 |
| Kaiser, CJ | 2 |
| Golshan, S | 1 |
| Maguire, GA | 1 |
| Sanger, T | 6 |
| Bymaster, FP | 1 |
| Dossenbach, M | 2 |
| Feldman, PD | 2 |
| Sutton, VK | 1 |
| Tollefson, GD | 29 |
| Zhang, F | 1 |
| Baldessarini, RJ | 2 |
| Van-Duong, Q | 1 |
| Müller, JL | 4 |
| Deuticke, C | 1 |
| Röder, CH | 2 |
| Hajak, G | 1 |
| Winkler, J | 1 |
| Yeh, IN | 1 |
| Lin, SK | 1 |
| Tsai, CJ | 1 |
| Liu, HC | 2 |
| Archie, S | 1 |
| Wilson, JH | 1 |
| Osborne, S | 1 |
| Hobbs, H | 1 |
| McNiven, J | 1 |
| Fogl, T | 1 |
| Margolese, HC | 2 |
| Fellows, L | 1 |
| Ahmad, F | 1 |
| Dusci, LJ | 1 |
| Bulsara, MK | 1 |
| Ilett, KF | 1 |
| Sungur, MZ | 1 |
| Guner, P | 1 |
| Ustun, B | 1 |
| Cetin, I | 1 |
| Soygur, H | 1 |
| Rosenheck, R | 3 |
| Perlick, D | 1 |
| Bingham, S | 1 |
| Liu-Mares, W | 1 |
| Collins, J | 1 |
| Warren, S | 1 |
| Leslie, D | 1 |
| Allan, E | 1 |
| Campbell, EC | 1 |
| Caroff, S | 1 |
| Corwin, J | 1 |
| Davis, L | 1 |
| Douyon, R | 1 |
| Dunn, L | 1 |
| Evans, D | 1 |
| Frecska, E | 1 |
| Grabowski, J | 1 |
| Graeber, D | 1 |
| Herz, L | 1 |
| Kwon, K | 1 |
| Lawson, W | 1 |
| Mena, F | 1 |
| Sheikh, J | 1 |
| Smelson, D | 1 |
| Smith-Gamble, V | 1 |
| Baksh, A | 1 |
| Tamminga, CA | 6 |
| Bitter, I | 1 |
| Dossenbach, MR | 2 |
| Brook, S | 2 |
| Metcalfe, S | 2 |
| Gagiano, CA | 1 |
| Füredi, J | 1 |
| Bartko, G | 1 |
| Janka, Z | 1 |
| Banki, CM | 1 |
| Kovacs, G | 1 |
| Ebenbichler, CF | 1 |
| Laimer, M | 1 |
| Eder, U | 2 |
| Mangweth, B | 2 |
| Weiss, E | 2 |
| Hofer, A | 2 |
| Hummer, M | 2 |
| Kemmler, G | 2 |
| Lechleitner, M | 2 |
| Patsch, JR | 1 |
| Fleischhacker, WW | 3 |
| Heresco-Levy, U | 2 |
| Ermilov, M | 2 |
| Lichtenberg, P | 2 |
| Bar, G | 1 |
| Javitt, DC | 2 |
| Schneider, B | 1 |
| Weber, B | 1 |
| Fritze, J | 1 |
| Zavitsanou, K | 2 |
| Katsifis, A | 1 |
| Yu, Y | 2 |
| Huang, XF | 3 |
| Matsumoto, I | 1 |
| Inoue, Y | 1 |
| Iwazaki, T | 1 |
| Deng, C | 1 |
| Sethuraman, G | 1 |
| Enerson, M | 1 |
| Dunayevich, E | 1 |
| Newell, KA | 1 |
| Jew, SK | 1 |
| Theisen, FM | 1 |
| Haberhausen, M | 1 |
| Schulz, E | 3 |
| Fleischhaker, C | 1 |
| Clement, HW | 3 |
| Heinzel-Gutenbrunner, M | 1 |
| Remschmidt, H | 3 |
| Sundram, S | 2 |
| Cowie, TF | 1 |
| Kanellakis, S | 1 |
| Pantelis, C | 1 |
| Borison, RL | 1 |
| Tamura, RN | 4 |
| Satoh, K | 1 |
| Takahashi, M | 1 |
| Baldwin, DS | 1 |
| Montgomery, SA | 1 |
| Lahti, AC | 1 |
| Satterlee, W | 3 |
| Hamilton, S | 2 |
| Littrell, K | 1 |
| Littrell, SH | 2 |
| Baker, RW | 1 |
| Umbricht, DS | 1 |
| Chengappa, KN | 1 |
| Schooler, NR | 3 |
| Busatto, GF | 1 |
| Taylor, M | 1 |
| Costa, DC | 1 |
| Sigmundsson, T | 1 |
| Ell, PJ | 2 |
| Nohria, V | 1 |
| Kerwin, RW | 2 |
| Weiden, P | 2 |
| Aquila, R | 3 |
| Standard, J | 1 |
| Lehman, AF | 1 |
| Fulton, B | 1 |
| Goa, KL | 2 |
| Street, JS | 1 |
| Krueger, JA | 1 |
| Graffeo, KA | 1 |
| Thieme, ME | 2 |
| Sanger, TM | 5 |
| Reus, VI | 1 |
| Hamilton, SH | 8 |
| Dellva, MA | 7 |
| Blin, O | 1 |
| Beuzen, JN | 2 |
| Potvin, JH | 3 |
| Kiesler, GM | 2 |
| Glazer, WM | 5 |
| Nemeroff, CB | 1 |
| Johnstone, BM | 4 |
| Dalheim, L | 1 |
| Standard, JM | 1 |
| Kuntz, AJ | 2 |
| Andersen, SW | 4 |
| Beasley, C | 5 |
| Sheitman, BB | 2 |
| Lindgren, JC | 1 |
| Early, J | 1 |
| Sved, M | 1 |
| Kando, JC | 1 |
| Shepski, JC | 1 |
| Patel, JK | 1 |
| Reams, SG | 1 |
| Wentley, AL | 2 |
| Flynn, SW | 1 |
| Altman, S | 1 |
| Black, LL | 1 |
| Greenidge, LL | 1 |
| Honer, WG | 1 |
| Genduso, LA | 4 |
| Martín, J | 1 |
| García-Bernardo, E | 1 |
| Cuesta, M | 1 |
| Gurpegui, M | 1 |
| Bredkjoer, SR | 1 |
| Gerlach, J | 1 |
| Capehart, BP | 1 |
| Holsinger, T | 1 |
| Mattes, JA | 1 |
| Whitcomb, SR | 1 |
| Ballús, C | 1 |
| Lu, Y | 1 |
| Littrell, S | 1 |
| Nordström, AL | 1 |
| Nyberg, S | 1 |
| Olsson, H | 1 |
| Farde, L | 1 |
| O'Brien, J | 1 |
| Barber, R | 1 |
| Josefson, D | 1 |
| al Jeshi, A | 1 |
| Thomas, SG | 1 |
| Labbate, LA | 1 |
| Kumra, S | 1 |
| Jacobsen, LK | 1 |
| Karp, BI | 1 |
| Frazier, JA | 1 |
| Smith, AK | 1 |
| Bedwell, J | 1 |
| Lee, P | 1 |
| Malanga, CJ | 1 |
| Hamburger, S | 1 |
| Andersson, C | 1 |
| Mailman, R | 1 |
| Lieberman, J | 2 |
| Zito, JM | 1 |
| Gheuens, J | 1 |
| Grebb, JA | 1 |
| Allan, ER | 1 |
| Sison, CE | 1 |
| Alpert, M | 1 |
| Connolly, B | 1 |
| Crichton, J | 1 |
| Ganguli, R | 3 |
| Brar, JS | 2 |
| Bever, KA | 1 |
| Morrison, D | 1 |
| Clark, D | 1 |
| Goldfarb, E | 1 |
| McCoy, L | 1 |
| Bartko, JJ | 1 |
| Richardson, C | 1 |
| Peszke, M | 1 |
| Lingle, J | 1 |
| Hegerty, J | 1 |
| Love, R | 1 |
| Gounaris, C | 1 |
| Zaremba, S | 1 |
| Kapur, S | 8 |
| Remington, G | 7 |
| Jones, C | 2 |
| DaSilva, J | 1 |
| Wilson, AA | 1 |
| Houle, S | 1 |
| McClure, RK | 1 |
| Klebanov, R | 1 |
| Chatterton, R | 1 |
| Wirshing, WC | 4 |
| Deirmenjian, JM | 1 |
| Erhart, SM | 2 |
| Wirshing, DA | 4 |
| Spellberg, BJ | 2 |
| Kasper, S | 7 |
| Küfferle, B | 2 |
| Licht, RW | 1 |
| Almeida, OP | 1 |
| Lemon, MD | 1 |
| Lewis, R | 1 |
| Jauss, M | 1 |
| Schröder, J | 1 |
| Pantel, J | 1 |
| Bachmann, S | 1 |
| Gerdsen, I | 1 |
| Mundt, C | 1 |
| Hanau, M | 1 |
| Jhamb, KK | 1 |
| Sonnenberg, SJ | 1 |
| Frank, B | 1 |
| Gale, EA | 1 |
| Rudnick, A | 1 |
| Gray, R | 1 |
| Sharif, ZA | 2 |
| Keks, NA | 1 |
| Baldacchino, AM | 2 |
| Stubbs, JH | 2 |
| Mountjoy, CQ | 2 |
| Pozo, P | 1 |
| Alcántara, AG | 1 |
| DeQuardo, JR | 1 |
| Henderson, DC | 1 |
| Nasrallah, RA | 1 |
| Goff, DC | 2 |
| John, V | 1 |
| Rapp, M | 1 |
| Pies, R | 1 |
| Grundy, S | 2 |
| Jeste, DV | 1 |
| Rockwell, E | 1 |
| Harris, MJ | 1 |
| Lohr, JB | 1 |
| Lacro, J | 1 |
| Laor, N | 1 |
| Tauscher, J | 2 |
| Asenbaum, S | 1 |
| Fischer, P | 1 |
| Pezawas, L | 1 |
| Barnas, C | 1 |
| Tauscher-Wisniewski, S | 1 |
| Brücke, T | 1 |
| Leucht, S | 1 |
| Pitschel-Walz, G | 1 |
| Abraham, D | 1 |
| Kissling, W | 1 |
| Swartz, JR | 1 |
| Ananth, J | 2 |
| Smith, MW | 1 |
| Burgoyne, KS | 1 |
| Gadasally, R | 1 |
| Arai, Y | 1 |
| Palmer, CS | 1 |
| Brown, RE | 1 |
| Moore, NA | 2 |
| Bymaster, F | 1 |
| Perry, KW | 1 |
| Nelson, DL | 1 |
| Wong, DT | 1 |
| Calligaro, DO | 1 |
| Morgenstern, H | 1 |
| Ferguson, K | 1 |
| Mandalos, GE | 1 |
| Szarek, BL | 1 |
| Chong, SA | 1 |
| de la Sablonnière, JF | 1 |
| Wahid, Z | 1 |
| Ali, S | 1 |
| Tandon, R | 1 |
| Milner, K | 1 |
| Jibson, MD | 1 |
| Stahl, SM | 2 |
| Buckley, PF | 1 |
| Fanous, A | 1 |
| Crook, JM | 4 |
| Copolov, D | 1 |
| Takhar, J | 1 |
| Emanuel, M | 1 |
| Hickey, C | 1 |
| Stewart, C | 1 |
| Lippmann, S | 1 |
| Herrán, A | 2 |
| Vázquez-Barquero, JL | 2 |
| Richardson, CM | 1 |
| Salin-Pascual, RJ | 1 |
| Herrera-Estrella, M | 1 |
| Galicia-Polo, L | 1 |
| Laurrabaquio, MR | 1 |
| Rafal, S | 1 |
| Tsuang, MT | 1 |
| Carpenter, WT | 1 |
| Gardner, DM | 2 |
| Milliken, J | 1 |
| Millson, RC | 1 |
| Delva, NJ | 1 |
| Kysar, L | 1 |
| Berisford, MA | 1 |
| Goldstein, D | 1 |
| Pashdag, J | 1 |
| Mintz, J | 2 |
| Marcus, EL | 1 |
| Vass, A | 1 |
| Zislin, J | 3 |
| Srisurapanont, M | 1 |
| Maneeton, N | 1 |
| Prior, TI | 1 |
| Chue, PS | 1 |
| Tibbo, P | 1 |
| Baker, GB | 1 |
| Tunis, SL | 2 |
| Croghan, TW | 1 |
| Heilman, DK | 1 |
| Obenchain, RL | 1 |
| Mager, T | 2 |
| Meisenzahl, E | 1 |
| Delassus-Guenault, N | 1 |
| Jegouzo, A | 1 |
| Odou, P | 1 |
| Seguret, T | 1 |
| Zangerlin, H | 1 |
| Vignole, E | 1 |
| Robert, H | 1 |
| Weiss, EL | 1 |
| Longhurst, JG | 1 |
| Bowers, MB | 1 |
| Mazure, CM | 1 |
| Kalinyak, CM | 1 |
| Joye, F | 1 |
| Orrillard, M | 1 |
| Marion, F | 1 |
| Michoux, I | 1 |
| Parisot, R | 1 |
| Naumann, R | 1 |
| Felber, W | 1 |
| Heilemann, H | 1 |
| Reuster, T | 1 |
| Ganoczy, D | 1 |
| Cohen, LJ | 1 |
| Raedler, TJ | 2 |
| Knable, MB | 2 |
| Lafargue, T | 2 |
| Urbina, RA | 2 |
| Egan, MF | 2 |
| Pickar, D | 2 |
| Weinberger, DR | 2 |
| Bird, PM | 1 |
| Binz, W | 1 |
| Akinli, L | 1 |
| Sanchez, C | 1 |
| Green, B | 1 |
| Yui, K | 1 |
| Li, XM | 1 |
| Juorio, AV | 1 |
| Chlan-Fourney, J | 1 |
| Shrikhande, S | 1 |
| Bennett, VL | 1 |
| Keegan, DL | 1 |
| Bird, DC | 1 |
| Flinn, J | 1 |
| Mattler, CA | 1 |
| Kraus, T | 4 |
| Schuld, A | 4 |
| Pollmächer, T | 4 |
| Loosbrock, DL | 1 |
| Dulisse, BK | 1 |
| Noordsy, DL | 1 |
| O'Keefe, C | 1 |
| Sajatovic, M | 1 |
| Perez, D | 1 |
| Brescan, D | 1 |
| Ramirez, LF | 1 |
| Adams, BB | 1 |
| Mutasim, DF | 1 |
| Foster, RH | 2 |
| Ho, BC | 1 |
| Nopoulos, P | 1 |
| Andreasen, NC | 2 |
| Bryden, KE | 1 |
| Kopala, LC | 2 |
| Alao, AO | 1 |
| Armenta, WA | 1 |
| Yolles, JC | 1 |
| Lapierre, YD | 1 |
| Osser, DN | 1 |
| Najarian, DM | 1 |
| Dufresne, RL | 1 |
| Jaffe, ME | 1 |
| Hale, A | 1 |
| Azorin, JM | 1 |
| Bosch, RF | 1 |
| Baumbach, A | 1 |
| Bitzer, M | 1 |
| Erley, CM | 1 |
| Linszen, DH | 4 |
| Reneman, L | 3 |
| Gersons, BP | 2 |
| van Royen, EA | 3 |
| Awad, AG | 1 |
| Voruganti, LN | 1 |
| Jones, BD | 1 |
| David, SR | 3 |
| Keck, PE | 2 |
| Strakowski, SM | 1 |
| McElroy, SL | 2 |
| Hennighausen, K | 2 |
| Heiser, P | 2 |
| Durst, R | 2 |
| Katz, G | 2 |
| Raskin, S | 2 |
| Kalman, I | 1 |
| Oyewumi, LK | 1 |
| Al-Semaan, Y | 1 |
| Ohaeri, JU | 1 |
| Light, GA | 1 |
| Geyer, MA | 1 |
| Clementz, BA | 1 |
| Cadenhead, KS | 1 |
| Braff, DL | 1 |
| Morozova, MA | 1 |
| Zharkova, NB | 1 |
| Beniashvili, AG | 1 |
| Opeskin, K | 1 |
| Copolov, DL | 3 |
| Bronson, BD | 1 |
| Kopelowicz, A | 1 |
| Zarate, R | 1 |
| Tripodis, K | 1 |
| Gonzalez, V | 1 |
| Hernández, J | 1 |
| Ruiz Carrasco, P | 1 |
| Antón Saiz, C | 1 |
| Fontova Carbonell, E | 1 |
| Kühn, M | 2 |
| Haack, M | 3 |
| Hinze-Selch, D | 3 |
| Lechner, C | 1 |
| Montejo, AL | 1 |
| Vieta, E | 1 |
| Jones, DW | 1 |
| Dorfman-Etrog, P | 1 |
| Hermesh, H | 1 |
| Munitz, H | 2 |
| Stephenson, CM | 1 |
| Bigliani, V | 1 |
| Mulligan, RS | 1 |
| Acton, PD | 1 |
| Ohlsen, RI | 1 |
| Pike, VW | 1 |
| Gacinovic, S | 1 |
| Gilbody, SM | 1 |
| Bagnall, AM | 1 |
| Tuunainen, A | 1 |
| Hilligoss, N | 1 |
| Boot, E | 1 |
| Almond, S | 1 |
| O'Donnell, O | 1 |
| Johal, BK | 1 |
| Shelly, MP | 1 |
| Lal, S | 1 |
| Iskandar, H | 1 |
| Leblanc, G | 1 |
| Lykouras, L | 4 |
| Zervas, IM | 1 |
| Gournellis, R | 1 |
| Malliori, M | 1 |
| Rigalleau, V | 1 |
| Gatta, B | 1 |
| Bonnaud, S | 1 |
| Masson, M | 1 |
| Bourgeois, ML | 1 |
| Vergnot, V | 1 |
| Gin, H | 1 |
| Tomaskovic-Crook, E | 2 |
| Chovil, I | 1 |
| Ishigooka, J | 3 |
| Murasaki, M | 2 |
| Järventausta, K | 1 |
| Leinonen, E | 1 |
| Aubry, JM | 1 |
| Simon, AE | 1 |
| Bertschy, G | 1 |
| Mullen, A | 1 |
| Avnon, M | 1 |
| Belmaker, RH | 2 |
| Elizur, A | 1 |
| Mark, M | 2 |
| Shoshani, D | 1 |
| Kratky, P | 2 |
| Grundy, SL | 2 |
| Boye, T | 1 |
| Carsuzaa, F | 1 |
| VanDenBerg, CM | 1 |
| Su, MH | 1 |
| Jann, MW | 1 |
| Stanfield, SC | 1 |
| Privette, T | 1 |
| Melkersson, KI | 2 |
| Hulting, AL | 2 |
| Brismar, KE | 1 |
| Geddes, J | 1 |
| Freemantle, N | 1 |
| Harrison, P | 1 |
| Bebbington, P | 1 |
| Hagger, R | 1 |
| Brown, C | 1 |
| Hurley, P | 1 |
| Basson, BR | 4 |
| Malcolm, S | 1 |
| Stauffer, VL | 1 |
| Teter, CJ | 1 |
| Early, JJ | 1 |
| Frachtling, RJ | 1 |
| Voss, SN | 1 |
| Sierra-Biddle, D | 1 |
| Diez-Aja, S | 1 |
| Gonzalez-Mata, JM | 1 |
| Vidal, E | 1 |
| Diez-Manrique, F | 1 |
| Konakanchi, R | 1 |
| Grace, JJ | 2 |
| Szarowicz, R | 1 |
| Pato, MT | 2 |
| Mata, I | 1 |
| Madoz, V | 1 |
| Arranz, MJ | 1 |
| Sham, P | 1 |
| Murray, RM | 1 |
| Swartz, CM | 1 |
| Klein, HE | 2 |
| Sahebjam, M | 1 |
| Serra, E | 1 |
| Shulman, RW | 1 |
| Rabinowitz, J | 2 |
| Kaplan, Z | 1 |
| Nahon, D | 1 |
| Davidson, M | 2 |
| Habraken, JB | 1 |
| Birkett, MA | 1 |
| Wood, AJ | 1 |
| Damodaran, SS | 1 |
| Thankamma, JK | 1 |
| Jureidini, JN | 1 |
| Bouchard, RH | 1 |
| Demers, MF | 1 |
| Simoneau, I | 1 |
| Alméras, N | 1 |
| Villeneuve, J | 1 |
| Cadrin, C | 1 |
| Lemieux, I | 1 |
| Després, JP | 1 |
| Raggi, MA | 1 |
| Casamenti, G | 1 |
| Mandrioli, R | 1 |
| Volterra, V | 1 |
| Hilger, E | 1 |
| Ascari-Raccagni, A | 1 |
| Baldari, U | 1 |
| Rossi, E | 1 |
| Alessandrini, F | 1 |
| Martín, JC | 1 |
| Palenciano, G | 1 |
| Pérez, R | 1 |
| Nagy, A | 1 |
| Tényi, T | 1 |
| Lénárd, K | 1 |
| Herold, R | 1 |
| Wilhelm, F | 1 |
| Trixler, M | 1 |
| Bhana, N | 1 |
| Olney, R | 1 |
| Plosker, GL | 1 |
| Llorca, PM | 1 |
| Vaiva, G | 1 |
| Lancon, C | 1 |
| Dulisse, B | 1 |
| Seeman, P | 1 |
| Milton, DR | 1 |
| Kodesh, A | 1 |
| Finkel, B | 1 |
| Lerner, AG | 1 |
| Kretzmer, G | 1 |
| Sigal, M | 1 |
| Verma, S | 1 |
| Orengo, CA | 1 |
| Kunik, ME | 1 |
| Hale, D | 1 |
| Molinari, VA | 1 |
| Seger, A | 1 |
| Lamberti, JS | 1 |
| Cuesta, MJ | 1 |
| Peralta, V | 1 |
| Zarzuela, A | 1 |
| Mujica, R | 1 |
| Mahmoud, R | 1 |
| Rifkin, A | 1 |
| Nelson, MW | 1 |
| Bonanno, DG | 1 |
| Davydov, L | 1 |
| Botts, SR | 1 |
| Zorn, SH | 1 |
| Ayrton, Z | 1 |
| Markianos, M | 3 |
| Hatzimanolis, J | 3 |
| Szymanski, KA | 1 |
| Umbricht, D | 1 |
| Flury, H | 1 |
| Bridler, R | 1 |
| Smith, RC | 3 |
| Singh, A | 2 |
| Parker, B | 2 |
| Chou, E | 1 |
| Kotsaftis, A | 1 |
| Vesce, J | 1 |
| Comaty, JE | 1 |
| Advokat, C | 1 |
| de Jong, J | 1 |
| Hoogenboom, B | 2 |
| van Troostwijk, LD | 1 |
| Basturk, M | 1 |
| Saffet Gonul, A | 1 |
| Tayfun Turan, M | 1 |
| Yabanoglu, I | 1 |
| Ipekçi, S | 1 |
| Birsöz, S | 1 |
| Ferchland, I | 2 |
| Alaka, KJ | 1 |
| Saunders, JC | 1 |
| Krueger, J | 1 |
| Bradley, P | 1 |
| San, L | 1 |
| Bernardo, M | 2 |
| Reinstein, M | 1 |
| Kolivakis, TT | 1 |
| Beauclair, L | 1 |
| Ball, MP | 1 |
| Coons, VB | 1 |
| Vaamonde, J | 1 |
| González, JM | 1 |
| Hernádez, A | 1 |
| Ibáñez, R | 1 |
| Gudin, MA | 1 |
| Del Real Francia, MA | 1 |
| Sauriol, L | 1 |
| Laporta, M | 1 |
| Edwardes, MD | 1 |
| Deslandes, M | 1 |
| Ricard, N | 1 |
| Suissa, S | 1 |
| Rosillon, D | 1 |
| Duchesne, I | 2 |
| Jones, M | 1 |
| Di Lorenzo, R | 1 |
| Tondelli, G | 1 |
| Genedani, S | 1 |
| Costa e Silva, JA | 1 |
| Alvarez, N | 1 |
| Mazzotti, G | 1 |
| Gattaz, WF | 1 |
| Ospina, J | 1 |
| Larach, V | 1 |
| Starkstein, S | 1 |
| Oliva, D | 1 |
| Cousins, L | 1 |
| Wang, J | 1 |
| Iskander, A | 1 |
| Narendran, R | 1 |
| Young, CM | 1 |
| Valenti, AM | 1 |
| Pristach, CA | 1 |
| Koren, G | 1 |
| Stephan, KE | 1 |
| Magnotta, VA | 1 |
| White, T | 1 |
| Arndt, S | 1 |
| Flaum, M | 1 |
| O'Leary, DS | 1 |
| Parellada, E | 1 |
| Lomeña, F | 1 |
| Catafau, AM | 1 |
| Font, M | 1 |
| López-Carrero, C | 1 |
| Gutiérrez, F | 1 |
| Pavía, J | 1 |
| Salamero, M | 1 |
| Scheepers, FE | 3 |
| Gispen-de Wied, CC | 2 |
| Westenberg, HG | 2 |
| Merrick, TC | 1 |
| Felo, JA | 1 |
| Jenkins, AJ | 1 |
| Harvey, EJ | 1 |
| Flanagan, RJ | 1 |
| Pedrosa Gil, F | 1 |
| Schneider, C | 1 |
| Grohmann, R | 1 |
| Rüther, E | 1 |
| Ebenbichler, C | 1 |
| Hong, X | 1 |
| Wang, X | 1 |
| Dewan, VK | 1 |
| Arnold, LM | 1 |
| Nathan, AM | 1 |
| Sussman, N | 1 |
| Gunatilake, S | 1 |
| Aquino, S | 1 |
| Bach, V | 1 |
| Costa, J | 1 |
| Agelink, MW | 1 |
| Infante, M | 1 |
| Khandat, A | 1 |
| Badía, X | 1 |
| Kind, P | 1 |
| Simpson, MM | 1 |
| Goetz, RR | 1 |
| Devlin, MJ | 1 |
| Goetz, SA | 1 |
| Walsh, BT | 1 |
| Gallinat, J | 1 |
| Riedel, M | 1 |
| Juckel, G | 1 |
| Sokullu, S | 1 |
| Moukhtieva, R | 1 |
| Mavrogiorgou, P | 1 |
| Nisslé, S | 1 |
| Müller, N | 1 |
| Danker-Hopfe, H | 1 |
| Hegerl, U | 1 |
| Wang, C | 1 |
| McInnis, J | 1 |
| Ross-Sanchez, M | 1 |
| Shinnick-Gallagher, P | 1 |
| Wiley, JL | 1 |
| Johnson, KM | 1 |
| Neumann, NU | 1 |
| Frasch, K | 1 |
| Gespen de Wied, CC | 1 |
| Snedkov, EV | 1 |
| Biswasl, PN | 1 |
| Wilton, LV | 1 |
| Pearcel, GL | 1 |
| Freemantle, S | 1 |
| Shakir, SA | 1 |
| Turrone, P | 1 |
| Seeman, MV | 1 |
| Flint, AJ | 1 |
| Johnson, RP | 1 |
| Al-Taher, MT | 1 |
| Madlock, LE | 1 |
| Guo, M | 1 |
| Nasdahl, CS | 1 |
| Cohen, H | 1 |
| Loewenthal, U | 1 |
| Matar, M | 1 |
| Kotler, M | 1 |
| Woodward, TS | 1 |
| Kuroki, T | 1 |
| Tashiro, N | 1 |
| Lewis, M | 1 |
| McCrone, P | 1 |
| Frangou, S | 1 |
| Masand, PS | 1 |
| Bromet, EJ | 1 |
| Shimoni, J | 1 |
| Shapira, B | 1 |
| Silipo, G | 1 |
| Dervaux, A | 1 |
| Artiges, E | 1 |
| Beuk, N | 1 |
| Dingemans, P | 1 |
| Zhao, Z | 1 |
| Stevens, A | 1 |
| Schwarz, J | 1 |
| Schwarz, B | 1 |
| Ruf, I | 1 |
| Kolter, T | 1 |
| Glick, ID | 1 |
| Hedges, DW | 1 |
| Jeppson, KG | 1 |
| Hennen, J | 1 |
| Lyoo, IK | 1 |
| Tsai, G | 1 |
| Wald, LL | 1 |
| Evins, AE | 1 |
| Yurgelun-Todd, DA | 1 |
| Renshaw, PF | 1 |
| Sernyak, MJ | 1 |
| Alarcon, RD | 1 |
| Losonczy, MF | 1 |
| Duggal, HS | 1 |
| Fetchko, J | 1 |
| Röder, C | 1 |
| Schuierer, G | 2 |
| Kelleher, JP | 1 |
| Centorrino, F | 1 |
| Albert, MJ | 1 |
| Nieman, DH | 1 |
| Koelman, JH | 1 |
| Bour, LJ | 1 |
| Ongerboer de Visser, BW | 1 |
| Madhusoodanan, S | 1 |
| Sinha, S | 1 |
| Brenner, R | 1 |
| Bogunovic, O | 1 |
| David, S | 1 |
| Sutton, V | 1 |
| Palmer, R | 1 |
| Kiesler, G | 1 |
| Klein, H | 1 |
| Cohen, LS | 1 |
| Horton, NJ | 1 |
| Lee, H | 1 |
| Crawford, A | 1 |
| Kim, KS | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Kim, DJ | 1 |
| Meyer, JM | 1 |
| Bilder, RM | 1 |
| Goldman, RS | 1 |
| Hoptman, M | 1 |
| Kunz, M | 1 |
| Horowitz, TL | 1 |
| Falk, B | 1 |
| Singer, P | 1 |
| Kairi, M | 1 |
| Phillip, M | 1 |
| Zigel, L | 1 |
| Poraz, I | 1 |
| Frishman, S | 1 |
| Constantini, N | 1 |
| Zalsman, G | 1 |
| Pashinian, A | 1 |
| Gil-Ad, I | 1 |
| Maayan, R | 1 |
| Dinakar, HS | 1 |
| Sobel, RN | 1 |
| Bopp, JH | 1 |
| Daniels, A | 1 |
| Mauro, S | 1 |
| Weissman, EM | 1 |
| Le Pen, G | 1 |
| Moreau, JL | 1 |
| Webster, D | 1 |
| Devarajan, S | 1 |
| Gallant, J | 1 |
| Harris, A | 1 |
| Kosky, N | 1 |
| Fuller, MA | 1 |
| Shermock, KM | 1 |
| Secic, M | 1 |
| Laich, JS | 1 |
| Durkin, MB | 1 |
| Patel, NC | 1 |
| Dorson, PG | 1 |
| Edwards, N | 1 |
| Mendelson, S | 1 |
| Brown, TL | 1 |
| Daskalakis, ZJ | 1 |
| Eschweiler, GW | 1 |
| Bartels, M | 1 |
| Längle, G | 1 |
| Wild, B | 1 |
| Gaertner, I | 1 |
| Nickola, M | 1 |
| Joyce, JN | 1 |
| Lexow, N | 1 |
| Kim, SJ | 1 |
| Artymyshyn, R | 1 |
| Senzon, S | 1 |
| Lawrence, D | 1 |
| Cassanova, MF | 1 |
| Kleinman, JE | 1 |
| Bird, ED | 1 |
| Winokur, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| A Randomized, Double-Blind, Comparison of the Efficacy and Safety of Risperidone Versus Risperidone Combined With Low Dose of Haloperidol in the Treatment of Schizophrenic Disorder[NCT00998608] | Phase 4 | 88 participants (Actual) | Interventional | 2007-08-31 | Terminated (stopped due to terminated) | ||
| CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia[NCT00007774] | Phase 4 | 600 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase[NCT01720316] | Phase 2 | 2 participants (Actual) | Interventional | 2012-12-10 | Completed | ||
| Muscarinic M1 Receptor Availability and Cognition in Schizophrenia[NCT05105542] | Phase 2 | 18 participants (Anticipated) | Interventional | 2021-04-20 | Recruiting | ||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study[NCT01399450] | Phase 4 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients[NCT00780702] | Phase 1 | 41 participants (Actual) | Interventional | 2008-05-08 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications[NCT05473741] | 180 participants (Anticipated) | Observational | 2023-01-09 | Recruiting | |||
| A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366] | 261 participants (Actual) | Interventional | 2004-05-31 | Completed | |||
| A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders[NCT02983188] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2018-04-25 | Completed | ||
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [NCT01615185] | Phase 4 | 96 participants (Actual) | Interventional | 2008-01-31 | Terminated | ||
| Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562] | Phase 3 | 20 participants (Actual) | Interventional | 2005-10-31 | Terminated | ||
| The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder[NCT01867398] | 12 participants (Actual) | Observational | 2013-04-29 | Terminated | |||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine[NCT02304432] | Early Phase 1 | 2 participants (Actual) | Interventional | 2015-09-27 | Completed | ||
| An Open-label, Randomized Trial of Intramuscular (IM) Olanzapine Versus Intramuscular Combination of Haloperidol and Lorazepam in the Treatment of Acute Agitation in Schizophrenia[NCT00797277] | Phase 3 | 67 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Auditory evoked potentials amplitude: P50 ratio (S2/S1). Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | ratio (Number) |
|---|---|
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | 44.51 |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 35.67 |
Auditory evoked potentials amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2 amplitude; mismatch negativity (MMN) at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 amplitude at fz | P300 amplitude at cz | P300 amplitude at pz | N100 amplitude at fz | N100 amplitude at cz | P200 amplitude at fz | P200 amplitude at cz | P50 S1 amplitude | P50 S2 amplitude | MMN amplitude at fz | MMN amplitude at cz | |
| Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 2 | 3.74 | 6.6 | 5.57 | -4.71 | -3.89 | 6.29 | 7.8 | 2.2 | 0.78 | -1.004 | -1.322 |
| Auditory ERPs Amplitude (Deg) Baseline: Subject 2 | -0.635 | 6.53 | 5.34 | -3.93 | -3.62 | 1.662 | 6.59 | 2.76 | 1.23 | -3.356 | -4.13 |
Auditory evoked potentials gamma: G40 hz phase locking at fz and cz; G20 hz phase locking response at fz and cz G30 hz phase locking response at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | microvolts squared (Number) | |||||
|---|---|---|---|---|---|---|
| G40 fz | G40 cz | G20 fz | G20 cz | G30 fz | G30 cz | |
| Auditory ERPs Gamma 6 Weeks of Glycine: Subject 2 | 0.255 | 0.29 | 0.107 | 0.108 | 0.177 | 0.242 |
| Auditory ERPs Gamma Baseline: Subject 2 | 0.135 | 0.168 | 0.023 | 0.03 | 0.19 | 0.163 |
Auditory evoked potentials latency: P300 at fz, cz, and pz); N100 at fz and cz); P200 at fz and cz. Participants were assessed at baseline and in week of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine
| Intervention | msec (Number) | ||||||
|---|---|---|---|---|---|---|---|
| P300 latency at fz | P300 latency at cz | P300 latency at pz | N100 latency at fz | N100 latency at cz | P200 latency at fz | P200 latency at cz | |
| Auditory ERPs Latency (ms) 6 Weeks of Glycine: Subject 2 | 300.78 | 293 | 294.92 | 94 | 94 | 205 | 203 |
| Auditory ERPs Latency (ms) Baseline: Subject 2 | 279.3 | 279.3 | 279.3 | 97.66 | 91.8 | 197.27 | 193.4 |
Magnetic resonance spectroscopy GABA/Cr. Participants were assessed 1) pre-glycine treatment (baseline) and 2) in week 6 of open-label glycine treatment measured in posterior occipital cortex. (NCT01720316)
Timeframe: Baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline GABA/Cr | Week 6 of glycine tx GABA/Cr | |
| Subject1: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.16 | 0.22 |
| Subject2: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine | 0.27 | 0.24 |
magnetic resonance spectroscopy - glutamate metabolite level. Participants were assessed 1) pre-glycine treatment and in week 6 of open-label glycine treatment. Measured in posterior occipital cortex. (NCT01720316)
Timeframe: baseline and week 6 of glycine
| Intervention | ratio (Number) | |
|---|---|---|
| Baseline brain glutamate/Cr ratio | Week 6 brain glutamate/Cr ratio | |
| Subject1: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 0.98 | 0.84 |
| Subject2: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine | 2.053 | 1.13 |
magnetic resonance spectroscopy: glycine/creatine ratio. Participants were assessed at 1) BASELINE PRE-GLYCINE TREATMENT: pre-glycine challenge drink, 60 minutes post challenge drink, 80 minutes post challenge drink, 100 minutes post challenge drink, and 120 minutes post challenge drink (0.4 g/kg up to max of 30 g); and 2) IN WEEK 6 OF OPEN-LABEL GLYCINE TREATMENT: pre-glycine dose, and 60 minutes, 80 minutes, 100 minutes and 120 minutes post daily dose of glycine. Measured in posterior occipital cortex (NCT01720316)
Timeframe: baseline (pre-challenge, 60, 80, 100, 120 minutes post-challenge), and week 6 of glycine (pre-dose and 60, 80, 100, 120 minutes post-dose
| Intervention | ratio (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - pre-challenge drink | Baseline 60 minutes post challenge drink | Baseline 80 minutes post challenge drink | Baseline 100 minutes post challenge drink | Baseline 120 minutes post challenge drink | Week 6 of glycine - pre-glycine dose | Week 6 of glycine - 60 minutes post glycine dose | Week 6 of glycine - 80 minutes post glycine dose | Week 6 of glycine - 100 minutes post glycine dose | Week 6 of glycine - 120 minutes post glycine dose | |
| Subject 2:Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.5691 | 0.3918 | 0.6428 | 0.6363 | 0.9559 | 0.3235 | 0.3807 | 0.5591 | 0.4142 | 0.3545 |
| Subject1: Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine | 0.2558 | 0.6157 | 0.6631 | 0.5938 | 0.6953 | 0.6573 | 0.2983 | 0.4577 | 0.5751 | 0.3842 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BPRS at baseline | BPRS at 2 weeks intervention 1 | BPRS at 4 weeks intervention 1 | BPRS at 6 weeks intervention 1 | BPRS, end of washout1 | BPRS at 2 weeks intervention 2 | BPRS at 4 weeks intervention 2 | BPRS at 6 weeks intervention 2 | BPRS, end of washout2 | BPRS at 2 weeks open label | BPRS at 4 weeks open label | BPRS at 6 weeks open label | BPRS, end of washout3 | |
| Glycine, Then Placebo | 39 | 38 | 32 | 21 | 22 | 37 | 31 | 37 | 32 | 23 | 22 | 21 | 19 |
| Placebo, Then Glycine | 46 | 38 | 39 | 28 | 34 | 32 | 20 | 23 | 24 | 20 | 18 | 19 | 23 |
Clinical Global Impression (CGI) severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT01720316)
Timeframe: CGI at baseline and at 2 weeks, 4 weeks, and 6 weeks per treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI severity score at baseline | CGI severity score at 2 weeks intervention 1 | CGI severity score at 4 weeks intervention 1 | CGI severity score at 6 weeks intervention 1 | CGI severity score, end of washout1 | CGI severity score at 2 weeks intervention 2 | CGI severity score at 4 weeks intervention 2 | CGI severity score at 6 weeks intervention 2 | CGI severity score, end of washout2 | CGI severity score at 2 weeks open label | CGI severity score at 4 weeks open label | CGI severity score at 6 weeks open label | CGI severity score, end of washout3 | |
| Glycine, Then Placebo | 4 | 4 | 3 | 2 | 2 | 4 | 4 | 4 | 4 | 3 | 3 | 2 | 2 |
| Placebo, Then Glycine | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 2 |
Clinical Global Impression (CGI) therapeutic effect scores measure degree of improvement as marked (1), moderate (5), minimal (9) or unchanged/worse (13). (NCT01720316)
Timeframe: at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | score (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI therapeutic effect at 2 weeks intervention 1 | CGI therapeutic effect at 4 weeks intervention 1 | CGI therapeutic effect at 6 weeks intervention 1 | CGI therapeutic effect, end of washout1 | CGI therapeutic effect at 2 weeks intervention 2 | CGI therapeutic effect at 4 weeks intervention 2 | CGI therapeutic effect at 6 weeks intervention 2 | CGI therapeutic effect, end of washout2 | CGI therapeutic effect at 2 weeks open label | CGI therapeutic effect at 4 weeks open label | CGI therapeutic effect at 6 weeks open label | CGI therapeutic effect, end of washout3 | |
| Glycine, Then Placebo | 13 | 5 | 5 | 5 | 13 | 13 | 13 | 13 | 5 | 5 | 1 | 1 |
| Placebo, Then Glycine | 5 | 5 | 5 | 5 | 13 | 5 | 5 | 5 | 1 | 1 | 1 | 1 |
Hamilton Depression Scale measures severity of depression symptoms. The sum of ratings for 9 depression symptoms are measured on a scale from 0-2 with 0 meaning no symptoms and 2 meaning some level of severity of that specific symptom. The rating for 1 depression symptom is measured on a scale from 0-3 with 0 meaning no symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms are measured on a scale from 0-4 with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression symptoms at baseline | Depression symptoms at 2 weeks intervention 1 | Depression symptoms at 4 weeks intervention 1 | Depression symptoms at 6 weeks intervention 1 | Depression symptoms, end of washout1 | Depression symptoms at 2 weeks intervention 2 | Depression symptoms at 4 weeks intervention 2 | Depression symptoms at 6 weeks intervention 2 | Depression symptoms, end of washout2 | Depression symptoms at 2 weeks open label | Depression symptoms at 4 weeks open label | Depression symptoms at 6 weeks open label | Depression symptoms, end of washout3 | |
| Glycine, Then Placebo | 18 | 17 | 11 | 3 | 1 | 19 | 5 | 7 | 3 | 2 | 2 | 1 | 2 |
| Placebo, Then Glycine | 12 | 5 | 5 | 0 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
Plasma glycine levels; normal range is 122-467 nM/mL (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | nM/mL (Number) | |||
|---|---|---|---|---|
| Baseline | Glycine double-blind | Placebo | Glycine open-label | |
| Glycine Then Placebo | 216 | 410 | 194 | 516 |
| Placebo Then Glycine | 271 | 761 | 347 | 634 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of ratings for 7 symptoms of mania is measured on a scale from 0-4 and the sum of 4 symptoms of mania is measured on a scale from 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manic symptoms at baseline | Manic symptoms at 2 weeks intervention 1 | Manic symptoms at 4 weeks intervention 1 | Manic symptoms at 6 weeks intervention 1 | Manic symptoms, end of washout1 | Manic symptoms at 2 weeks intervention 2 | Manic symptoms at 4 weeks intervention 2 | Manic symptoms at 6 weeks intervention 2 | Manic symptoms, end of washout2 | Manic symptoms at 2 weeks open label | Manic symptoms at 4 weeks open label | Manic symptoms at 6 weeks open label | Manic symptoms, end of washout3 | |
| Glycine, Then Placebo | 4 | 1 | 0 | 0 | 0 | 17 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Placebo, Then Glycine | 7 | 7 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution; standard deviation of 10. Only overall composite score is entered. (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine
| Intervention | units on a scale (Number) | |
|---|---|---|
| Participant 1 | Participant 2 | |
| Baseline | 45 | 48 |
| Composite Score on Glycine, Double-blind | 52 | 52 |
| Composite Score on Glycine, Open-label | 49 | 46 |
| Composite Score on Placebo | 52 | 55 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms are measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period and after each treatment period
| Intervention | units on a scale (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive symptoms at baseline | Positive symptoms at 2 weeks intervention 1 | Positive symptoms at 4 weeks intervention 1 | Positive symptoms at 6 weeks intervention 1 | Positive symptoms, end of washout1 | Positive symptoms at 2 weeks intervention 2 | Positive symptoms at 4 weeks intervention 2 | Positive symptoms at 6 weeks intervention 2 | Positive symptoms, end of washout2 | Positive symptoms at 2 weeks open label | Positive symptoms at 4 weeks open label | Positive symptoms at 6 weeks open label | Positive symptoms, end of washout3 | |
| Glycine, Then Placebo | 13 | 12 | 9 | 8 | 7 | 12 | 11 | 14 | 14 | 9 | 9 | 7 | 7 |
| Placebo, Then Glycine | 19 | 20 | 19 | 13 | 13 | 12 | 10 | 11 | 11 | 8 | 7 | 8 | 8 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | Units/mL per 10 minutes (Mean) |
|---|---|
| Rosiglitazone | -151 |
| Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
| Intervention | microUnits/mL (Mean) |
|---|---|
| Rosiglitazone | 3.2 |
| Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Rosiglitazone | .002 |
| Placebo | -0.01 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
Auditory evoked potential amplitude: P50 ratio (P50 S2/S1) (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Number) | |
|---|---|---|
| P50 ratio: Baseline | P50 ratio: Week 8 of DCS | |
| First Open Label DCS | 44.51 | 30 |
Auditory evoked potential amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2; mismatch negativity (MMN) at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P50 S1: Baseline | P50 S2: Baseline | MMN at fz: Baseline | MMN at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | P50 S1: Week 8 of DCS | P50 S2: Week 8 of DCS | MMN at fz: Week 8 of DCS | MMN at cz: Week 8 of DCS | |
| First Open Label DCS | -0.635 | 6.529 | 5.340 | -3.926 | -3.615 | 1.662 | 6.591 | 2.759 | 1.23 | -3.356 | -4.130 | 3.030 | 6.810 | 6.620 | -3.260 | -3.940 | 8.200 | 8.160 | 1.36 | 0.4 | -3.330 | -1.540 |
Auditory evoked potential gamma: G40 hz phase locking at fz and cz; G30 hz phase locking at fz and cz; G20 hz phase locking at fz and cz (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | microvolts squared (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G40 hz phase locking at fz: Baseline | G40 hz phase locking at cz: Baseline | G30 hz phase locking at fz: Baseline | G30 hz phase locking at cz: Baseline | G20 hz phase locking at fz: Baseline | G20 hz phase locking at cz: Baseline | G40 hz phase locking at fz: Week 8 of DCS | G40 hz phase locking at cz: Week 8 of DCS | G30 hz phase locking at fz: Week 8 of DCS | G30 hz phase locking at cz: Week 8 of DCS | G20 hz phase locking at fz: Week 8 of DCS | G20 hz phase locking at cz: Week 8 of DCS | |
| First Open Label DCS | 0.135 | 0.168 | 0.190 | 0.163 | 0.023 | 0.030 | 0.344 | 0.381 | 0.168 | 0.19 | 0.01 | -0.01 |
Auditory evoked potential latency: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | msec (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P300 at fz: Baseline | P300 at cz: Baseline | P300 at pz: Baseline | N100 at fz: Baseline | N100 at cz: Baseline | P200 at fz: Baseline | P200 at cz: Baseline | P300 at fz: Week 8 of DCS | P300 at cz: Week 8 of DCS | P300 at pz: Week 8 of DCS | N100 at fz: Week 8 of DCS | N100 at cz: Week 8 of DCS | P200 at fz: Week 8 of DCS | P200 at cz: Week 8 of DCS | |
| First Open Label DCS | 279.297 | 279.297 | 279.297 | 97.656 | 91.797 | 197.266 | 193.359 | 294.920 | 294.000 | 294 | 87.9 | 88.000 | 212.890 | 212.000 |
Proton magnetic resonance spectroscopy at 4T: brain glycine/CR ratio. Participants were assessed at baseline (pre-glycine challenge dose and 60, 80, 100 and 120 minutes post glycine dose) and in week 8 of of open-label DCS treatment: pre-DCS dose, and 60, 80, 100 and 120 minutes post DCS dose. Measured in posterior occipital cortex. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment
| Intervention | ratio (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Baseline at 60 minutes | Baseline at 80 minutes | Baseline at 100 minutes | Baseline at 120 minutes | Week 8 of DCS: Baseline | Week 8 of DCS: 60 minutes | Week 8 of DCS: 80 minutes | Week 8 of DCS: 100 minutes | Week 8 of DCS: 120 minutes | |
| Open Label DCS | 0.41245 | 0.50375 | 0.65295 | 0.61505 | 0.8256 | 0.10977 | 0.248885 | 0.32609 | 0.32052 | 0.312155 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline BPRS | 2 weeks BPRS | 4 weeks BPRS | 6 weeks BPRS | 8 weeks BPRS | 10 weeks BPRS | 12 weeks BPRS | 14 weeks BPRS | 16 weeks BPRS | 18 weeks BPRS | 20 weeks BPRS | 22 weeks BPRS | 24 weeks BPRS | |
| First Open Label DCS | 37 | 25 | 26 | 24 | 24.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 31.5 | 30.5 | 28 | 25.5 | 26 | 26.5 | 26 | 25.5 | 28.5 | 27 | 25 | 24.5 | 26.5 |
Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline BPRS for first intervention | 2 weeks BPRS for first intervention | 4 weeks BPRS for first intervention | 6 weeks BPRS for first intervention | Baseline BPRS for second intervention | 2 weeks BPRS for second intervention | 4 weeks BPRS for second intervention | 6 weeks BPRS for second intervention | |
| DCS First, Then Placebo | 26 | 25 | 25 | 26 | 39 | 45 | 45 | 38 |
| Placebo First, Then DCS | 29 | 35 | 33 | 35 | 36 | 30 | 27 | 28 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline CGI | 2 weeks CGI | 4 weeks CGI | 6 weeks CGI | 8 weeks CGI | 10 weeks CGI | 12 weeks CGI | 14 weeks CGI | 16 weeks CGI | 18 weeks CGI | 20 weeks CGI | 22 weeks CGI | 24 weeks CGI | |
| First Open Label DCS | 4 | 2 | 2 | 2 | 2 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3 | 2.5 | 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline CGI for first intervention | 2 weeks CGI for first intervention | 4 weeks CGI for first intervention | 6 weeks CGI for first intervention | Baseline CGI for second intervention | 2 weeks CGI for second intervention | 4 weeks CGI for second intervention | 6 weeks CGI for second intervention | |
| DCS First, Then Placebo | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 |
| Placebo First, Then DCS | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline HAM | 2 weeks HAM | 4 weeks HAM | 6 weeks HAM | 8 weeks HAM | 10 weeks HAM | 12 weeks HAM | 14 weeks HAM | 16 weeks HAM | 18 weeks HAM | 20 weeks HAM | 22 weeks HAM | 24 weeks HAM | |
| First Open Label DCS | 5 | 1.5 | 1 | 0.5 | 1.5 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0.5 | 1 | 1 | 0 | 2.5 | 0 | 0 | 0 | 3.5 | 0 | 0 | 0 | 0 |
Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline HAM for first intervention | 2 weeks HAM for first intervention | 4 weeks HAM for first intervention | 6 weeks HAM for first intervention | Baseline HAM for second intervention | 2 weeks HAM for second intervention | 4 weeks HAM for second intervention | 6 weeks HAM for second intervention | |
| DCS First, Then Placebo | 0 | 1 | 0 | 0 | 2 | 12 | 9 | 2 |
| Placebo First, Then DCS | 4 | 5 | 2 | 10 | 0 | 0 | 0 | 0 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline YMRS | 2 weeks YMRS | 4 weeks YMRS | 6 weeks YMRS | 8 weeks YMRS | 10 weeks YMRS | 12 weeks YMRS | 14 weeks YMRS | 16 weeks YMRS | 18 weeks YMRS | 20 weeks YMRS | 22 weeks YMRS | 24 weeks YMRS | |
| First Open Label DCS | 2 | 1 | 1 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline YMRS for first intervention | 2 weeks YMRS for first intervention | 4 weeks YMRS for first intervention | 6 weeks YMRS for first intervention | Baseline YMRS for second intervention | 2 weeks YMRS for second intervention | 4 weeks YMRS for second intervention | 6 weeks YMRS for second intervention | |
| DCS First, Then Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo First, Then DCS | 1 | 0 | 0 | 0 | 4 | 1 | 1 | 1 |
Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution, standard deviation of 10. Higher scores signify better functioning. (NCT02304432)
Timeframe: Baseline and Week 8 of open-label DCS treatment
| Intervention | T scores (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Processing Speed | Baseline Attention/Vigilance | Baseline Working Memory | Baseline Verbal Learning | Baseline Visual Learning | Baseline Reasoning/Problem Solving | Baseline Social Cognition | Baseline Overall Composite Score | Week 8 of open-label DCS Processing Speed | Week 8 of open-label DCS Attention/Vigilance | Week 8 of open-label DCS Working Memory | Week 8 of open-label DCS Verbal Learning | Week 8 of open-label DCS Visual Learning | Week 8 of open-label DCS Reasoning/Problem Solving | Week 8 of open-label DCS Social Cognition | Week 8 of open-label DCS Overall Composite Score | |
| Open Label DCS | 48.5 | 44.5 | 38.5 | 54 | 50.5 | 52.5 | 48 | 46.5 | 52.5 | 47.5 | 50.5 | 43.5 | 54.5 | 66.5 | 44.5 | 51.5 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive | Baseline negative | 2 weeks positive | 2 weeks negative | 4 weeks positive | 4 weeks negative | 6 weeks positive | 6 weeks negative | 8 weeks positive | 8 weeks negative | 10 weeks positive | 10 weeks negative | 12 weeks positive | 12 weeks negative | 14 weeks positive | 14 weeks negative | 16 weeks positive | 16 weeks negative | 18 weeks positive | 18 weeks negative | 20 weeks positive | 20 weeks negative | 22 weeks positive | 22 weeks negative | 24 weeks positive | 24 weeks negative | |
| First Open Label DCS | 14.5 | 14.5 | 10 | 12 | 10.5 | 12 | 9 | 12 | 9 | 12 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Second Open Label DCS | 11 | 14 | 11 | 14 | 10.5 | 13.5 | 9 | 13 | 9.5 | 12 | 10.5 | 13 | 11 | 12 | 10 | 12 | 10.5 | 12 | 10.5 | 12 | 10.5 | 12 | 9.5 | 12 | 10 | 12 |
Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)
| Intervention | units on a scale (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline positive for first intervention | Baseline negative symptoms for first intervention | 2 weeks positive for first intervention | 2 weeks negative for first intervention | 4 weeks positive for first intervention | 4 weeks negative for first intervention | 6 weeks positive for first intervention | 6 weeks negative for first intervention | Baseline positive for second intervention | Baseline negative for second intervention | 2 weeks positive for second intervention | 2 weeks negative for second intervention | 4 weeks positive for second intervention | 4 weeks negative for second intervention | 6 weeks positive for second intervention | 6 weeks negative for second intervention | |
| DCS First, Then Placebo | 10 | 15 | 10 | 15 | 10 | 15 | 10 | 15 | 15 | 18 | 15 | 18 | 15 | 18 | 14 | 18 |
| Placebo First, Then DCS | 11 | 9 | 12 | 15 | 11 | 13 | 13 | 13 | 13 | 13 | 10 | 11 | 9 | 11 | 9 | 11 |
Agitation was further assessed by the Agitation Calmness Evaluation Scale (ACES) (Copyright 1998, Eli Lilly and Company), a single-item scale developed by Eli Lilly and Company on which 1 indicates marked agitation; 2, moderate agitation; 3, mild agitation; 4, normal; 5, mild calmness; 6, moderate calmness; 7, marked calmness; 8, deep sleep; and 9, unable to be aroused. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | 2.14 |
| 2. IM Haloperidol Pus Lorazepam | 2.23 |
The primary efficacy measure was PANSS-EC, which was derived from the PANSS by its originators using a principal-components factor analysis, and includes the items of tension, uncooperativeness, hostility, poor impulse control and excitement.22 The score of each item ranges from 1 (normal) to 7 (most severe), with a total sum score ranging from 5 to 35. The changes in PANSS-EC from baseline to 2 hours after the first injection were compared. (NCT00797277)
Timeframe: from baseline to 120 minutes after first injection
| Intervention | units on a scale (Mean) |
|---|---|
| 1. IM Olanzapine | -10.2 |
| 2. IM Haloperidol Plus Lorazepam | -9.9 |
110 reviews available for pirenzepine and Schizophrenia
| Article | Year |
|---|---|
Economic evaluations of olanzapine and risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Humans; Olanzapine; Pirenzepine; Rando | 2002 |
Continuum of care: stabilizing the acutely agitated patient.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Continuity of Patient Care; Cost-Be | 2002 |
Olanzapine-associated neuroleptic malignant syndrome.
Topics: Benzodiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepine; Retrospective Stud | 2002 |
Olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Randomi | 2003 |
Economic evaluations of novel antipsychotic medications: a literature review.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Costs; Humans; Olanzapine; Pirenz | 2003 |
Clinical trial response and dropout rates with olanzapine versus risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Patient Compliance; Patient | 2003 |
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.
Topics: Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition; Comorbi | 2003 |
Pharmacological approaches to the management of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiaze | 2003 |
Olanzapine induced neuroleptic malignant syndrome--a case review.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Pirenzepi | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Respon | 2003 |
[An introduction to antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Humans; Indoles; Is | 2003 |
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Ant | 2003 |
Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dopamine Antagonists; Humans; Imida | 1995 |
The new generation of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; | 1996 |
Olanzapine: a new atypical antipsychotic.
Topics: Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Humans; Olanzapine; Patient Care T | 1996 |
Cognitive function in schizophrenic patients.
Topics: Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Clozapine; Cognition Disorders; Dopamine; Gl | 1996 |
Atypical antipsychotic drugs and long-term outcome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Follow-Up Studies | 1996 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Evaluating outcomes of treatments for persons with psychotic disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Costs; Health Care Reform; Humans; Olanzapine; Pirenzepi | 1996 |
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders | 1997 |
The promise of new drugs for schizophrenia treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Imidazoles; Indoles; Olanzapine; Pirenzepi | 1997 |
Efficacy of olanzapine: an overview of pivotal clinical trials.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Male | 1997 |
Safety of olanzapine.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Clini | 1997 |
Olanzapine and the new generation of antipsychotic agents: patterns of use.
Topics: Antipsychotic Agents; Benzodiazepines; Child; Comorbidity; Dementia; Depressive Disorder; Developmen | 1997 |
Dosing the antipsychotic medication olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Respons | 1997 |
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cost-Benefit Analysis; Data Collect | 1997 |
Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia.
Topics: Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Clinical Trials as Topic; Humans; Olanz | 1997 |
New antipsychotic medications: strategies for evaluation and selected findings.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Topic; Clozapine; Drug Ad | 1997 |
[Olanzapine. A new antipsychotic agent].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Schizophrenia | 1997 |
Treatment of the refractory schizophrenic patient.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Diagnosis, Differential; | 1998 |
Olanzapine, sertindole and schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Imidazoles; Indoles; Ol | 1997 |
Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia.
Topics: Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Clozapine; Family Health; Humans; Olanza | 1997 |
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Clozapine; Dibenzothiazepines; Dopamine | 1998 |
Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Cost-Benefit Analysis; H | 1998 |
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dopamine Antagonists; Humans; Obses | 1998 |
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.
Topics: Adolescent; Adolescent Psychiatry; Age Factors; Antipsychotic Agents; Benzodiazepines; Cholinergic F | 1998 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Cost-Benefit Analysis; Dibenz | 1998 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Comorb | 1998 |
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Adult; Age Factors; Aged; Algorithms; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clini | 1998 |
Treatment refractory schizophrenia: how should we proceed?
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Humans; Olanzapine; Pire | 1998 |
[Use of novel agents in the treatment of schizophrenia and a look to the future].
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Cognition Disorders; Hum | 1998 |
Common treatment goals of antipsychotics: acute treatment.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Drug Administration Schedu | 1998 |
Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome.
Topics: Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Electroconvulsive Therapy; Episode o | 1998 |
The routine use of atypical antipsychotic agents: maintenance treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Caregivers; Dyskinesia, Drug-Induced; Humans; Olanzapine; Pir | 1998 |
Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Humans; Olanzapine; Pirenzepine; Ri | 1998 |
Conventional vs. newer antipsychotics in elderly patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re | 1999 |
Use of atypical neuroleptics in child and adolescent psychiatry.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Child; Child Development Diso | 1998 |
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dibenzothiazepines; Double-Blind Meth | 1999 |
Cognitive improvement in schizophrenia with novel antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dibenzothiazepines; Humans; O | 1999 |
Tardive dyskinesia and atypical antipsychotic drugs.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 1999 |
Antipsychotic drugs and relapse prevention.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Olanzapine; Pirenzepine; Risperidone; Schi | 1999 |
Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Humans; Olanzapine; Pirenze | 1999 |
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; D | 1999 |
Tardive dyskinesia in affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 1999 |
Cognitive deficit in schizophrenia and its neurochemical basis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Glutamic Acid; Haloperidol; H | 1999 |
Olanzapine in the long-term treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; H | 1999 |
Review of recent clinical studies with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Drug Resistance; Humans; Olan | 1999 |
Olanzapine: preclinical pharmacology and recent findings.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Cholinergic Antagonists; Clozapine | 1999 |
Olanzapine: a basic science update.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Gene Expression; Humans; Olanzapine; Pirenzepine; Re | 1999 |
Antipsychotics from theory to practice: integrating clinical and basic data.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Cl | 1999 |
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.
Topics: Amoxapine; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dopamine Antagonists; Haloperi | 1999 |
Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepi | 1999 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
Clozapine: a comparison with other novel antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; Double-Blind | 1999 |
Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Confidence Intervals; Dibenzothiazep | 1999 |
Drug metabolism and atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cytochrome P-450 Enzyme System; Dibenzothiazepines | 1999 |
Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Nurse Clinicians; Olanzapine; Pirenzepine; | 1998 |
Focus on olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Interactions; Humans; Olanzapi | 1999 |
[Clinical efficacy of olanzapine].
Topics: Antipsychotic Agents; Benzodiazepines; Binding Sites; Clinical Trials as Topic; Clozapine; Dopamine | 1999 |
Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Costs and Cost Analysis; Dyskinesia, Drug-Induced; Humans; Ol | 1999 |
Pharmacologic treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Pirenzepin | 1999 |
Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Humans; Imidazoles; Indoles | 1999 |
New antipsychotic medications: more than old wine and new bottles.
Topics: Agranulocytosis; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzot | 2000 |
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
The treatment of tardive dyskinesia and tardive dystonia.
Topics: Adult; Akathisia, Drug-Induced; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Decisi | 2000 |
[Atypical neuroleptics in child- and adolescent psychiatry].
Topics: Adolescent Psychiatry; Antipsychotic Agents; Benzodiazepines; Child; Child Psychiatry; Clozapine; Ge | 2000 |
Olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Schizop | 2000 |
Risperidone side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Inc | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
Psychopharmacology of olanzapine. A review.
Topics: Antipsychotic Agents; Humans; Pirenzepine; Quality of Life; Randomized Controlled Trials as Topic; S | 1999 |
Risperidone versus other atypical antipsychotic medication for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Olanzapine; Pirenzepine; Randomized Contro | 2000 |
[Atypical antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Netherlands; Olanzapin | 2000 |
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dose-Response Relationship, Drug; Fe | 2000 |
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Dose-Response Relationship, Drug; Haloper | 2000 |
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Costs; Human | 2000 |
Atypical neuroleptics in child and adolescent psychiatry.
Topics: Adolescent; Adolescent Psychiatry; Antipsychotic Agents; Benzodiazepines; Binding Sites; Brain; Cloz | 2000 |
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2001 |
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].
Topics: Aged; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Controlled Clinical Trials as T | 2000 |
Olanzapine: an updated review of its use in the management of schizophrenia.
Topics: Adolescent; Aged; Animals; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Cognition | 2001 |
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Dopamine D2 Receptor Antagonists; Haloperid | 2001 |
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.
Topics: Acute Disease; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Death, Sudden; Female; H | 2001 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up | 2001 |
Olanzapine: an atypical antipsychotic for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Humans; Olanzapine; Pirenzepine; Sc | 2000 |
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Female; Humans; Longitudin | 2001 |
Antipsychotic-induced weight gain: a review of the literature.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Female; Humans; Mal | 2001 |
The pharmacology of weight gain with antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Eating; Humans; Olanz | 2001 |
Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Therapy, Combination; Haloperi | 2001 |
Ziprasidone: a new atypical antipsychotic.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Dopamine Antago | 2001 |
Hyperglycemia associated with the use of atypical antipsychotics.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; | 2001 |
Review of atypical antipsychotics and weight gain.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clinical Trials as Topic; C | 2001 |
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Models, N | 2001 |
[Efficacy of rispolept and zyprexa in the treatment of patients with schizophrenia].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Quality of Life; Risperidone | 2001 |
[Clinical and pharmacological studies of the second generation antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Cytoskeletal Proteins; Dibenz | 2001 |
[Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Hostility; Humans; Olanzapine; Pirenze | 2002 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage For | 2002 |
Use of olanzapine for elderly patients with psychotic disorders: a review.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; R | 2001 |
175 trials available for pirenzepine and Schizophrenia
| Article | Year |
|---|---|
Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.
Topics: Adolescent; Adult; Antipsychotic Agents; Asia, Eastern; Asia, Southeastern; Benzodiazepines; Drug Ad | 2002 |
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Huma | 2002 |
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Female; H | 2002 |
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzamides; Benzodiazepines; Contrast Media; Corpus Striatum; Dop | 2002 |
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
Topics: Adult; Benzodiazepines; Chemotherapy, Adjuvant; Chronic Disease; Drug Interactions; Female; Fluvoxam | 2002 |
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; | 2002 |
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Donepezil; Drug Therapy, Combinat | 2003 |
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cross-Over Studies; Double-Bli | 2002 |
Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bone Density; Clopenthixol; Cloz | 2002 |
Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Female; Humans; Male; | 2002 |
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; B | 2002 |
[Zyprexa (olanzapine)--new possibilities in the treatment of schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzap | 2002 |
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Chronic Disease; Drug Re | 2002 |
Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; M | 2002 |
Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dru | 2002 |
5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Hu | 2002 |
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Re | 2003 |
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagnosis, Differential; Femal | 2003 |
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Double-Blind Metho | 2003 |
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Middle Ag | 2003 |
Olanzapine treatment for patients with schizophrenia and cocaine abuse.
Topics: Antipsychotic Agents; Benzodiazepines; Cocaine-Related Disorders; Double-Blind Method; Humans; Male; | 2002 |
A prospective, open-label trial of olanzapine in adolescents with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Female; Humans; Male; Olanzapine; Pirenzep | 2003 |
Effects of olanzapine on auditory P300 in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Event-Related Potentials, P300; Evoked Potentials, Aud | 2003 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double- | 2003 |
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Corpus Striatum; D | 2003 |
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
Topics: Adolescent; Adult; Arousal; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2003 |
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.
Topics: Adolescent; Adult; Analysis of Variance; Benzodiazepines; Double-Blind Method; Female; Fluoxetine; H | 2003 |
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Diseas | 2003 |
Do atypical antipsychotics fail to exert cognitive sparing effects?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition; Double-Blind Method; Evok | 2003 |
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Caffeine; Chromatography, High Pressure Liquid; Cytoch | 2003 |
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Depressive | 2003 |
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Diagnostic and Statistical Manual o | 2003 |
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Benzodiazepines; Double-Blind Method; Drug Therapy, C | 2003 |
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-I | 2003 |
Tc-99 HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Cerebrovascular Circulation; Female; | 2003 |
Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Female; Humans | 2003 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
Topics: Adult; Antipsychotic Agents; Australia; Benzodiazepines; Cost-Benefit Analysis; Dose-Response Relati | 2003 |
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Femal | 2003 |
The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; O | 2003 |
Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Benzodiazepines; Female; Hu | 2003 |
Calming versus sedative effects of intramuscular olanzapine in agitated patients.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dementia; Doubl | 2003 |
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Double-Blin | 2003 |
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cogn | 2003 |
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 2003 |
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Metho | 2003 |
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Huma | 2003 |
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Middle Aged; Ol | 2003 |
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Fe | 2003 |
A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Benzodiazepines; Canada; Cognition; Female; Human | 2003 |
Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Histamine H2 Antagonists; Humans; Male; Nizati | 2003 |
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Histamine H2 Antagonists; | 2003 |
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Method; Female; Human | 2003 |
Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial.
Topics: Adult; Antipsychotic Agents; Asian People; Benzodiazepines; Brief Psychiatric Rating Scale; Female; | 2003 |
The effect of olanzapine on anxiety among patients with schizophrenia: preliminary findings.
Topics: Adult; Anxiety; Benzodiazepines; Female; Humans; Male; Olanzapine; Pirenzepine; Schizophrenia | 2003 |
The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Gonadal Steroid Hormones; Humans; Leptin; Midd | 2003 |
The effects of an educational intervention on antipsychotic-induced weight gain.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Body Mass Index; Female; Health Kn | 2003 |
5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Genotype; Humans; Olanzapine; Pirenzepine; Polymorphism, Gene | 2003 |
Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Hospitalization; Humans; Ma | 2003 |
Olanzapine effects on auditory sensory gating in schizophrenia.
Topics: Acoustic Stimulation; Adolescent; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; | 2003 |
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists | 2003 |
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebral Cortex; Dopamine; Female; Fingers; Functional | 2003 |
Optimal treatment project for schizophrenia: results from a randomized, controlled, longitudinal study.
Topics: Adaptation, Psychological; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Case Management | 2003 |
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Benztropine; Double-Blind Met | 2003 |
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; | 2004 |
Olanzapine induces insulin resistance: results from a prospective study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Composition; Body Weight; Dose-Res | 2003 |
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Cross-Over Studies; Dose-Response | 2004 |
Reduction of clozapine-induced hypersalivation by pirenzepine is safe.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Clozapine; Cross-Over Studies; Do | 2004 |
A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administration Schedule; Fem | 2005 |
First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Hu | 1995 |
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Respon | 1996 |
Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Obsessive-Compulsive Disorder; O | 1996 |
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Olanzapine; | 1996 |
Olanzapine for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Constipation; Costs and Cost Analysis; Dizziness; Dose-Respon | 1997 |
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depre | 1997 |
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response | 1997 |
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male | 1997 |
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 1997 |
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Cost-Benefit Analysis; Data Collect | 1997 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration | 1997 |
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; | 1997 |
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Cross-Sectional Studies; Dopa | 1997 |
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; | 1997 |
Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Pirenze | 1997 |
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloper | 1998 |
Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale | 1997 |
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Depressive Disorder; Double-Blind Method; | 1998 |
Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Female; Humans; M | 1998 |
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Haloperidol; Humans; Mal | 1998 |
The effects of risperidone and olanzapine on the indications for clozapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Olanzapine; Pirenzepine; Risperidone; Schi | 1998 |
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Topics: Adult; Antipsychotic Agents; Anxiety; Benzodiazepines; Depression; Dose-Response Relationship, Drug; | 1998 |
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; | 1998 |
5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Dose-Response Relationship, Drug | 1998 |
Olanzapine-induced reversible priaprism: a case report.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; Humans | 1998 |
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Humans; Olanzapine; Pirenzepine; Psychot | 1998 |
Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Clozapine; Cross-Over | 1998 |
Olanzapine versus haloperidol treatment in first-episode psychosis.
Topics: Age of Onset; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Ratin | 1999 |
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Clozapine; Contrast | 1999 |
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Ben | 1999 |
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Topics: Antipsychotic Agents; Anxiety; Benzodiazepines; Brief Psychiatric Rating Scale; Depression; Double-B | 1999 |
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; D | 1999 |
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; H | 1999 |
Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; | 1999 |
Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Resistance; Femal | 1999 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I | 1999 |
Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Cost-Bene | 1999 |
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Double-Blind Method; | 1999 |
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cluster Analysis; Cognition Disorders; Depressive Diso | 1999 |
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Europe; Fem | 1999 |
Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Humans; Male; Olanzapine; Pir | 1999 |
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cross-Over Studies; Double-Blind Method; Fe | 1999 |
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Double-Blind Method; Drug Costs | 1999 |
Olanzapine therapy in elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Pi | 1998 |
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Haloperidol; Humans; Olanzapine; | 1999 |
The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Haloperidol; Hospital Costs; Humans; O | 1999 |
A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Follow-Up Studie | 1999 |
Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dose-Response Relation | 1999 |
Olanzapine increases weight and serum triglyceride levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Hospitalizat | 1999 |
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Brain; Brain Mapping; Contrast | 1999 |
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Double-Blind Me | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
[The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia].
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rat | 2000 |
Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cross-Sectional Studies; Drug | 2000 |
Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.
Topics: Adult; Age of Onset; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; | 2000 |
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepi | 2000 |
A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Therapy, Combination; Electroenc | 2000 |
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
Topics: Activities of Daily Living; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Femal | 2000 |
Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric | 2000 |
Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Drug Therapy, Combination; Female; Hu | 2000 |
The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Olanzapine; Pirenzepine; Schizophrenia; Se | 2000 |
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Administrat | 2000 |
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Body Weight; Clozapine; Double-Blind M | 2001 |
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Brain; Brain Chemi | 2000 |
Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.
Topics: Acute-Phase Reaction; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male | 2001 |
Switching clozapine responders to olanzapine.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Adm | 2000 |
Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
Topics: Adult; Aged; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter St | 2000 |
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Double- | 2001 |
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric | 2001 |
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Humans; Male; | 2001 |
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Female; Haloperidol; H | 2001 |
Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Humans; Male; Olanzapine; Pirenz | 2001 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Female; Humans; Longitudin | 2001 |
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.
Topics: Acute Disease; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agent | 2001 |
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Olanzapine; Pirenzepine; Pr | 2001 |
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, | 2001 |
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Female; Humans; Japa | 2001 |
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Double-Blind | 2001 |
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperi | 2001 |
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
Topics: Adult; Affective Disorders, Psychotic; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; | 2001 |
Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cerebellum; Cognition Disorders; Female; Humans; Magne | 2001 |
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Benzodiazepines; Contrast Media; Corpus Stri | 2001 |
The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 2001 |
Association of olanzapine-induced weight gain with an increase in body fat.
Topics: Adipose Tissue; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass Index; Fee | 2001 |
Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine.
Topics: Adult; Antipsychotic Agents; Autonomic Nervous System; Benzodiazepines; Blood Vessels; Clozapine; Fe | 2001 |
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Double-Blind Method; Dyskinesia, | 2001 |
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2001 |
P300 and symptom improvement in schizophrenia.
Topics: Adult; Affective Symptoms; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Ev | 2001 |
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Dose-Response Relatio | 2001 |
The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia.
Topics: Adrenocorticotropic Hormone; Adult; Analysis of Variance; Area Under Curve; Benzodiazepines; Double- | 2001 |
Olanzapine treatment for patients with schizophrenia and substance abuse.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine | 2001 |
Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dose-Response Relation | 2002 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Cyclo | 2002 |
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Cyclo | 2002 |
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Cyclo | 2002 |
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Topics: Adult; Antibiotics, Antitubercular; Antipsychotic Agents; Benzodiazepines; Cross-Over Studies; Cyclo | 2002 |
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin | 2002 |
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Haloperidol; Humans; Male | 2002 |
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relatio | 2002 |
Sex differences in clinical response to olanzapine compared with haloperidol.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; H | 2002 |
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
Topics: Adolescent; Adult; Amenorrhea; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female | 2002 |
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Double-Blind Method; Female; Hal | 2002 |
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Eating; Energy Inta | 2002 |
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Therapy, Co | 2002 |
304 other studies available for pirenzepine and Schizophrenia
| Article | Year |
|---|---|
Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Female; Humans; | 2013 |
Toward rational use of benzodiazepines in posttraumatic stress disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Utilization; Female; Humans; Male; Pirenzepine; Schizoph | 2013 |
Dr. Lund and colleagues reply.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Utilization; Female; Humans; Male; Pirenzepine; Schizoph | 2013 |
An investigation of the factors that regulate muscarinic receptor expression in schizophrenia.
Topics: Adult; Blotting, Western; Brain; Cohort Studies; Humans; Middle Aged; Piperidines; Pirenzepine; Poly | 2014 |
Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.
Topics: Allosteric Regulation; Cations, Divalent; Cerebral Cortex; Female; Humans; Male; Middle Aged; N-Meth | 2016 |
Changes in cholinergic and glutamatergic markers in the striatum from a sub-set of subjects with schizophrenia.
Topics: Autoradiography; Blotting, Western; Corpus Striatum; Disks Large Homolog 4 Protein; Female; Glial Fi | 2015 |
Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Monitoring; Female; Humans; Male; Middle Aged; Ol | 2016 |
Levels of [(3)H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1.
Topics: Adult; Aged; Autoradiography; Binding Sites; Cathepsin B; Cerebral Cortex; Female; Humans; Male; Mid | 2008 |
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Clozapine; DNA Primer | 2008 |
Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype.
Topics: Adult; Aged; Cell Membrane; Female; GTP-Binding Protein alpha Subunits, Gq-G11; Guanosine 5'-O-(3-Th | 2009 |
Effects of benzodiazepine treatment on cortical GABA(A) and muscarinic receptors: studies in schizophrenia and rats.
Topics: Adult; Aged; Analysis of Variance; Animals; Benzodiazepines; Cerebral Cortex; Female; Flumazenil; GA | 2010 |
Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia.
Topics: Adult; Aged; Animals; Cerebral Cortex; Cohort Studies; Female; Humans; Male; Mice; Mice, Knockout; M | 2013 |
Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid.
Topics: Antipsychotic Agents; Benzodiazepines; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Female; Hum | 2012 |
Excessive recruitment of neural systems subserving logical reasoning in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Brain Mapping; Clozapine; Female; Functional La | 2002 |
Fatality from olanzapine induced hyperglycemia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Dehydration; Diabetes Complicati | 2002 |
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Estradiol; Female; Humans; Hyperprolactinem | 2002 |
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cohort Studies; Diabetes M | 2002 |
Marked improvement of Meige's syndrome with olanzapine in a schizophrenic patient.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Male; Meige Syndrome; Middle Aged; Olanzapine; Pirenz | 2002 |
Emergence of compulsive symptoms with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Humans; Male; Obsessive-Compulsive Di | 2002 |
Weight loss associated with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Retrospective S | 2002 |
The value of atypical antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dopamine Antagonists; Drug Lab | 2002 |
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Child; Clozapine; Double-Blind Method; Fem | 2002 |
[Zyprexa with superior effectiveness-risk relation. For every therapy situation a suitable dosage form].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Nursing Assessment; Olanzapine; Pirenzepine; Psychiat | 2002 |
Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Combined Modality Therapy; Electroconvulsive Therapy; | 2002 |
From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Administ | 2002 |
Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients.
Topics: Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiepins; Hostility; Humans; Ola | 2002 |
[Olanzapine-induced diabetes mellitus].
Topics: Adult; Benzodiazepines; Body Weight; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Dose-Response | 2002 |
Clinical issues associated with maintenance treatment of patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Continuity of Patient Ca | 2002 |
Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depression; Female; Humans; Male; Middle Aged; Olanzap | 2002 |
"Normalization" of brain activation in schizophrenia. An fMRI study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Female; Humans; Magnetic Resonance Imaging; Mid | 2002 |
Weight gain associated with atypical antipsychotics.
Topics: Adolescent; Benzodiazepines; Child; Dopamine Antagonists; Female; Haloperidol; Humans; Male; Obesity | 2002 |
Effects of olanzapine and clozapine upon pulse rate variability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cross-Sectional Studies; Female; Heart Rate | 2002 |
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Benzodiazepines; Case-Co | 2002 |
Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Biological Availability; Dose-Re | 2002 |
Comparable dopamine 2 receptor occupancy.
Topics: Benzodiazepines; Cognition Disorders; Dopamine Antagonists; Haloperidol; Humans; Olanzapine; Pirenze | 2002 |
D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manua | 2002 |
Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Topics: Acetylcholine; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Cognition Disorders; Dopamine; Ma | 2002 |
Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; | 2002 |
Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia.
Topics: Adult; Aged; Cause of Death; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Organ Sp | 2002 |
Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dr | 2003 |
Peripheral oedema in patients taking olanzapine.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Edema; Female; Humans; Male; Middle Aged; | 2003 |
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition; Cognition Disorders; Female; Hal | 2002 |
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Diagnostic and Statistical Manual of Menta | 2003 |
Prescribing second-generation antipsychotics and the evolving standard of care in Italy.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Benzodiazepines; Brief Psychiatri | 2002 |
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.
Topics: Adult; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Olanz | 2003 |
The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment.
Topics: Activities of Daily Living; Antipsychotic Agents; Benzodiazepines; Europe; Humans; Olanzapine; Outpa | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Trials as Topic; Clozapine; | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Blind Met | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administrat | 2003 |
Local-global processing in early-onset schizophrenia: evidence for an impairment in shifting the spatial scale of attention.
Topics: Adolescent; Affect; Antipsychotic Agents; Attention; Benzodiazepines; Clopenthixol; Diazepam; Female | 2003 |
Olanzapine and risperidone.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Humans; Olanzapine; Pirenzepine; Rispe | 2003 |
Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Antipsychotic Agents; Benzodiazep | 2003 |
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Estrogens | 2003 |
The influence of olanzapine on immune cells in patients with schizophrenia.
Topics: Adolescent; Adult; Benzodiazepines; Female; Humans; Immunity, Cellular; Lymphocytes; Male; Middle Ag | 2003 |
Role of ethnicity in predicting antipsychotic medication adherence.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Ethnicity; Female; Haloper | 2003 |
Cost evaluation of risperidone compared with olanzapine.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Costs and Cost Analysis; Hospitalization; Hu | 2003 |
Acute dystonia caused by low dosage of olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dystonia; Female; Humans; M | 2003 |
Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Brain; Brain-Derived Neurotrophic Factor; Dizocilpin | 2003 |
Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Dose-Response Relationship | 2003 |
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dibenzothiazepines; Female | 2003 |
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost-Benefit Analysis; Costs and Cost | 2003 |
The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Europe; Female; Humans; Male; Middle | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepin | 2003 |
Treatment of cervical dystonia by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Male | 2003 |
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Black or African American; Drug Utilization; Fem | 2003 |
Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cost of Illness; Drug Costs; Female; Health Care Costs | 2003 |
Rehospitalization risk with second-generation and depot antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Data Collection; Delayed-Action Preparation | 2003 |
Should lipids be monitored during the first year of treatment with an atypical antipsychotic?
Topics: Antipsychotic Agents; Benzodiazepines; Cholesterol; Clozapine; Humans; Hyperglycemia; Hyperlipidemia | 2003 |
Potential risk of diabetes mellitus with the use of atypical antipsychotic medication.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus; Humans; Male; Middle Aged; Olanzapine; Pir | 2003 |
Treatment noncompliance with orally disintegrating olanzapine tablets.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Humans; Middle | 2003 |
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middl | 2003 |
Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia.
Topics: Adolescent; Adult; Benzodiazepines; Cognition; Female; Follow-Up Studies; Humans; Male; Middle Aged; | 2003 |
Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Black or African American; Contraindications; Diagnosi | 2003 |
Eruptive xanthomas associated with olanzapine use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperlipidemias; Male; Middle Aged; Ol | 2003 |
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.
Topics: Absorptiometry, Photon; Adolescent; Adult; Benzodiazepines; Bone Density; Female; Humans; Middle Age | 2003 |
Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics.
Topics: Adult; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Benzodiazepines; Fat | 2003 |
Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex.
Topics: Action Potentials; Animals; Benzodiazepines; Depressive Disorder; Dose-Response Relationship, Drug; | 2003 |
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Topics: Benzodiazepines; Brief Psychiatric Rating Scale; Drug Therapy, Combination; Humans; Male; Olanzapine | 2003 |
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Dibenzothiaze | 2003 |
[Neuroleptics and cognition].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Drug Therapy, Combinat | 2003 |
[3-D ultrasound-assisted gait analysis of schizophrenic patients. Comparison between conventional neuroleptics and olanzapine].
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Equipment Design; Female; Gait Disorders, Neurol | 2003 |
Schizophrenia, VI: Treatments.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Perphenazi | 2003 |
Racial disparity in the use of atypical antipsychotic medications among veterans.
Topics: Antipsychotic Agents; Benzodiazepines; Black or African American; Clozapine; Dibenzothiazepines; Dru | 2003 |
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].
Topics: Acute Kidney Injury; Adult; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Fever; H | 2003 |
Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; | 2003 |
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double | 2003 |
Reducing the risk for suicide in schizophrenia and affective disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Cause of Death; Clozapine; Cross-Sectional Studies; Humans; I | 2003 |
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Dibenzothiazepines; Drug The | 2003 |
Rapid onset of dyskinesia induced by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Female; Humans; O | 2003 |
Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Exercise; Female; Fitness Centers; Health | 2003 |
Fungal dermatitis with olanzapine in schizophrenia.
Topics: Adult; Antifungal Agents; Antipsychotic Agents; Benzodiazepines; Drug Eruptions; Humans; Ketoconazol | 2003 |
Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Monitoring; Fem | 2003 |
High-dose olanzapine and prolactin levels.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Hum | 2003 |
M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia.
Topics: Brain Chemistry; Cognition Disorders; Humans; Muscarinic Agonists; Muscarinic Antagonists; Pirenzepi | 2004 |
M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders.
Topics: Adult; Age of Onset; Analysis of Variance; Autoradiography; Brain Mapping; Case-Control Studies; Dos | 2005 |
5-HT2A and muscarinic receptors in schizophrenia: a postmortem study.
Topics: Aged; Aged, 80 and over; Autoradiography; Brain; Case-Control Studies; Female; Humans; Ketanserin; M | 2005 |
Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia.
Topics: Adult; Autoradiography; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Musc | 2005 |
Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia.
Topics: Adult; Aged; Autoradiography; Female; GABA Agonists; Gyrus Cinguli; Humans; Male; Middle Aged; Musca | 2007 |
Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication.
Topics: Adolescent; Adult; Age Factors; Anorexia Nervosa; Antipsychotic Agents; Benzodiazepines; Child; Drug | 2006 |
Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia.
Topics: Adult; Aged; Autoradiography; Cohort Studies; Female; Hippocampus; Humans; Male; Middle Aged; Pirenz | 2007 |
Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Cohort Studies; Down-Regulation; Female; Human | 2009 |
Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Costs | 1996 |
Using the proportional odds model to assess the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials, Phase II as Topic; Humans; Linear Models; Mu | 1996 |
Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Benzamides; Benzodiazepines; Corpus Striatum; Haloperidol; Humans; Midd | 1996 |
Olanzapine: a novel atypical neuroleptic agent.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Humans; Olanzapine; Pirenzepine; Ps | 1997 |
Switching antipsychotic medications.
Topics: Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Routes; Drug | 1997 |
[Olanzapin: a new perspective in the management of schizophrenia. X. Congress of the World Psychiatric Association, Madrid, August 1996].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Schizophrenia; Serotonin Ant | 1996 |
High-dose olanzapine for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chronic Disease; Drug Administ | 1997 |
Prolongation of clozapine-induced granulocytopenia associated with olanzapine.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Humans; Olanza | 1997 |
[Olanzapine--a new atypical neuroleptic. A chance for advancement in the therapy of schizophrenia].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Schizophrenia | 1997 |
Olanzapine on trial.
Topics: Advertising; Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as Topic; Drug Indust | 1998 |
Olanzapine on trial.
Topics: Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as Topic; Double-Blind Method; Hum | 1998 |
Olanzapine on trial.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Haloperidol; Humans; Olanzapi | 1998 |
Marked reduction of tardive dyskinesia with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Olanzapine; Ph | 1998 |
Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Clozapine; Corpus St | 1998 |
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hallucinations; Humans; Male; | 1998 |
Marketing of antipsychotic drugs attacked.
Topics: Advertising; Antipsychotic Agents; Benzodiazepines; Drug Industry; Federal Government; Government Re | 1998 |
Paranoia and agitation associated with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Paranoid Disorders; | 1998 |
Management of treatment-resistant schizophrenia with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Humans; Male; Olanzapine; Pirenzepine | 1998 |
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi | 1998 |
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psychotic Disorders; Risperi | 1998 |
Worsening of obsessive-compulsive symptoms following treatment with olanzapine.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Humans; Male; Obsessive-Co | 1998 |
Hypersalivation coincident with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Olanzapine; Pirenzepine; Schizophrenia | 1998 |
Olanzapine-induced manic-like syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Administration Schedule; Hospit | 1998 |
Experiences with clozapine and olanzapine.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Male; Midd | 1998 |
The new antipsychotic compounds: is a clinical choice algorithm possible?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Pirenzepin | 1998 |
Olanzapine for primary negative symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Controlled Clinical Trials as | 1998 |
[Schizophrenia and depression. Special aspects in the therapy of women].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Female; Humans; Olanzapine; P | 1998 |
Olanzapine for the treatment of tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Biperiden; Dyskinesia, Drug-Induced; Female; Haloperido | 1998 |
Two new atypical antipsychotics: advantages and disadvantages.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Interactions; Humans; Ola | 1998 |
Severe akathisia during olanzapine treatment of acute schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Female; Humans; Middle Aged; | 1998 |
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Female; Galactorrhea; Humans; Hyperprolact | 1998 |
Olanzapine augmentation of clozapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Drug Resistance; Drug Th | 1998 |
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan | 1998 |
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan | 1998 |
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan | 1998 |
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Illicit Drugs; Male; Middle Aged; Olan | 1998 |
Quality of life and atypical antipsychotics.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Psych | 1998 |
Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Patient Selection; Pirenzepine; Schizophr | 1998 |
Novel antipsychotics and new onset diabetes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Humans; Male; Mi | 1998 |
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Hal | 1998 |
Olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Resistance; Humans; Olanzapine; Pirenzepine; Retrospecti | 1998 |
Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Humans; Middle Aged; Olanzapine; Pi | 1998 |
Aggression, agitation, and mania with olanzapine.
Topics: Adult; Aggression; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 1998 |
British experience with high-dose olanzapine for treatment-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Schizophrenia; United Kingdo | 1999 |
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Carbon Radioisotopes; Clozapine; Drug Administration S | 1999 |
Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Follow-Up Studies; Humans; | 1999 |
Hyperprolactinemia and male sexual dysfunction.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Hyperprolactinemia; Male; Olanzapine; Pirenzep | 1999 |
A cost-effectiveness clinical decision analysis model for schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; Decision Support Systems, C | 1998 |
Atypical antipsychotics and formulary decisions.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Costs; Efficiency; Formularies as | 1998 |
New-onset panic attacks in a patient treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Olanzapine; Panic Disorder; Pirenzepin | 1999 |
Plasma olanzapine and clinical response.
Topics: Benzodiazepines; Humans; Olanzapine; Pirenzepine; Schizophrenia | 1999 |
Olanzapine-induced obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Comp | 1999 |
Side effects of olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Eye Diseases; Humans; Male; Mucus; Olanzapine; Pirenze | 1999 |
The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia.
Topics: Adult; Aged; Animals; Antipsychotic Agents; Caudate Nucleus; Female; Humans; Male; Middle Aged; Musc | 1999 |
Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Drug Resistance; Drug Therapy, Comb | 1999 |
Weight gain and antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid | 1999 |
Olanzapine and NMS.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Neuroleptic Malignant Syndrome; Olanzapi | 1999 |
Tardive dyskinesia associated with olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Humans; Olanza | 1999 |
Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delta Rhythm; Dose-Response Relationship, Drug; Female | 1999 |
A dilemma born of progress: switching from clozapine to a newer antipsychotic.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Benzodiazepines; Clozapine; Drug Monitoring; Humans | 1999 |
Olanzapine overdose.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Overdose; Female; Hallucinations; Humans; Olanzap | 1999 |
Clozapine to olanzapine.
Topics: Adult; Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Administration Schedule; Huma | 1999 |
Marked elevation of serum creatine kinase associated with olanzapine therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Creatine Kinase; Humans; Male; Olanza | 1999 |
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Case-Control Studi | 1999 |
Clozapine-olanzapine: a potentially dangerous switch. A report of two cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Male; Middle Aged; Olanzapine; Pire | 1999 |
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Female; H | 1999 |
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Hum | 1999 |
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].
Topics: Adult; Alprazolam; Antipsychotic Agents; Benzodiazepines; Bradycardia; Carbamazepine; Disseminated I | 1999 |
Olanzapine-induced agranulocytosis.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine | 1999 |
Benefits of olanzapine as first-line schizophrenia therapy.
Topics: Antipsychotic Agents; Benzodiazepines; Olanzapine; Pirenzepine; Schizophrenia | 1999 |
In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.
Topics: Adult; Benzamides; Benzodiazepines; Case-Control Studies; Contrast Media; Corpus Striatum; Dose-Resp | 1999 |
Olanzapine-induced elevation of plasma triglyceride levels.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administr | 1999 |
A new mechanism for the actions of olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Gene Expression; Humans; Neuroprotective Agents; Olanzapine; | 1999 |
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Leg; Male; Olanzapine; Pirenzepine; Restless L | 1999 |
Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Case Management; Clini | 1999 |
Pustular eruption induced by olanzapine, a novel antipsychotic agent.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Drug Eruptions; Humans; Male; | 1999 |
Evaluation of outcomes for atypical antipsychotic therapy and psychosocial rehabilitation in a community mental health center setting. Based on a presentation by Douglas Noordsy, MD.
Topics: Antipsychotic Agents; Benzodiazepines; Community Mental Health Centers; Health Services Research; Hu | 1999 |
Weight gain associated with antipsychotic drugs.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Clozapine; Delayed-Action Preparations; | 1999 |
Body mass index increase of 58% associated with olanzapine.
Topics: Adolescent; Benzodiazepines; Body Mass Index; Humans; Male; Obesity; Olanzapine; Pirenzepine; Schizo | 1999 |
High-dose olanzapine therapy in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Humans; Male; Olanza | 1999 |
Reduction of tardive dystonia with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dystonic Disorders; Humans; Male; Olanzapine; Pirenzep | 1999 |
Differential olanzapine plasma concentrations by sex in a fixed-dose study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Male | 1999 |
Intoxication with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Overdose; Humans; Male; Olanzapine; Pirenzepine; | 2000 |
Quality of life and new antipsychotics in schizophrenia. Are patients better off?
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; P | 1999 |
Olanzapine. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Chlorpromazine; Clinical Trials as Topic; Dopamine Antagonist | 2000 |
Rabbit syndrome treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Humans; Olanzapine; | 2000 |
Olanzapine: safe during clozapine-induced agranulocytosis.
Topics: Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Male; Middle Aged; Olanza | 2000 |
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorde | 2000 |
Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Topics: Acoustic Stimulation; Adult; Antipsychotic Agents; Auditory Perception; Benzodiazepines; Clozapine; | 2000 |
Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia.
Topics: Adult; Aged; Caudate Nucleus; Female; Humans; In Situ Hybridization; Male; Middle Aged; Parasympatho | 2000 |
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Benzodiazepines; Corpus | 2000 |
Novel antipsychotic use in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Dibenzothiepins; Drug Administration Sche | 2000 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Utilizat | 2000 |
In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Female; Humans; Male; Middle Aged; Olanzapine; | 2000 |
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Obsessive-Compulsiv | 2000 |
Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzamides; Benzodiazepines; Corpus Striatum; Fem | 2000 |
Antipsychotics during pregnancy.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Olanzapine; Pirenzepine; Pregnancy; Pregnancy | 2000 |
Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Creatine Kinase; Dibenzothiazepines; Humans | 2000 |
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Cytokines; Female; Granulo | 2000 |
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Costs and Cost Analysis; Haloperido | 2000 |
Olanzapine overdose.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Overdose; Humans; Male; Olanzapine; Pirenzepine; | 2000 |
St. John's wort and schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hypericum; Male; Olanza | 2000 |
Olanzapine: keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Pirenzepine; Schizophrenia | 2000 |
Olanzapine and obsessive-compulsive symptoms.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Obsessive-Compulsive Disorder; O | 2000 |
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Diabetes Mellitus; Gly | 2000 |
Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation.
Topics: Adult; Aged; Autoradiography; Female; Hippocampus; Humans; Male; Middle Aged; Muscarinic Antagonists | 2000 |
First person account: I and I, dancing fool, challenge you the world to a duel.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Schizophrenia; | 2000 |
Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Cytokines; Humans; Olanzapine; Pirenzepine; Recept | 2000 |
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Humans; Methotrimeprazine; Neu | 2000 |
Risperidone and tardive dyskinesia: a case of blepharospasm.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blepharospasm; Dyskinesia, Drug-Induced; Humans; Male; | 2000 |
[Bullae induced by acute neuroleptic intoxication].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Hypersensitivity; Eccrine Glands; Humans; Male; N | 2000 |
Disposition of olanzapine in Chinese schizophrenic patients.
Topics: Adult; Asian People; Benzodiazepines; Drug Tolerance; Humans; Male; Middle Aged; Olanzapine; Pirenze | 2000 |
Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.
Topics: Adult; Anti-Bacterial Agents; Antipsychotic Agents; Benzodiazepines; Bromocriptine; Combined Modalit | 2000 |
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Chromatography, High Press | 2000 |
Olanzapine and pancreatitis.
Topics: Adult; Alcohol Drinking; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Humans; Male; Olanz | 2000 |
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Administrat | 2000 |
Hematologic reference ranges in a population of patients with schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Blac | 2000 |
Neuropletic malignant syndrome and olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Neuroleptic Malignant Syndrome; Olanza | 2000 |
Olanzapine prolongation of granulocytopenia after clozapine discontinuation.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Olanzapine | 2000 |
Olanzapine: concordant response in monozygotic twins with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Diseases in Twins; Female; Humans; Middle Aged; Olanzapine; P | 2001 |
Misdiagnosis of schizophrenia for a patient with epilepsy.
Topics: Antipsychotic Agents; Benzodiazepines; Diagnosis, Differential; Diagnostic Errors; Electroencephalog | 2001 |
Neuroleptic therapy influences basal ganglia activation: a functional magnetic resonance imaging study comparing controls to haloperidol- and olanzapine-treated inpatients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Haloperidol; Hospitalization; Hu | 2000 |
[Olanzapine (Zyprexa)].
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Chemistry, Pharmaceutical; Clinical Tri | 2000 |
Drug review "surprises" reader.
Topics: Aged; Alanine Transaminase; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug In | 2000 |
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Hospitalization; Humans; Isra | 2001 |
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.
Topics: Adult; Benzodiazepines; Brain Mapping; Carrier Proteins; Corpus Striatum; Dopamine Plasma Membrane T | 2001 |
Reversal of rabbit syndrome with olanzapine.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Female; Haloperidol; Humans; M | 2000 |
Epidemic of schizophrenia in children or inappropriate prescribing?
Topics: Antipsychotic Agents; Australia; Benzodiazepines; Child; Child, Preschool; Disease Outbreaks; Drug U | 2000 |
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Cardiovascular Diseases; Cross-Sectional | 2001 |
A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure.
Topics: Antipsychotic Agents; Benzodiazepines; Chromatography, High Pressure Liquid; Electrochemistry; Human | 2001 |
Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Middle Aged; Olanzapine; Pirenzepine; Psorias | 2000 |
The effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Drug Therapy, Combinatio | 2000 |
[Olanzapine and pregnancy].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Humans; Olanzapine; Pirenzepine; Pregnancy; Pr | 2001 |
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; Ps | 2001 |
Introduction: a new era in the pharmacotherapy of psychotic disorders.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Administration Schedule | 2001 |
Dose-dependent olanzapine-associated leukopenia: three case reports.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; | 2001 |
Priapism associated with polypharmacy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Fluvoxamine; Humans; Male; | 2001 |
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Emergency Se | 2001 |
Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass I | 2001 |
Olanzapine and negative and positive symptoms.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Models, Psychological; Olanzapine; Pirenzepine; Schiz | 2001 |
Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Cost of Illness; Drug Costs; Hospitals, Psychiatric; Hospital | 2001 |
Olanzapine-induced diabetes mellitus.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus; Humans; Male; Olanza | 2001 |
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Follow-Up Studies; Humans; Ma | 2001 |
Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Ra | 2001 |
Hypothesis and hypothesis testing in the clinical trial.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Humans; Olanzap | 2001 |
Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment.
Topics: Adolescent; Adult; Aged; Animals; Antipsychotic Agents; Autoradiography; Benztropine; Cause of Death | 2001 |
Cognitive behavior therapy for weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Cognitive Behavioral Ther | 2001 |
Hyperglycemia in patients with schizophrenia who are treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperglycemia; Ma | 2001 |
Antiaggressive action of atypical antipsychotics in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Risperidon | 2001 |
Interaction of olanzapine with fluvoxamine.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Depressive D | 2001 |
Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine.
Topics: Adult; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Examination; Olanzapine; | 2001 |
Olanzapine-induced somnambulism.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Pirenzepine; S | 2001 |
A program for treating olanzapine-related weight gain.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Diet, Redu | 2001 |
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Budgets; Clozapine; Comorbidity; Depressiv | 2001 |
Writer's cramp induced by olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Dystonic Disorders; Female; Humans; Olanzapine; P | 2001 |
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Benzodiazepines; Cross-Cultural Comparison; Dose-Res | 2001 |
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study.
Topics: Adult; Benzodiazepines; Cost-Benefit Analysis; Cross-Cultural Comparison; Drug Costs; Europe; Female | 2001 |
Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Brain; Female; Human | 2001 |
Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; | 2001 |
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Drug Resistance; Female; Human | 2001 |
Maternal obesity and risk of neural tube defects.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Folic Acid; Humans; Infant, Newborn; Neural Tube Defe | 2001 |
Olanzapine: new preparation. Keep an eye on this neuroleptic.
Topics: Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Humans; Pirenzepine; Risperidone; Sc | 1999 |
Tissue distribution of olanzapine in a postmortem case.
Topics: Adult; Antipsychotic Agents; Autopsy; Benzodiazepines; Drug Overdose; Forensic Anthropology; Gas Chr | 2001 |
D2 receptor occupancy under recommended and high doses of olanzapine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Child; Child, Pre | 2001 |
[Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy].
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Creatine Kinase; Drug Interactions; Genet | 2001 |
Agranulocytosis and neutropenia with typical and atypical neuroleptics.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Humans; Leukocyte | 2001 |
Re: Weight change with antipsychotic use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Fructose; Humans; Male; Olanzapin | 2001 |
Are African American patients at a higher risk for olanzapine-induced glucose intolerance?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Black People; Blood Glucose; Diabetes Mellitus, Type 2 | 2001 |
Global index of safety (GIS): a new instrument to assess drug safety.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Benzodiazepines; Consumer Product Saf | 2001 |
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu | 2001 |
Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia.
Topics: Animals; Antipsychotic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Behavior, Anima | 2001 |
[Olanzapine and pregnancy. 2 case reports].
Topics: Adult; Benzodiazepines; Female; Follow-Up Studies; Humans; Infant, Newborn; Male; Olanzapine; Pirenz | 2001 |
The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Chil | 2001 |
Elevation of prolactin levels by atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Male; Middle Aged; Olanzapine; Pire | 2002 |
Increasing insulin dose for olanzapine-related diabetes.
Topics: Benzodiazepines; Blood Glucose; Body Mass Index; Diabetic Ketoacidosis; Dose-Response Relationship, | 2002 |
[Heart rate variability in schizophrenic patients treated with antipsychotic agents].
Topics: Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Female; Haloperidol; | 2001 |
Service use and costs of treating schizophrenia with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cost-Benefit Analysis; Dos | 2001 |
Olanzapine versus other antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Humans; Olanzapine; Pirenze | 2001 |
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder, Majo | 2001 |
Olanzapine for violent schizophrenia and Klinefelter syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Humans; Klinefelter Syndrome; Male; Olanzapine; Pirenz | 2002 |
A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Cost of Illness; Drug Costs; Female; H | 2002 |
Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Conditioning, Psychological; Fem | 2002 |
New-onset seizure associated with quetiapine and olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Humans; Olanzapine; Pirenz | 2002 |
Significant dissociation of brain and plasma kinetics with antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Clon | 2002 |
Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Creatine; Female; Glutamic Acid; Gyru | 2002 |
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Benzodiazepines; Clozapi | 2002 |
Serotonin syndrome and atypical antipsychotics.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; | 2002 |
Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzodiazepines; Brain; Brain Mapping; Female; Fingers; | 2002 |
Clinical and neuropsychological correlates of the P300 in schizophrenia.
Topics: Adult; Benzodiazepines; Depression; Event-Related Potentials, P300; Female; Humans; Male; Neuropsych | 2002 |
Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study.
Topics: Adult; Basal Ganglia; Benzodiazepines; Cerebellum; Cerebral Cortex; Female; Haloperidol; Humans; Lin | 2002 |
Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Glutamic Acid; Humans; Male; Ola | 2002 |
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Dia | 2002 |
Atypical antipsychotics and cognition in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Cognition; Cognition Disorders; Dose-Response Relationship, D | 2002 |
Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Female; Hospitals, Psychiatric; | 2002 |
Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Prescription | 2002 |
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clozapine; Disease Models, Animal; Haloperidol; Hipp | 2002 |
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clomipramine; Clozapine; Haloperidol; | 2002 |
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Follow-Up Stud | 2002 |
A possible association between high normal and high dose olanzapine and prolongation of the PR interval.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Electrocardiography; Heart Block; Heart Conduction Sys | 2002 |
Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine.
Topics: Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Hospitals, Veterans; Humans; Male; Ment | 2002 |
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Humans; Middle Aged; Olanzapine; Pat | 2002 |
A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia.
Topics: Adult; Analysis of Variance; Benzodiazepines; Chi-Square Distribution; Electromagnetic Fields; Evoke | 2002 |
Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Electrocardiography; Elec | 2002 |
Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: alterations in limbic regions of schizophrenics.
Topics: Adult; Autopsy; Autoradiography; Brain; Cell Membrane; Female; Humans; Imipramine; Iodine Radioisoto | 1992 |